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1 Zusammenfassung	  Hereditäres	   non-­‐polypöses	   kolorektales	   Karzinom	   (HNPCC)	   oder	   Lynch-­‐Syndrom	   ist	   eine	   vererbte	   genetische	   Erkrankung	   mit	   hohem	   Risiko	   für	  verschiedene	   Krebsarten,	   einschließlich	   kolorektales	   Karzinom,	   Endometrium-­‐	  und	  Eierstockkarzinom.	  Die	  Ursache	  für	  HNPCC	  liegt	   in	  einem	  Defekt	  der	  DNA-­‐Fehlpaarungsreparatur	  (englisch:	  DNA	  mismatch	  repair	  oder	  kurz	  MMR)	  durch	  Mutationen	   in	   MMR-­‐Genen.	   Viele	   Studien	   untersuchten	   funktionell	   die	  verschiedenen	  Mutationen,	  die	  in	  Patienten	  entdeckt	  wurden	  und	  klassifizierten	  diese.	  Einige	  Varianten	  sind	  bis	  heute	  jedoch	  nicht	  eindeutig	  klassifiziert	  worden,	  wie	   z.B.	   die	   MutL	   homolog	   1	   (MLH1)	   Variante	   R659Q.	   Die	   Entwicklung	  neuartiger	   Methoden	   und	   Systeme	   erscheint	   notwendig,	   um	   auch	   diese	  Varianten	  verlässlich	  klassifizieren	  zu	  können.	  Unser	   Labor	   hat	   vor	   kurzem	   das	   "all-­‐in-­‐one"	   Proteinersetzungssystem	  vorgestellt.	   Dabei	   wird	   das	   endogene	   Protein	   mithilfe	   von	   shRNA	  herunterreguliert	   und	   gleichzeitig	   eine	   Proteinvariante	   von	   cDNA	   induziert.	  Sowohl	  die	  shRNA	  als	  auch	  die	  cDNA	  sind	  auf	  einem	  einzigen	  Plasmid	  vorhanden	  und	  sind	  mit	  Doxycyclin	   induzierbar.	  Das	  System	  wurde	  erfolgreich	  verwendet,	  um	  die	  endogene	  DNA-­‐Polymerase	  δ	  durch	  Mutanten	  zu	  ersetzen.	  In	   dieser	   Arbeit	   haben	   wir	   das	   ursprüngliche	   pAIO-­‐System	   durch	   einige	  Veränderungen	  verbessert	  und	  genutzt,	  um	  als	  Proof-­‐of-­‐Principle	  den	  Phänotyp	  der	  MLH1-­‐Mutante	  R659Q	  zu	  studieren.	  Wir	  haben	  das	  Gateway-­‐System	  in	  das	  Plasmid	   eingefügt,	   was	   die	   Generierung	   von	   verschiedenen	   Varianten	   extrem	  vereinfacht.	  Weiterhin	   haben	  wir	   eine	   FRT-­‐Stelle	   (englisch:	   Flp	  Recombination	  Target)	   eingefügt,	   die	   die	   Herstellung	   von	   stabilen	   Zelllinien	   effizienter	   und	  einfacher	  macht.	  Ebenso	  wurden	  Möglichkeiten	  gefunden,	  den	  CMV-­‐Promoter	  so	  zu	  verändern,	  dass	  	  die	  Expression	  der	  cDNA	  in	  verschiedenen	  Stärken	  möglich	  ist.	  	  Anschließend	   haben	   wir	   Zelllinien	   mit	   GFP-­‐MLH1	   Wildtyp	   (WT),	   der	   MMR-­‐defizienten	   Variante	   K84E	   und	   der	   Variante	   R659Q	   generiert	   und	   analysiert.	  Unsere	   Ergebnisse	   zeigen,	   dass	   die	   R659Q-­‐Mutation	   zu	   reduzierten	  Proteinmengen	   sowohl	   im	   Zellkern	   als	   auch	   im	   Zytoplasma	   führt.	   Weiterhin	  konnten	   wir	   bestätigen,	   dass	   die	   R659Q-­‐Mutation	   in	   MMR	   funktionell	   ist.	  
Zusammenfassung	  
7	  	  	  	  	  
Allerdings	  konnten	  wir	  mithilfe	  von	  Pulldown-­‐Experimenten	  zeigen,	  dass	  MLH1	  R659Q	   im	  Gegensatz	   zum	  WT	   und	  K84E	   viel	  weniger	   an	   die	   Proteine	   Fanconi	  anemia	   group	   J	   protein	   (FANCJ)	   und	   FANCD2/FANCI-­‐associated	   nuclease	   1	  (FAN1)	  bindet,	  die	  beide	  mit	  der	  Reparatur	  von	  DNA-­‐Interstrang-­‐Vernetzungen	  (englisch:	  DNA	  interstrand	  crosslinks	  oder	  kurz	  ICLs)	  assoziiert	  werden.	  Dieser	  Linie	   folgend	   konnten	   wir	   mit	   Zellvitalitätsexperimenten	   zeigen,	   dass	   beide	  MLH1-­‐Mutanten	   resistenter	   gegenüber	   Mitomycin	   C	   (MMC),	   das	   DNA-­‐Vernetzungen	   auslöst,	   sind	   und	   weniger	   stark	   in	   der	   G2/M-­‐Phase	   gestoppt	  werden.	   Aufgrund	   unserer	   Resultate	   vermuten	   wir,	   dass	   nicht	   eine	  Einschränkung	   von	  MMR,	   sondern	   eine	   veränderte	   Reparatur	   von	   ICLs	  wegen	  eingeschränkter	  Bindung	  von	  MLH1	  R659Q	  mit	  FANCJ	  und	  FAN1	  zu	  Mutationen	  führt	  und	  damit	  zur	  Krebsentwicklung	  beiträgt.	  	  Der	   zweite	   Teil	   dieser	   Arbeit	   beschäftigt	   sich	   mit	   der	   Charakterisierung	   der	  Proteininteraktionen	  von	  MMR.	  Obwohl	  das	  minimale	  System	   für	  MMR	   in	  vitro	  	  bekannt	   ist,	   bleibt	   noch	   zu	   klären	  welche	   Faktoren	   einen	   Einfluss	   auf	  MMR	   in	  
vivo	   haben	   oder	   die	   Reparatur	   unterstützen.	   Ebenso	   ist	   offen	  welche	   Faktoren	  eine	   Rolle	   in	   nicht-­‐kanonischer	   MMR	   spielen.	   Wir	   haben	   die	   MMR-­‐Faktoren	  MLH1	   und	   MutS	   homolog	   2	   (MSH2)	   mit	   GFP	   bzw.	   eGFP	   fusioniert	   und	   sie	  anschließend	   mit	   allen	   gebundenen	   Proteinen	   mithilfe	   von	   GFP-­‐Trap	  angereichert	   und	   mit	   Flüssigchromatografie-­‐Massenspektrometrie	   (englisch:	  liquid	   chromatography	   mass	   spectrometry	   oder	   kurz	   LC-­‐MS)	   	   analysiert.	   Wir	  haben	   einige	   interessante	   Faktoren	   wie	   z.B.,	   WD	   Repeat	   And	   HMG-­‐Box	   DNA	  Binding	  Protein	  1	  (WDHD1)	  als	  Faktoren	  für	  MMR	  identifiziert,	  konnten	  aber	  mit	  dieser	   Methode	   keine	   Proteine	   speziell	   für	   nicht-­‐kanonische	   MMR	   entdecken.	  Um	  dieses	  Hindernis	  zu	  überwinden,	  haben	  wir	  neuartige	  Techniken	  wie	  BioID	  und	  APEX	  ausprobiert	  und	   für	  unsere	  Forschungsfrage	  nutzbar	  gemacht.	  Beide	  Techniken	   basieren	   auf	   der	   Biotinylierung	   von	   endogenen	   Proteinen	   in	  unmittelbarer	   Nähe.	   Für	   beide	   Techniken	   wurden	   MMR-­‐Fusionsproteine	  generiert	   und	   die	   Biotinylierung	   von	   endogenen	   Proteinen	   erfolgreich	  durchgeführt.	   Ebenso	   wurden	   Techniken	   für	   die	   Isolierung	   der	   biotinylierten	  Proteine	  wie	  auch	  für	  die	  anschließende	  Analyse	  mit	  LC-­‐MS	  entwickelt.	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2 Summary	  
Hereditary	   nonpolyposis	   colorectal	   cancer	   (HNPCC)	   or	   Lynch	   syndrome	   is	   an	  autosomal	   dominant	   genetic	   disease	   associated	   with	   a	   high	   risk	   of	   colorectal,	  endometrial	   and	   ovarian	   cancer.	   The	   cause	   of	   HNPCC	   is	   a	   defect	   in	   DNA	  mismatch	  repair	  (MMR)	  due	  to	  germline	  mutations	  in	  MMR	  genes.	  Cells	  defective	  in	  MMR	   show	   a	  mutator	   phenotype	   and	  microsatellite	   instability	   (MSI).	   Many	  studies	   have	   been	   conducted	   to	   characterize	   the	   phenotype	   of	   individual	  mutations	   in	   order	   to	   classify	   them	   and	   estimate	   the	   risk	   for	   the	   mutation	  carriers.	  Although	  most	  of	   the	  mutations	  have	  been	  classified	  as	  pathogenic	  or	  non-­‐pathogenic,	   some	   remain	   uncertain	   such	   as	   the	   MutL	   homolog	   1	   (MLH1)	  R659Q	   mutant.	   To	   classify	   those	   variants,	   it	   is	   required	   to	   develop	   new	  techniques.	  	  Our	   group	   previously	   reported	   on	   the	   development	   of	   an	   inducible	   protein	  replacement	   system,	   which	   we	   used	   for	   the	   phenotypic	   characterization	   of	  missense	   mutations	   in	   polymerase-­‐δ.	   Our	   all-­‐in-­‐one	   plasmid	   (pAIO)	   inducibly	  expresses	  an	  shRNA	  that	  knocks	  down	  an	  endogenous	  mRNA	  and	  concurrently	  expresses	  an	  exogenous	  mRNA	  encoding	  the	  protein	  of	  interest	  or	  its	  variant.	  We	  now	  describe	   an	   improved	  pAIO	  plasmid	  with	   several	   new	   features.	  AttR	   sites	  for	   Gateway	   cloning	   and	   an	   FRT	   site	   (Flp-­‐In	   system)	   for	   faster	   generation	   of	  stable	   cell	   lines	   were	   introduced.	   In	   addition,	   strategies	   to	   alter	   the	   CMV	  promoter	   to	   obtain	   strong,	   medium,	   low	   and	   very	   low	   cDNA	   expression	  were	  developed.	  	  We	  took	  advantage	  of	  the	  second	  generation	  pAIO	  plasmid	  to	  study	  phenotypic	  variants	   of	   the	   MMR	   factor	   MLH1.	  We	   generated	   stable	   Flp-­‐In	   T-­‐REx-­‐293	   cell	  lines	  expressing	  GFP-­‐MLH1	  wild	  type	  (wt),	  an	  MMR-­‐deficient	  K84E	  mutant	  and	  an	  R659Q	  mutant.	  Subsequently,	  we	   induced	  our	  system,	  which	  resulted	   in	   the	  replacement	  of	  endogenous	  MLH1	  with	  GFP-­‐MLH1.	  We	  found	  that	  protein	  levels	  of	  GFP-­‐MLH1	  K84E	  were	  more	  abundant	  and	  MLH1	  R659Q	  levels	  were	  reduced	  in	   whole	   cell	   extracts.	   The	   K84E	   mutant,	   but	   not	   the	   R659Q	   mutant,	   showed	  MMR	   deficiency	   in	   vitro	   and	   in	   vivo.	   Pulldown	   experiments	   with	   GFP-­‐Trap	  revealed	   that	   the	   binding	   of	   the	   R659Q	  mutant	   to	   DNA	   repair	   factors	   Fanconi	  anemia	   group	   J	   protein	   (FANCJ)	   and	   FANCD2/FANCI-­‐associated	   nuclease	   1	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(FAN1)	   was	   diminished.	   Hence,	   we	   studied	   cell	   viability	   of	   the	   variants	   after	  treatment	  with	  DNA	  interstrand	  crosslink	  (ICL)	   inducing	  agents	  and	  found	  that	  the	   K84E	   mutant	   as	   well	   as	   the	   R659Q	   mutant	   showed	   resistance	   against	  mitomycin	   C	   (MMC).	   In	   addition,	   both	   mutants	   showed	   reduced	   G2/M	   phase	  arrest	  after	  MMC	  treatment.	  These	  results	  imply	  erroneous	  MLH1-­‐dependent	  ICL	  repair	   in	   MLH1	   R659Q	   cells,	   which	   provides	   a	   potential	   explanation	   of	   how	  MLH1	  R659Q	  carriers	  acquire	  mutations	  leading	  to	  tumor	  development.	  	  Together,	   our	   experiments	   demonstrate	   that	   the	   improved	   pAIO	   system	   is	  generally	   suitable	   to	   study	  genotype-­‐phenotype	   correlations	  and	  might	  help	   to	  elucidate	   a	  mechanism	  underlying	   disease	   development	   for	   specific	  mutations.	  With	  the	  help	  of	  our	  system,	  we	  could	  show	  that	  the	  MLH1	  R695Q	  variant	  does	  not	  have	  a	  defect	  in	  MMR	  but	  that	  its	  impaired	  binding	  to	  FANCJ	  and	  FAN1	  might	  result	   in	   alternative,	   probably	   mutagenic,	   ICL	   repair,	   which	   leads	   to	   tumor	  development.	  	  	  	  	  The	   second	   part	   of	   this	   thesis	   focuses	   on	   the	   characterization	   of	   the	   MMR	  interactome	   under	   different	   aspects	   of	   DNA	   metabolism.	   Although	   the	  mechanism	  of	  MMR	   in	  vitro	  is	   largely	  known,	  we	  still	  require	  more	  information	  about	   how	   MMR	   is	   facilitated	   in	   vivo	   to	   explain	   the	   whole	   mechanism	   in	   the	  setting	   of	   a	   living	   cell.	   Moreover,	   additional	   information	   about	   the	   MMR	  interactome	   is	   needed	   to	   better	   understand	   non-­‐canonical	   MMR,	   which	  describes	   a	   process	   that	   works	   independently	   of	   DNA	   replication.	   It	   can	   be	  activated	  outside	  of	  S	  phase	  by	  alkylating	  agents	  and	  was	  shown	  to	  be	  mutagenic.	  GFP	  and	  eGFP-­‐tagged	  MMR	  proteins	  were	  generated	  and	  stable	   cell	   lines	  were	  produced	   using	   the	   pAIO	   system.	   GFP-­‐Trap	   pulldown	   followed	   by	   liquid	  chromatography	   mass	   spectrometry	   (LC-­‐MS)	   helped	   identify	   some	   interesting	  proteins	   including	  WD	  Repeat	  And	  HMG-­‐Box	  DNA	  Binding	  Protein	  1	  (WDHD1).	  Unfortunately,	  the	  approach	  was	  not	  suitable	  to	  identify	  specific	  factors	  for	  non-­‐canonical	   MMR.	   Hence,	   novel	   techniques	   such	   as	   BioID	   and	   APEX,	   which	   are	  based	   on	   proximity-­‐dependent	   biotinylation,	  were	   explored	   and	   tested	   for	   the	  study	  of	  the	  MMR	  interactome	  after	  DNA	  damage.	  MLH1	  BioID	  and	  APEX	  fusion	  proteins	  were	   cloned	   and	   stable	   cell	   lines	   generated.	  Moreover,	  we	   developed	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strategies	  to	  efficiently	  pull	  down	  biotinylated	  proteins	  and	  analyze	  them	  by	  LC-­‐MS.	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3 Introduction	  	  
3.1 General	  aspects	  of	  cancer	  development	  	  Cancer	   is	  described	  as	   a	   group	  of	  diseases	   that	  have	  one	   thing	   in	   common:	  All	  types	  of	  cancer	  derive	  from	  normal	  tissue	  and	  proliferate	  without	  control.	  They	  have	   the	   potential	   to	   leave	   their	   initial	   site	   and	   spread	   all	   over	   the	   body	   in	   a	  process	  known	  as	  metastases	  formation,	  which	  is	  the	  main	  cause	  of	  death	  among	  patients.	   Cancers	   are	   often	   referred	   to	   as	   tumors,	   although	   not	   all	   tumors	   are	  cancerous.	   In	  general,	   tumors	  are	  divided	   into	   two	  groups:	  benign	   tumors	   that	  do	  not	  metastasize	  and	  malignant	  tumors	  (cancers)	  that	  do	  metastasize.	  A	  lot	  of	  time	   and	   resources	   have	   been	   spent	   to	   find	   the	   origins	   of	   cancer	   and	   many	  substances	   called	   carcinogens	   have	   been	   associated	   with	   tumor	   development	  (1).	   They	   are	   divided	   into	   three	   categories:	   physical	   carcinogens	   such	   as	   ultra	  violet	   and	   ionizing	   radiation,	   chemical	   carcinogens	   including	   tobacco	   smoke	  or	  substances	  produced	  by	  living	  organisms,	  e.g.	  aflatoxin,	  and	  oncogenic	  viruses.	  In	  principle,	   they	   all	   cause	   cancer	   by	   producing	   genotoxic	   stress,	   which	   leads	   to	  mutations	   in	   the	   genome	   (2).	   These	   mutations	   can	   either	   activate	   pro-­‐proliferative	  genes	  called	  oncogenes	  or	  inactivate	  anti-­‐proliferative	  genes	  called	  tumor	   suppressors.	   Both	   events	   can	   transform	   normal	   tissue	   cells	   into	   cancer	  cells	  that	  grow	  in	  an	  uncontrolled	  manner	  and	  can	  metastasize	  in	  the	  body	  and	  lead	  to	  the	  disease	  we	  call	  cancer	  (1).	  	  	  	  Not	   all	   cancers,	   however,	   are	   caused	   by	   carcinogens.	   5-­‐10%	   of	   all	   cancers	   are	  caused	   by	   inherited	   mutations.	   This	   phenomenon	   is	   called	   familial	   cancer.	  Mutations	   in	   tumor	   suppressor	   genes	   involved	   in	   cell	   proliferation	   such	   as	  
restinoblastoma	  (RB)	  and	  adenomatous	  polyposis	  coli	   	  (APC)	  or	  DNA	  repair	  such	  as	  breast	  cancer	  1	   (BRCA1)	   and	  mutL	  homolog	  1	   (MLH1)	   are	   causes	   of	   familial	  cancer	  (1,3).	  In	  most	  cases,	  only	  one	  allele	  is	  mutated	  and	  the	  normal,	  wild	  type	  (wt)	   allele	   is	   affected	   over	   time	   by	   another	  mutation	   or	   loss	   of	   heterozygosity	  (LOH),	   which	   is	   consistent	   with	   the	   "two-­‐hit	   hypothesis"	   by	   Knudson	   (1971),	  which	   states	   that	   both	   alleles	   of	   a	   tumor	   suppressor	   need	   to	   be	   inactivated	  before	  a	   cell	   transforms	   (4).	  Once	  a	   cell	   has	   lost	   its	   remaining	   functional	   copy,	  key	   mechanisms	   such	   as	   cell	   growth,	   proliferation,	   apoptosis	   control	   or	   DNA	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repair	  are	  significantly	   impaired	  and	  the	  chance	  of	   this	  cell	   to	   transform	  into	  a	  cancer	  cell	  increases	  dramatically	  (1,2).	  	  
	  
3.1.1 Mutations	  and	  loss	  of	  heterozygosity	  –	  the	  second	  hit	  on	  the	  road	  to	  
cancer	  	  	  	  Usually,	  familial	  cancer	  patients	  inherit	  only	  one	  mutated	  allele	  and	  the	  second	  is	  wt,	   though	   rare	   cases	   with	   homozygosity	   for	   the	   mutant	   allele	   have	   been	  described	   such	   as	   inherited	   biallelic	   mismatch	   repair	   deficiency.	   In	   such	   a	  scenario,	   both	   parents	   need	   to	   be	   carriers.	   Then,	   the	   patients	   develop	   tumors	  very	   early	   and	   have	   dramatically	   decreased	   life	   expectancy	   (5).	   Heterozygous	  carriers	  are	  diagnosed	  much	  later,	  which	  can	  be	  explained	  by	  the	  fact	  that	  the	  wt	  allele	   gives	   raise	   to	   a	   functional	   protein	   that	   is	   dominant	   over	   the	   mutant.	  Obviously,	   the	   wt	   allele	   needs	   to	   be	   inactivated	   in	   order	   to	   acquire	   the	  phenotype,	   which	   can	   lead	   to	   a	   cancerous	   cell,	   such	   as	   higher	   mutation	   rates	  because	   of	   impaired	  DNA	   repair	   pathways.	   The	   functional	   copy	   can	   be	   lost	   or	  inactivated	   by	   different	   mechanisms,	   including	   deleterious	   point	   mutations,	  deletions,	   or	   hypermethylation	   of	   the	   promoter	   region	   known	   as	   epigenetic	  silencing.	   Hypermethylation	   of	   the	   promoter	   region,	   which	   shuts	   down	  transcription,	   has	   been	   observed	   for	   many	   tumor	   suppressor	   genes.	  MLH1	   in	  particular	   is	   frequently	   inactivated	   by	   epigenetic	   silencing	   (6).	   LOH	   can	   occur	  through	  chromosome	  missegregation	  or	  mitotic	  recombination.	  In	  the	  process	  of	  chromosome	  missegregation,	  a	  heterogeneous	  cell	  loses	  its	  functional	  allele	  due	  to	   a	   failure	   of	   the	   spindle-­‐assembly	   checkpoint	   (see	   Figure	   1	   A).	   Figure	   1	   B	  illustrates	   how	   mitotic	   recombination	   between	   homologous	   chromatids	   can	  cause	  LOH	  (7).	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Figure	  1:	  Mechanisms	  of	  LOH	  	  
(A)	  A	  heterozygous	  cell	  can	  lose	  the	  functional	  copy	  of	  a	  gene	  by	  failure	  of	  the	  spindle-­‐assembly	  checkpoint.	  	  In	  such	  a	  scenario,	  the	  two	  daughter	  cells	  receive	  the	  alleles	  not	  in	  a	  2:2,	  but	  in	  a	  3:1	  ratio.	  In	  the	  next	  cell	  cycle,	  one	  daughter	  cell	  can	  lose	  the	  third	  allele	  with	   the	   functional	   copy.	   (B)	   In	   the	   process	   of	   mitotic	   recombination,	   an	   exchange	  between	   homologous	   chromosomes	   after	   duplication	   of	   the	   genome	   results	   in	   two	  homozygous	   daughter	   cells:	   one	   with	   two	   wt	   alleles	   and	   the	   other	   with	   two	   mutant	  alleles	  (modified	  from	  Lodish	  et	  al.,	  2004).	  	  	  	  	  	  	  	  
3.2 Hereditary	  non-­‐polyposis	  colon	  cancer	  	  Hereditary	   non-­‐polyposis	   colon	   cancer	   (HNPCC)	   or	   Lynch	   syndrome	   is	   a	  prominent	  example	  of	  familial	  cancer.	  It	  accounts	  for	  about	  4%	  of	  all	  colorectal	  cancers	   (CRC)	  and	   is	   characterized	  by	  an	   inherited	  dominant	  predisposition	   to	  early	  onset	  of	  colon	  cancer	  as	  well	  as	  extracolonic	  cancers	  including	  endometrial,	  ovary,	  stomach	  and	  small	  intestine	  cancer.	  Cancers	  in	  the	  typical	  sites	  are	  usually	  diagnosed	  before	  the	  age	  of	  50.	  The	  cumulative	  risk	  for	  CRC	  in	  HNPCC	  families	  is	  about	   80%	   and	   the	   lifetime	   risk	   for	   females	   to	   develop	   endometrial	   cancer	  amounts	   to	   about	   60%	   (8).	   At	   12%,	   the	   risk	   for	   ovarian	   cancer	   is	   also	   much	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higher	  compared	  to	  the	  general	  population	  with	  a	  risk	  of	  about	  1.3%	  (see	  Figure	  2)	  (9,10).	  	  	  	  	  	  	  	  	  	  	  
Figure	  2:	  Lifetime	  risk	  of	  HNPCC	  mutation	  carriers	  and	  general	  population	  	  	  	  HNPCC	  is	  caused	  by	  a	  defect	   in	  DNA	  mismatch	  repair	  (MMR),	  which	  recognizes	  and	   repairs	   errors	   arising	   during	   DNA	   replication	   and	   recombination	   (11,12).	  MMR-­‐deficient	  cells	  acquire	  point	  mutations,	   insertions	  and	  deletions	   in	  coding	  and	  non-­‐coding	  sequences	  and	  are	  thus	  hypermutagenic,	  which	  eventually	  leads	  to	   tumor	   development.	   DNA	   polymerases	   display	   increased	   error	   rates	   when	  they	  replicate	  repetitive	  motifs	  known	  as	  microsatellites,	  such	  as	  (A)n	  or	  (CA)n.	  If	  these	  are	  left	  unrepaired	  by	  MMR,	  shortening	  of	  those	  areas	  can	  be	  observed	  –	  a	  phenomenon	  known	  as	  DNA	  microsatellite	  instability	  (MSI)(13).	  MSI	  is	  typically	  used	  for	  diagnosis	  of	  HNPCC	  (14).	  	  	  	  Many	   studies	   have	   been	   conducted	   to	   identify	   HNPCC-­‐predisposing	   genes	   and	  four	  MMR	  genes	  were	   found	   to	  be	   frequently	  mutated:	  MLH1,	  PMS2,	  MSH2	  and	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3.2.1 Diagnosis,	  treatment	  and	  prognosis	  of	  HNPCC	  HNPCC	  is	  described	  as	  a	  cancer	  syndrome	  with	  an	  early	  onset	  of	  CRC	  and	  other	  tumors	   caused	   by	   mutations	   that	   impair	   MMR.	   Although	   this	   description	   is	  rather	   comprehensible,	   it	   turned	   out	   to	   be	   not	   that	   simple	   in	   clinical	   practice.	  Specific	   guidelines	   were	   needed	   to	   clearly	   separate	   HNPCC	   from	   sporadic	  cancers	   also	   caused	   by	  mutations	   in	  MMR	   genes	   and	   other	   cancer	   syndromes	  such	   as	   familial	   adenomatous	   polyposis	   (FAP).	   The	   International	   Collaborative	  Group	   for	   HNPCC	   (ICG-­‐HNPCC)	   introduced	   standardized	   criteria	   for	   HNPCC	  diagnostics	   in	   1991.	   According	   to	   these	   criteria,	   known	   as	   the	   Amsterdam	  Criteria,	   a	   candidate	   needs	   to	   fulfill	   all	   of	   the	   following:	   three	   or	   more	   family	  members	   with	   a	   confirmed	   CRC	   (Amsterdam	   Criteria	   I)	   or	   HNPCC-­‐related	  cancers	  (Amsterdam	  Criteria	  II)	  and	  one	  should	  be	  a	  first-­‐degree	  relative	  of	  the	  other	  two,	  one	  or	  more	  cancers	  need	  to	  be	  diagnosed	  before	  the	  age	  of	  50	  years	  and	   FAP	   should	   be	   excluded	   (17,18).	   As	   an	   alternative,	   the	   National	   Cancer	  Institute	   introduced	   the	   Bethesda	   guidelines	   in	   1997,	  which	   are	   similar	   to	   the	  Amsterdam	  Criteria	  but	  also	  include	  patients	  with	  HNPCC-­‐related	  cancers	  under	  the	  age	  of	  60,	  but	  with	  MSI	  (19).	  Once	  a	  family	  has	  been	  identified,	  the	  affected	  persons	  undergo	  genetic	  screening	  to	  search	  for	  mutations	  in	  MMR	  genes.	  Other	  family	   members	   are	   also	   screened	   for	   these	   mutations	   and	   carriers	   are	  recommended	   to	   join	   early-­‐detection	   programs	   that	   include	   physical	   exam,	  colonoscopy	   and	   gynecologic	   methods	   for	   endometrial	   and	   ovarian	   cancer.	  Prognosis	   for	  HNPCC	  depends	  on	  the	  stage	  of	   the	  tumor	  at	  diagnosis.	  Although	  HNPCC-­‐related	   CRCs	   in	   general	   are	   poorly	   differentiated,	   which	   normally	  correlates	   with	   poor	   prognosis,	   they	   have	   a	   better	   outcome	   than	   comparable	  sporadic	  cancers.	  To	  date,	  surgery	  is	  still	  the	  most	  effective	  treatment	  for	  HNPCC	  (14).	   Adjuvant	   chemotherapy	   does	   not	   improve	   the	   prognosis,	   but	   seems	   to	  slightly	  decrease	  the	  outcome	  in	  patients	  with	  high	  MSI	  (20).	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3.3 Defects	   in	   DNA	   mismatch	   repair	   as	   a	   source	   of	   genome	  
instability	  When	   a	   cell	   divides,	   its	   genome	   must	   be	   duplicated	   with	   as	   few	   errors	   as	  possible.	   A	   large	   set	   of	   proteins	   described	   as	   the	   replication	   machinery	   takes	  part	   in	   this	   process	   known	   as	  DNA	   replication.	   The	   actual	   copying	   of	   the	  DNA	  strands	   is	   carried	  out	  by	   a	   specific	   group	  of	   enzymes	   called	  DNA	  polymerases.	  Several	  DNA	  polymerases	  with	  widely	  different	   fidelities	  have	   evolved	   in	   cells.	  The	  error	  rates	  range	  from	  10-­‐1	  to	  10-­‐8	  falsely	  incorporated	  bases	  per	  nucleotide	  for	   low-­‐fidelity	   and	   high-­‐fidelity	   polymerases,	   respectively	   (21).	   In	   addition	   to	  base	  substitutions,	  insertion	  or	  deletion	  loops	  (IDLs)	  that	  occur	  due	  to	  incorrect	  primer	   annealing	   during	   DNA	   replication	   or	   due	   to	   polymerase	   slippage	  especially	   at	   microsatellites,	   are	   a	   source	   of	   replication	   errors	   (see	   Figure	   3)	  (13,22).	  Moreover,	   replication	   errors	   can	   be	   induced	   by	   environmental	   stress,	  such	  as	  high	  oxygen	  radical	   levels,	  DNA-­‐methylating	  agents	  or	  radiation.	  Under	  normal	  conditions,	  the	  replication	  error	  rate	  is	  estimated	  to	  be	  around	  10-­‐7	  to	  10-­‐8	   (21).	   The	   post-­‐replicative	   MMR	   system	   that	   recognizes	   spontaneous	   base	  substitutions	   and	   IDLs	   increases	   replication	   fidelity	   by	  50	   to	  1,000-­‐fold,	  which	  results	  in	  a	  total	  error	  rate	  of	  about	  10-­‐9	  to	  -­‐10	  (23).	  A	  defect	  of	  the	  MMR	  system	  therefore	   results	   in	   increased	   genome	   instability	   due	   to	   higher	  mutation	   rates	  accompanied	  by	  MSI,	  which	  eventually	  leads	  to	  cancer	  development.	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Figure	  3:	  Formation	  of	  insertion	  and	  deletion	  loops	  In	   the	  process	  of	  DNA	  replication,	   the	  primer	  and	   the	   template	   strand	  can	  separate.	   If	  the	   strands	   re-­‐anneal	   incorrectly,	   insertions	   or	   deletions	   can	   occur.	   These	   are	  recognized	   and	   repaired	   by	   the	   MMR	   system	   (adapted	   from	   Levinson	   and	   Gutman,	  1987).	  	  	  	  	  	  
	  
3.3.1 DNA	  mismatch	  repair	  mechanism	  in	  Escherichia	  coli	  The	  mechanism	  of	  DNA	  mismatch	  recognition	  and	  repair	  was	  first	  elucidated	  in	  studies	   with	   Escherichia	   coli	   (E.	   coli).	   Genetic	   screens,	   in	   which	   strains	   with	  "mutator"	  phenotypes	  were	  suggested	  to	  be	  MMR-­‐deficient,	  helped	  identify	  key	  players	  of	  DNA	  MMR.	  Finally,	   the	   factors	  encoded	  by	   the	   identified	  genes	  were	  purified	  and	  the	  MMR	  system	  could	  be	  reconstituted	  in	  vitro	  (24).	  The	  first	  step	  of	  the	  MMR	  mechanism	  consists	  of	  recognition	  of	  the	  replication	  error,	  such	  as	  a	  base-­‐base	  mismatch	   or	   IDL	   by	   the	  MutS	   homodimer,	   followed	   by	   binding	   of	   a	  MutL	   homodimer.	   The	   complex	   formation	   is	   ATP-­‐dependent	   and	   allows	   its	  translocation	  on	  the	  DNA	  towards	  the	  closest	  hemi-­‐methylated	  GATC	  site	  bound	  by	   the	   endonuclease	   MutH,	   which	   becomes	   activated.	   The	   hemi-­‐methylated	  GATC	  site	  plays	  an	  important	  role	  in	  strand	  discrimination	  in	  E.	  coli.	  In	  order	  to	  maintain	  genome	  instability	  and	  prevent	  mutations,	  the	  newly	  synthesized	  DNA	  strand	   that	   contains	   the	   replication	   error	   has	   to	   be	   degraded.	   The	   enzyme	  responsible	   for	  methylation	  on	   the	  adenine,	  deoxyadenine	  methylase	   (Dam),	   is	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slower	   than	   the	   replication	   machinery,	   resulting	   in	   transiently	   unmethylated	  GATC	   sites	   in	   the	   newly	   synthesized	   strand.	   Activated	   MutH	   incises	   the	  unmethylated	   GATC	   and	   UvrD	   helicase	   unwinds	   the	   nicked	   error-­‐containing	  strand.	   Now,	   one	   of	   several	   exonucleases	   (ExoI,	   RecJ,	   ExoVII	   or	   ExoX)	   can	  degrade	   the	   strand	   beyond	   the	   mismatch,	   which	   could	   be	   up	   to	   1	   kb.	   The	  excision	   can	   be	   either	   5'-­‐3'	   or	   3'-­‐5'	   depending	   on	   the	   localization	   of	   the	  mismatch.	   The	   resulting	   gap	   is	   then	   resynthesized	   by	  DNA	  polymerase	   III	   and	  the	  remaining	  nick	  is	  sealed	  by	  DNA	  ligase	  (13,23).	  	  	  It	  turned	  out	  that	  the	  main	  factors	  of	  MMR	  are	  highly	  conserved	  except	  for	  MutH.	  Only	   Gram-­‐negative	   bacteria	   express	   MutH	   and	   no	   functional	   homologue	   was	  found	  in	  other	  organisms.	  Interestingly,	  MutH	  negative	  E.	  coli	  strains	  can	  repair	  mismatches	  under	  the	  condition	  that	  the	  DNA	  substrate	  contains	  a	  nick	  close	  to	  the	  mispair.	   This	   observation	   led	   to	   the	   conclusion	   that	   DNA	   nicks	   in	   general	  might	  provide	   the	  discrimination	   signal	   and	   the	   entry	  point	   for	  MMR.	  The	  key	  question	  is:	  Where	  do	  the	  nicks	  come	  from?	  An	  elegant	  solution	  is	  given	  by	  the	  DNA	   replication	   process	   itself:	   During	   replication,	   the	   lagging	   strand	   contains	  free	  termini	  at	  the	  5'	  or	  3'	  ends	  of	  Okazaki	  fragments	  and	  in	  the	  leading	  strand,	  at	  the	  3'	  end	  (13,25).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
3.3.2 DNA	  mismatch	  repair	  in	  humans	  DNA	   mismatch	   repair	   is	   highly	   conserved	   in	   different	   organisms.	   Functional	  homologs	  of	  the	  bacterial	  MMR	  factors	  could	  be	  identified	  in	  yeast,	  humans	  and	  other	  species	  (23).	  Moreover,	  the	  mechanism	  of	  MMR	  is	  similar	  and	  studies	  from	  bacteria	   and	   yeast	   helped	   us	   understand	   mammalian	   MMR.	   In	   mammals,	   a	  mismatch	   or	   a	   small	   IDL	   are	   recognized	   by	   the	   heterodimer	   MutSα,	   which	  consists	   of	  MutS	  homolog	  2	   (MSH2)	   and	  MutS	  homolog	  6	   (MSH6).	   IDLs	   longer	  than	   2	   nucleotides	   are	   bound	   by	   MutSβ,	   a	   heterodimer	   of	   MSH2	   and	   MutS	  homolog	   3	   (MSH3)	   (13).	   MutSα	   contains	   an	   ATPase	   domain	   (Walker	   ATP-­‐binding	  motif)	   and	  biochemical	   studies	  with	  nuclear	   extracts	   and	   recombinant	  proteins	   showed	   that	   MMR	   is	   ATP-­‐dependent.	   MutSα	   has	   strong	   affinity	   for	  mispairs	   in	   its	  ADP-­‐bound	   state.	  Upon	  binding,	  ADP	   is	   replaced	  by	  ATP,	  which	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brings	  about	  a	  rapid	  conformational	  change	  of	  MutSα	  and	  converts	  the	  complex	  into	  a	  sliding	  clamp	  on	  the	  DNA	  (23,25).	  	  	  Similar	   to	   MMR	   in	   E.	   coli,	  MutSα	   recruits	   MutL	   homologs	   to	   the	   site	   of	   DNA	  damage.	   The	   most	   important	   MutL	   homolog	   is	   MutLα,	   which	   is	   again	   a	  heterodimer	  of	  MutL	  homolog	  1	  (MLH1)	  and	  PMS1	  homolog	  2	  (PMS2).	  The	  name	  was	  derived	   from	  its	  homolog	   in	  yeast	  PMS1,	  which	  was	  discovered	  before	   the	  human	  protein.	  MLH1	  also	  forms	  heterodimers	  with	  PMS1	  and	  MLH3,	  which	  are	  called	   MutLβ	   and	   MutLγ,	   respectively.	   While	   the	   function	   of	   MutLβ	   remains	  enigmatic,	   MutLγ	   plays	   a	   role	   in	   meiotic	   recombination	   and	   can	   serve	   as	   a	  backup	  for	  MutLα	  (13,25).	  	  	  In	  mammalian	  MMR,	  MutSα	  together	  with	  MutLα	  are	  believed	  to	  slide	  along	  the	  DNA	  until	  they	  encounter	  replication	  factor	  C	  (RFC)	  and	  proliferating	  cell	  nuclear	  antigen	  (PCNA)	  bound	  to	  a	  nick,	  which	  serves	  as	  the	  strand	  discrimination	  signal.	  RFC	   is	   removed	  and	  EXO1	   is	   loaded	   to	  degrade	   the	  strand	  with	   the	  replication	  error.	   Interestingly,	   it	   turned	   out	   that	   degradation	   in	   both	   directions	   required	  only	   Exonuclease-­‐1	   (EXO1).	   Because	   EXO1	   is	   a	   5'-­‐3'	   nuclease,	   it	   remained	  unclear	   how	   3'-­‐5'	   directed	   MMR	   functions	   in	   mammalian	   cells.	   Prominent	  explanations	   included	   the	   3'-­‐5'	   proofreading	   activities	   of	   DNA	   polymerases	   δ	  (Polδ)	  and	  ε	  	  (Polε),	  the	  3'-­‐5'	  exonuclease	  activity	  of	  MRE11	  or	  the	  involvement	  of	   RFC	   (13).	   In	   2006,	   Kadyrov	   and	   colleagues	   solved	   the	   problem	   when	   they	  discovered	  an	  endonucleolytic	  activity	  in	  the	  MutLα	  complex.	  It	  was	  localized	  at	  a	  DQHA(X)2E(X)2	  motif	   in	  PMS2.	  With	  this	  observation,	   the	  model	  changed	  in	  a	  way	  that	  MutLα,	  after	  encountering	  the	  strand	  discrimination	  signal	  protected	  by	  PCNA	   and	   RFC,	   becomes	   activated	   and	   slides	   along	   the	   DNA	   to	   set	   additional	  nicks,	  which	  can	  be	  used	  as	  entry	  points	   for	  EXO1.	   In	   the	  case	  of	  3'-­‐5'	  directed	  MMR,	  nicks	  have	  to	  be	  set	  beyond	  the	  mispair	  in	  order	  to	  include	  the	  error	  in	  the	  degradation	   (26).	   The	   resulting	   single-­‐strand	   gap	   is	   protected	   by	   replication	  protein	   A	   (RPA).	   As	   soon	   as	   the	   mismatch	   is	   removed,	   MutSα	   and	   MutLα	  dissociate	  from	  the	  DNA	  and	  EXO1	  function	  is	  inhibited.	  Polδ	  is	  loaded	  at	  the	  3'	  terminus	   by	   interaction	   with	   PCNA	   and	   resynthesizes	   DNA	   to	   fill	   the	   gap.	  Remaining	  nicks	  in	  the	  duplex	  are	  sealed	  by	  DNA	  ligase	  I	  (13,23).	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Figure	  4:	  Mismatch	  repair	  in	  Escherichia	  coli	  and	  Humans	  In	   E.	   coli,	   the	   replication	   error	   is	   recognized	   by	   MutS	   which	   than	   recruits	   MutL.	  Together,	   they	   slide	   along	   the	   DNA	   to	   the	   closest	   GATC	   site	   to	   activate	   MutH,	   which	  incises	  the	  unmethylated	  strand.	  Depending	  on	  the	  location	  of	  the	  mispair	  relative	  to	  the	  GATC	   site	   exonucleases	   ExoI	   or	   RecJ	   degrade	   the	   strand	   5'-­‐3'	   and	   ExoVII	   or	   ExoX	  degrade	   the	   strand	   3'-­‐5'	   beyond	   the	   mismatch,	   respectively.	   Ssb	   binds	   to	   the	   single	  stranded	  gap	  and	  DNA	  polymerase	  III	  is	  recruited	  to	  resynthesize	  the	  DNA	  duplex.	  The	  remaining	   nick	   is	   sealed	   by	   DNA	   ligase.	   In	   humans,	   the	   DNA	   mismatch	   is	   bound	   by	  MutSα,	  which	  recruits	  MutLα.	  They	  slide	  along	  the	  DNA	  until	  they	  encounter	  a	  nick.	  The	  MutLα	  endonuclease	  becomes	  activated	  by	  PCNA	  and	  RFC	  and	   starts	   to	   set	   additional	  nicks	  also	  beyond	  the	  mismatch.	  EXO1	  is	  loaded	  and	  degrades	  the	  nicked	  strand	  in	  a	  5'-­‐3'	  direction.	  The	  single	  stranded	  DNA	  is	  protected	  by	  RPA	  until	  Polδ,	  recruited	  by	  PCNA,	  fills	   the	   gap.	  DNA	   ligase	   I	   seals	   the	   remaining	  nick	   in	   the	  DNA	   (modified	   from	   Jiricny,	  2006).	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As	  mentioned	   above,	   hemi-­‐methylated	  DNA	   does	   not	   provide	   a	   discrimination	  signal	   in	   mammals	   due	   to	   the	   lack	   of	   a	   MutH	   homolog	   and	   therefore	   the	  explanation	  with	  nicks	  provided	  by	  Okazaki	  fragments	  or	  the	  3'	  terminus	  in	  the	  leading	  strand	  is	  accepted	  also	  for	  MMR	  in	  humans	  (25).	  Over	  the	  course	  of	  the	  last	   few	   years,	   however,	   additional	   mechanisms	   that	   provide	   nicks	   for	   strand	  discrimination	   have	   been	   discovered.	   In	   2013,	   two	   studies	   showed	   that	  ribonucleotides	   falsely	   incorporated	   during	   DNA	   synthesis	   are	   removed	   by	  RNase-­‐H2	  and	  the	  remaining	  nick	  can	  be	  used	  as	  strand	  discrimination	  signal	  for	  MMR	   (27,28).	   Also,	   7,8-­‐dihydro-­‐8-­‐oxo-­‐guanine	   (8-­‐oxoG),	   a	   result	   of	   oxidative	  stress,	  when	  incorporated	  into	  the	  newly	  synthesized	  DNA	  strand,	  can	  provide	  a	  signal	   for	   MMR	   when	   removed	   by	   factors	   of	   base	   excision	   repair	   (BER)	   that	  generate	  a	  nick	  in	  the	  DNA	  (29).	  	  
	  
3.3.3 Regulation	  of	  the	  mismatch	  repair	  system	  in	  vivo	  	  Most	  of	  the	  studies	  on	  the	  MMR	  mechanism	  were	  conducted	  in	  cell-­‐free	  systems	  with	   plasmids	   as	   substrates	   for	   MMR.	   This	   helped	   identify	   the	   minimal	  requirements	  for	  MMR	  in	  vitro.	  In	  the	  context	  of	  chromatin,	  however,	  additional	  factors	  for	  efficient	  MMR	  might	  be	  required.	  Following	  this	  line,	  Li	  and	  colleagues	  identified	   an	   MMR-­‐related	   interaction	   of	   MutSα	   with	   the	   histone	   mark	  H3K36me3.	   According	   to	   their	   model,	   MutSα	   is	   recruited	   onto	   chromatin	  through	  interaction	  of	  H3K36me3	  with	  the	  PWWP	  domain	  of	  MSH6	  (30).	  Recent	  data	  suggest	  that	  minichromosome	  maintenance	  complex	  component	  9	  (MCM9)	  plays	  a	  role	  in	  MMR.	  MCM9	  might	  help	  unwind	  the	  DNA	  with	  its	  helicase	  domain	  for	  in	  vivo	  MMR	  (31).	  Other	  studies	  addressed	  the	  question	  of	  how	  MMR	  is	  timed	  in	   the	   context	   of	   chromatin	   assembly.	   MMR	   needs	   nucleosome-­‐free	   DNA	   to	  repair	  replication	  errors.	  Recent	  data	  have	  shown	  that	  MMR	  factors	  travel	  with	  the	   replication	   folk	   (32)	   and	   therefore	   the	   replication	   machinery	   induces	  chromatin	  disassembly,	  which	   is	  needed	   for	  MMR.	  Reassembly	  of	  nucleosomes	  induced	  by	  chromatin	  assembly	  factor	  1	  (CAF-­‐1)	  is	  rapid	  and	  leaves	  only	  a	  250	  bp	   long	   gap	   of	   naked	   DNA,	   which	   might	   not	   be	   enough	   for	   MMR.	   Data	   from	  Schöpf	   et	   al.	   indicate	   that	  MMR	   delays	   nucleosome	   assembly	   by	   interaction	   of	  MutSα	  with	   CAF-­‐1	   (33).	   In	   addition	   to	   timing	   and	   recruiting	  MMR	   factors,	   the	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protein	  levels	  need	  to	  be	  tightly	  regulated.	  One	  mechanism	  is	  deacetylation	  and	  ubiquitination	   of	   MSH2	   by	   histone	   deacetylase	   6	   (HDAC6),	   which	   leads	   to	  degradation	   of	  MSH2	   (34).	  Moreover,	  MSH2	   levels	   are	   regulated	   at	   the	  mRNA	  level	  by	  RNA	  interference	  (RNAi).	  MicroRNA-­‐21	  has	  been	  shown	  to	  be	  a	  potent	  regulator	  of	  MSH2	  mRNA	  levels	  and	  microRNA-­‐155	  has	  been	  found	  to	  negatively	  regulate	  MSH2,	  MSH6	  and	  MLH1	  levels	  (35,36).	  	  	  	  	  	  	  
3.4 The	  role	  of	  mismatch	  repair	  in	  DNA	  damage	  repair	  and	  
response	  As	  the	  name	  suggests,	  the	  main	  function	  of	  the	  mismatch	  repair	  system	  is	  to	  take	  care	   of	   DNA	  mismatches	   that	   occur	   during	   replication	   including	  mispairs	   and	  IDLs.	   However,	   MMR	   factors	   have	   been	   shown	   to	   act	   in	   several	   DNA	   repair	  pathways	  and	  in	  DNA	  damage	  signaling.	  MMR	  was	  shown	  to	  play	  an	   important	  role	   in	  the	  repair	  of	  alkylation	  damage,	  oxidative	  damage	  and	  crosslinks	  within	  the	  DNA	  among	  others	  (37,38).	  In	  addition	  to	  active	  involvement	  in	  the	  repair	  of	  DNA	   lesions,	  MMR	   factors	  mediate	  DNA	  damage	  signaling	  by	  direct	   interaction	  with	  cell	  cycle	  checkpoint	  kinases	  such	  as	  ATR,	  Chk1	  and	  Ck2	  (37,39).	  	  	  
3.4.1 MMR-­‐dependent	  repair	  of	  alkylation	  DNA	  damage	  	  	  Alkylation	  DNA	  damage	  can	  be	   induced	  by	  several	  components,	  which	  are	  also	  among	   the	   oldest	   anticancer	   drugs.	   The	   most	   common	   compounds	   are	  monofunctional	   methylating	   agents	   such	   as	   N-­‐methyl-­‐N'-­‐nitro-­‐N-­‐nitrosoguanidine	   (MNNG),	   N-­‐methyl-­‐N-­‐nitrosourea	   (MNU)	   or	   temozolomide	  (TMZ),	  bifunctional	  alkylating	  agents	   including	  nitrogen	  mustards	  chlorambucil	  and	   cyclophospamide,	   and	   chloroethylating	   agents	   such	   as	   nimustine	   or	  carmustine.	   Unimolecular	   nucleophilic	   substitution	   (SN1)	   type	   methylating	  agents	  such	  as	  MNNG	  or	  MNU	  cause	   the	   formation	  of	  adducts	  at	   the	  N-­‐	  and	  O-­‐atoms	   of	   DNA	   bases.	   More	   than	   80%	   of	   methylated	   bases	   consist	   of	   N-­‐methylation	  adducts	  and	  can	  have	  long	  persistence	  in	  the	  DNA.	  For	  instance,	  N7-­‐methylguanine	   has	   a	   half-­‐life	   of	   more	   than	   80	   h.	   O6-­‐methylguanine	   (MeG)	  accounts	  only	  for	  about	  0.3%	  to	  8%	  of	  methyl	  adducts	  in	  the	  DNA,	  but	  they	  are	  very	   stable	   and	   persist	   in	   the	   DNA	   for	   a	   long	   time	   in	   the	   absence	   of	   O6-­‐
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methylguanine-­‐DNA	   methyltransferase	   (MGMT).	   Other	   adducts	   including	   N3-­‐methyladenine,	   N3-­‐methylcytosine	   and	   O4-­‐methylthymine	   are	   generated	   much	  less	   frequently.	  Different	  DNA	  repair	  mechanisms	  play	  a	  role	   in	   the	  removal	  of	  alkylation	  damage.	  N-­‐alkylated	  bases	  are	  either	  repaired	  by	  BER	  or	  human	  AlkB	  homologues	   (hABH)	   (40).	   O6-­‐	  MeG	   is	   mainly	   repaired	   by	  MGMT.	   In	   a	   one-­‐step	  repair	  process,	  the	  methyl	  group	  is	  transferred	  from	  the	  guanine	  in	  the	  DNA	  to	  a	  cysteine	  in	  the	  catalytic	  pocket	  of	  MGMT	  (41).	  	  	  O6-­‐MeG	   lesions	   that	  are	  not	   repaired	  by	  MGMT,	   for	   instance	   in	  MGMT-­‐deficient	  cells,	   are	   recognized	   as	  mispairs	   by	  MutSα	   (42).	   The	  modification	   takes	   place	  before	   replication	  and	   therefore	  O6-­‐MeG	   is	   found	   in	   the	   template	   strand.	  When	  MMR	  is	  activated,	   it	  will	  ultimately	  degrade	   the	  nascent	  strand	  with	   the	  C	  or	  T	  and	   the	   O6-­‐MeG	   remains	   untouched.	   The	   conclusive	   regeneration	   of	   the	   DNA	  strand	  results	  in	  O6-­‐MeG-­‐C	  or	  O6-­‐MeG-­‐T	  mismatches,	  which	  repeatedly	  reactivate	  MMR	  and	  resynthesis	  of	  the	  nascent	  strand,	  a	  phenomenon	  called	  "futile	  cycling".	  At	   some	  point,	  MMR	  might	  abandon	   the	   lesion	  but	   leaves	  behind	   single-­‐strand	  gaps	  opposite	  O6-­‐MeG,	  which	  could	  cause	  double-­‐strand	  breaks	  (DSB)	  in	  the	  next	  round	   of	   replication	   when	   the	   replication	   fork	   approaches.	   The	   formation	   of	  double-­‐strand	  breaks	  leads	  to	  the	  activation	  of	  ATR	  and	  ATM	  checkpoint	  systems	  followed	  by	  cell	  cycle	  arrest	  in	  G2/M	  (43,44).	  In	  addition,	  persistent	  repair	  of	  the	  O6-­‐MeG	   lesion	   might	   directly	   activate	   ATR	   (45).	   In	   contrast,	   cells	   deficient	   in	  MMR	  are	  not	  able	  to	  recognize	  the	  O6-­‐MeG	  mispairs	  and	  therefore	  do	  not	  undergo	  "futile	  cycling"	  and	  consequent	  ATR	  and	  ATM	  activation.	   In	   fact,	  MMR-­‐deficient	  cells	   are	   up	   to	   100	   times	   more	   resistant	   to	   MNNG	   treatment	   than	   MMR-­‐proficient	  cells	  (13).	  	  
3.4.2 MMR	  in	  intra-­‐	  and	  interstrand	  crosslink	  repair	  	  MMR-­‐deficient	  cells	  are	  slightly	  resistant	  to	  cis-­‐diammine-­‐dichloro-­‐platinum	  (II)	  (CDDP	   or	   known	   as	   cisplatin)	   (46,47).	   Cisplatin	  mainly	   causes	   1,2-­‐intrastrand	  crosslinks	   between	   two	   adjacent	   purines.	   Although	  MutSα	   has	   been	   shown	   to	  bind	   to	   1,2-­‐G-­‐G	   adducts	   (37),	   the	   role	  MMR	  plays	   in	   the	   repair	   of	   these	   lesion	  remains	   largely	   unknown.	   Cisplatin-­‐induced	   intrastrand	   crosslinks	   are	   mostly	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repaired	  by	  nucleotide	  excision	  repair	  (NER)	  and	  cause	  a	  rapid	  S-­‐phase	  cell	  cycle	  arrest.	  Some	  data	  suggest	  that	  MMR	  is	  activated	  by	  mismatches	  occurring	  during	  the	  repair	  of	  1,2-­‐G-­‐G	  adducts	  and	  might	  therefore	  be	  involved	  in	  the	  induction	  of	  the	  cell	  cycle	  arrest	  (39,48).	  	  	  For	   interstrand	   crosslinks	   (ICL),	   the	   picture	   is	   not	   quite	   clear.	   Studies	   using	  MMR-­‐deficient	  cells	  revealed	  higher	  sensitivity	  against	  ICL	  inducing	  mitomycin	  C	  (MMC)	   compared	   to	   their	   matched	   MMR-­‐corrected	   cells	   (49,50).	   In	   contrast,	  studies	   conducted	   with	   RNAi	   revealed	   a	   different	   situation.	   Cells	   with	   MLH1	  knockdown	   behaved	   as	   wt	   or	   were	   slightly	  more	   resistant	   to	   MMC	   treatment	  (51,52).	  In	  some	  cases,	  MSH2	  knockdown	  with	  RNAi	  led,	  however,	  to	  increased	  sensitivity	   (51).	   These	   differences	   suggest	   that	   canonical	  MMR	   is	   not	   essential	  for	  ICL	  repair,	  but	  that	  MMR	  factors	  might	  individually	  contribute	  to	  the	  repair.	  	  	  	  	  	  	  
3.4.3 ICL	  repair	  mechanism	  and	  contribution	  of	  MMR	  factors	  ICLs	   are	   induced	  by	   agents	   such	   as	  MMC	  or	   nitrogen	  mustards,	   but	   also	   occur	  during	   normal	   cell	  metabolism.	   Defects	   in	   ICL	   repair	   result	   in	  Fanconi	  anemia	  (FA),	  which	  is	  characterized	  by	  an	  early	  onset	  of	  cancer,	  mainly	  acute	  leukemia,	  and	  bone	  marrow	   failure	  before	   the	   age	  of	   45.	   In	   addition,	  most	  patients	  have	  congenital	   defects	   such	   as	   short	   stature,	   abnormal	   skin	   and	   developmental	  defects.	  Genetic	  studies	  revealed	  19	  FA	  or	  FA-­‐like	  genes	  such	  as	  FANCA,	  FANCD2	  or	  FANCI.	  In	  addition,	  factors	  from	  other	  DNA	  repair	  pathways	  were	  found	  such	  as	   the	   DSB	   repair	   proteins	   BRCA1	   (FANCS)	   and	   BRCA2	   (FANCD1)	   or	   the	   NER	  endonuclease	  DNA	  repair	  endonuclease	  XPF	  (ERCC4)	  (53).	  	  	  The	   mechanism	   of	   ICL	   repair	   is	   intensely	   discussed	   and	   depends	   on	   the	  recognition	  pattern.	  Nevertheless,	  for	  all	  situations,	  repair	  of	  ICL	  lesions	  is	  a	  two-­‐step	   process	   after	   recognition:	   Firstly,	   the	   ICL	   needs	   to	   be	   unhooked	   in	   one	  strand	  and	  secondly,	  the	  remaining	  adduct	  needs	  to	  be	  removed	  from	  the	  other	  strand.	  In	  replicating	  cells,	  most	  ICLs	  are	  recognized	  by	  approaching	  replication	  forks,	  which	  stall	  at	  the	  lesion.	  The	  FA	  core	  complex	  is	  recruited	  to	  the	  lesion	  and	  FANCD2	  and	  FANCI	  are	  modified	  by	  ubiquitinylation	  and	  phosphorylation	  (53).	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One	  model	   suggests	   that	   the	   leading	  strand	   is	   incised	  by	   the	  MUS81	  structure-­‐specific	   endonuclease	   subunit	   (Mus81)	   -­‐	   essential	   meiotic	   structure-­‐specific	  endonuclease	  1	  (EME1)	  and	  XPF	  -­‐	  Excision	  repair	  cross-­‐complementation	  group	  1	   (ERCC1),	  which	   generates	   a	   DSB	   at	   the	   replication	   fork.	   The	   gap	   is	   filled	   by	  translesion	  synthesis	  (TLS)	  polymerases	  such	  as	  Polζ	  together	  with	  REV1,	  Polκ,	  Polι	  or	  Polη.	  NER	  is	  activated	  to	  remove	  the	  single	  adduct	  and	  to	  fill	   the	  gap	  in	  the	  parental	  strand.	  With	  the	  help	  of	  homologues	  recombination	  (HR),	  the	  stalled	  fork	   is	   reconstructed	   and	  DNA	   replication	  moves	   on.	   In	   a	   situation	  where	   two	  forks	   converge,	   the	   first	   incision	   can	   occur	   on	   either	   strand.	   Again,	   the	   gap	   is	  filled	  by	  TLS	  polymerases.	  NER	  takes	  care	  of	  the	  remaining	  adduct	  and,	  with	  the	  help	  of	  HR,	  the	  replication	  fork	  is	  renewed	  (54,55).	  ICLs	  can	  also	  be	  recognized	  in	  the	   absence	   of	   DNA	   replication,	   either	   in	   the	   DNA	   duplex	   by	   NER	   with	  Xeroderma	   pigmentosum,	   complementation	   group	   C	   (XPC)	   as	   the	   main	  recognition	   factor	   or	   during	   transcription	   by	   a	   stalling	   of	   RNA	   polymerase.	  Xermoderma	  pigmentosum,	  complementation	  group	  G	  (XPG-­‐1)	   incises	  3'	  of	   the	  adduct	  and	  ERCC1	  -­‐	  XPF	  5'	  of	  the	  adduct	  to	  unhook	  the	  ICL.	  TLS	  polymerases	  are	  recruited	  to	  fill	  the	  gapped	  structure.	  In	  the	  second	  repair	  step,	  the	  mono-­‐adduct	  is	   recognized	   by	   a	   complex	   of	   damage-­‐specific	   DNA	   binding	   protein	   1	   and	   2	  (DDB1	  and	  2)	  and	  NER	   is	  recruited	  to	  remove	  the	  adduct	  and	  resynthesize	   the	  DNA	  (56).	  	  	  The	  role	  of	  MMR	  factors	  in	  the	  repair	  process	  is	  still	  under	  discussion.	  MutSα	  has	  been	   associated	   with	   the	   recognition	   of	   ICL	   lesions	   and	   DDR	   signaling,	   while	  another	  model	  predicts	  that	  the	  endonucleolytic	  function	  of	  MutLα	  can	  assist	  in	  the	  unhooking	  of	  ICLs	  at	  stalled	  replication	  forks.	  Alternatively,	  MLH1	  might	  play	  a	   role	   in	   the	   recruitment	   of	   repair	   factors	   (54,56,57).	   MLH1	   was	   shown	   to	  directly	   interact	  with	  FANCJ	  and	  FANCD2/FANCI-­‐associated	  nuclease	  1	   (FAN1)	  (58,59).	  FANCJ	  is	  believed	  to	  be	  the	  preferred	  helicase	  to	  unwind	  the	  DNA	  after	  unhooking	  at	  stalled	  replication	  forks	  before	  DNA	  synthesis	  by	  TLS	  polymerases	  and	   FAN1	   was	   shown	   to	   process	   ICL-­‐like	   structures	   (55,60-­‐62).	   Moreover,	  FANCJ-­‐	  and	  also	  FAN1-­‐deficient	  cells	  are	  hypersensitive	  to	  MMC	  treatment	  (63-­‐65).	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3.4.4 MMR	  in	  oxidative	  DNA	  damage	  and	  signaling	  	  MMR	  repair	   factors	  MSH2	  and	  MSH6	  were	   shown	   to	  play	  an	   important	   role	   in	  the	   removal	   of	   DNA	   lesions	   caused	   by	   oxidative	   stress.	   Although	   the	   primary	  pathway	   of	   oxidative	   damage	   repair	   is	   BER,	   deficiency	   of	   MSH2	   leads	   to	  increased	   levels	  of	  8-­‐oxoG	   in	   the	  DNA.	  An	  explanation	   for	   this	  observation	  was	  given	   by	   the	   Kannouche	   lab	   when	   they	   showed	   that,	   in	   response	   to	   oxidative	  stress,	   cells	  monoubiquitinylate	  PCNA	   to	   recruit	   the	   low-­‐fidelity	  Polη	   to	   repair	  DNA	  lesions,	  which	  is	  dependent	  on	  MutSα	  but	  not	  BER	  (38).	  	  	  Altogether,	  these	  observations	  made	  in	  different	  settings	  of	  DNA	  damage	  hint	  to	  an	  essential	  role	  of	  MMR	  factors	  not	  only	  in	  the	  repair	  of	  replication	  errors,	  but	  also	   in	   other	   aspects	   of	   DNA	   repair.	   In	   addition	   to	   the	   active	   repair	   of	   DNA	  lesions,	  MMR	  proteins	  are	  involved	  in	  DNA	  damage	  signaling.	  Consistent	  binding	  of	  MSH2	   to	  DNA	   lesions,	   even	  without	   repair,	   can	   trigger	   the	   activation	   of	   cell	  cycle	   checkpoints	  by	   activation	  of	  ATR,	  CHK1	  and	  CHK2,	  which	   are	   among	   the	  main	  signaling	  kinases	   in	  DDR	  (39).	  This	  activation	   leads	   to	  cell	   cycle	  arrest	   to	  gain	  time	  for	  repair	  of	  the	  lesions	  or,	  if	  the	  damage	  is	  beyond	  a	  certain	  threshold,	  it	   leads	   to	   apoptosis	   and	   cell	   death.	   Overexpression	   of	   MLH1	   or	   MSH2	   is	  sufficient	  for	  the	  induction	  of	  apoptosis;	  an	  observation	  that	  underlines	  the	  role	  of	  MMR	   factors	   in	   damage	   signaling	   (66).	   The	  molecular	  mechanism	  by	  which	  MMR	  triggers	  apoptosis	  is	  still	  under	  discussion.	  Treatment	  of	  cells	  with	  MNNG	  leads	   to	   phosphorylation	   of	   tumor	   protein	   p53	   (p53)	   at	   serine	   15	   in	   MMR	  proficient	   cells	   and	   is	   reduced	   in	  MMR-­‐deficient	   cells	   (67).	   Also,	   UVB-­‐induced	  phosphorylation	   of	   p53	   and	   induction	   of	   apoptosis	   is	   largely	  MSH2-­‐dependent	  (68).	   However,	   cells	   lacking	   p53	   also	   die	   efficiently	   after	   MNNG	   treatment	   in	  MMR-­‐proficient	  cell	  lines	  which	  indicates	  two	  independent	  pathways	  (69).	  MMR	  was	   also	   implicated	   in	   the	   induction	   of	   tumor	   protein	   p73,	   the	   functional	  homolog	   of	   p53,	   in	   cisplatin-­‐induced	   apoptosis.	   The	   accumulation	   and	  stabilization	  of	  p73	  was	  shown	  to	  depend	  on	  MLH1	  and	  PMS2	  (70,71).	  	  	  In	   summary,	   MMR	   factors	   clearly	   play	   a	   role	   in	   DNA	   damage	   recognition,	   cell	  cycle	  checkpoint	  activation	  and	  cell	  death,	  which	  seem	  to	  be	  independent	  of	  the	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processing	  of	  the	  lesions.	  Interestingly,	  subnormal	  levels	  of	  MutLα	  are	  sufficient	  for	  efficient	  MMR,	  but	  for	  checkpoint	  activation,	  full	  levels	  of	  MLH1	  are	  required	  (72).	  	  	  	  	  	  
3.4.5 Non-­‐canonical	  mismatch	  repair	  as	  a	  source	  of	  mutagenesis	  	  	  	  The	  mismatch	  repair	  system	  evolved	  to	  maintain	  genomic	  integrity	  by	  increasing	  the	   fidelity	  of	  DNA	  replication	  by	   two	  to	   three	  orders	  of	  magnitude.	  Hence,	   the	  idea	  that	  MMR	  might	  be	  involved	  in	  mutagenesis	  appears	  quite	  counterintuitive.	  Still,	  there	  is	  evidence	  that,	  under	  certain	  circumstances	  such	  as	  upon	  alkylating	  or	   oxidative	   damage,	  MMR	   factors	   trigger	   the	   ubiquitinylation	   of	   PCNA,	  which	  ultimately	  leads	  to	  the	  recruitment	  of	  low	  fidelity	  (error-­‐prone)	  polymerase	  Polη	  (38,73).	  Under	  conditions	  of	  DNA	  damage,	  PCNA	  ubiquitination	  and	  subsequent	  Polη	   recruitment	   helps	   the	   cell	   to	   bypass	   lesions	   and	   to	   survive	  massive	   DNA	  damage,	  but	  at	  the	  cost	  of	   increased	  mutation	  rates.	  Not	  only	  DNA	  damage,	  but	  also	  the	  processing	  of	  U-­‐G	  mismatches	  can	  trigger	  the	  ubiquitinylation	  of	  PCNA.	  Uracils	   in	   the	   DNA	   can	   arise	   by	   spontaneous	   deamination	   of	   cytosine	   or	   by	  incorporation	   of	   uridines	   during	   DNA	   replication	   and	   are	   mainly	   repaired	   by	  BER.	   However,	   if	   the	   BER	   pathway	   is	   inhibited,	   MMR	   is	   activated	   by	   U-­‐G	  mismatches	   and	   processes	   the	   lesion	   with	   recruitment	   of	   Polη.	   Because	   non-­‐canonical	  MMR	  is	  mutagenic,	  the	  question	  of	  the	  biological	  function	  besides	  cell	  survival	  arises.	  An	  explanation	  is	  given	  by	  the	  idea	  that	  increased	  mutation	  rates	  in	  B	  cells	  could	  help	  to	  increase	  antibody	  diversity	  during	  B	  cell	  maturation	  (74).	  Recent	   work	   by	   Bregenhorn	   et	   al.	   further	   suggests	   that	   MMR	   plays	   a	   role	   in	  generating	  DSBs	  needed	  for	  class	  switch	  recombination	  during	  B	  cell	  maturation	  (75).	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3.5 Mismatch	  repair	  deficiency	  in	  carcinogenesis	  	  Effective	  MMR	  is	  needed	  to	  maintain	  genome	  stability	  by	  reduction	  of	  mutation	  rates.	   Indeed,	  MMR	  increases	  the	  fidelity	  of	  DNA	  replication	  by	  up	  to	  1000-­‐fold	  (23).	   Constant	   absence	   of	  MMR	   results	   in	   higher	  mutation	   rates	   that	   affect	   all	  regions	   of	   the	   genome.	   Microsatellite	   regions	   are	   particularly	   prone	   to	  mutagenesis	  by	  deletion	  through	  forward	  slippage	  during	  DNA	  replication	  (76).	  The	   mutations	   do	   not	   only	   occur	   in	   non-­‐coding	   regions,	   but	   also	   hit	   coding	  regions.	   Besides	   silent	   mutations,	   missense	   mutations	   that	   change	   the	   amino	  acid,	   non-­‐sense	   mutations	   that	   lead	   to	   truncated	   proteins	   or	   frame	   shift	  mutations	   occur.	   When	   certain	   oncogenes	   or	   tumor	   suppressor	   genes	   are	  affected,	   these	   cells	   can	   acquire	   a	   selective	   advantage	   leading	   to	   increased	  growth	   and	   proliferation	   rates.	   This	   starts	   an	   evolutionary	   process	   which	   can	  mark	  the	  origin	  of	  a	  tumor.	  	  	  Development	   of	   CRC	   is	   one	   of	   the	   best-­‐studied	   models	   of	   tumor	   progression.	  However,	  MMR-­‐dependent	  CRC	  development	  shows	  significant	  differences	  from	  the	   general	   model	   of	   CRC	   development.	   According	   to	   the	   hypothesis	   of	  Vogelstein	   and	   Kinzler,	   general	   CRC	   starts	  with	  mutations	   in	  APC	   or	  β-­‐catenin	  (CTNNB1)	  genes	  followed	  by	  kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog	  (k-­‐Ras),	  
deleted	  in	  colorectal	  carcinoma	   (DCC),	  Mothers	  against	  decapentaplegic	  homolog	  
2	   or	   4	   (Smad2/Smad4)	   and	   finally	   p53	   at	   the	   transition	   from	   adenoma	   to	  carcinoma	   (Figure	   5)	   (77).	   In	   contrast,	   CRCs	   that	   develop	   because	   of	   MMR	  deficiency	  establish	  a	  complex	  signaling	  network	  in	  between	  a	  series	  of	  activated	  and	  inactivated	  pathways	  including	  signal	  transduction	  (TGFβRII,	  IGFIIR,	  PTEN),	  transcription	  regulation	  (TCF4),	  DNA	  repair	  (MSH3,	  MSH6,	  MBD4),	  apoptosis	  and	  inflammation	  (BAX,	  CASP1)	  (78-­‐80).	   In	  humans,	  both	  alleles	  of	  an	  MMR	  gene	  in	  one	  cell	  have	  to	  be	  non-­‐functional	  in	  order	  to	  inactivate	  MMR.	  In	  HNPCC,	  the	  first	  hit	   is	   a	   germline	   mutation	   (inherited	   from	   the	   parents)	   and	   the	   second	   hit	   a	  somatic	  mutation	  or	  LOH.	  In	  sporadic	  cancers,	  however,	  both	  hits	  are	  somatic.	  	  	  	  	  	  	  
Introduction	  




















Figure	  5:	  Development	  of	  colorectal	  cancers	  in	  MMR-­‐proficient	  and	  -­‐deficient	  cells	  In	  MMR-­‐proficient	  epithelial	  cells,	  the	  first	  mutation	  occurs	  in	  the	  APC	  gene,	  followed	  by	  mutations	   in	   K-­‐Ras,	   which	   transforms	   normal	   cells	   and	   gives	   rise	   to	   early	   and	   later	  intermediate	  adenoma,	  respectively.	  Additional	  mutations	  in	  DCC,	  SMAD2	  or	  SMAD4	  and	  
p53	  turn	  the	  lesion	  into	  late	  adenoma	  and	  finally	  into	  carcinoma.	  Normal	  epithelial	  cells	  that	   lose	  MMR	   genes	   develop	   a	   mutator	   phenotype	   and	   acquire	   mutations	   in	   many	  genes,	  but	  with	  mutation	  hotspots	  in	  TGFβRII,	  BAX,	  MSH6,	  MSH3,	  TCF4,	  CASP1	  and	  PTEN.	  Together,	   these	   mutations	   drive	   cancer	   development	   (adapted	   from	   Vogelstein	   and	  Kinzler,	  1993	  and	  Narayan	  and	  Roy,	  2003	  (81)).	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3.5.1 Constitutive	  MMR	  deficiency	  	  In	  HNPCC	  patients,	  only	  one	  allele	  of	  an	  MMR	  factor	  is	  mutated	  and	  a	  second	  hit	  is	  needed	  to	  inactivate	  MMR.	  Thus,	  only	  individual	  cells	  in	  particular	  tissues	  are	  affected	   and	   lead	   to	   tumor	   development.	   However,	   some	   individuals	   carry	   bi-­‐allelic	   germline	  MMR	   gene	  mutations.	   Typically,	   such	   patients	   are	   offspring	   of	  consanguineous	   marriages	   in	   families	   with	   HNPCC	   history.	   Homozygous	  MMR	  gene	  mutations	  are	   associated	  with	  hematological	  malignancies	   and	   symptoms	  of	  neurofibromatosis	  type	  1	  (NF1)	  including	  neurofibromas,	  axillary	  freckles	  and	  café-­‐au-­‐lait	  spots.	  Obviously,	  timing	  of	  the	  inactivation	  has	  a	  large	  impact	  on	  the	  resulting	  phenotype	  and	  on	  the	  genotype	  as	  well	  (80,82).	  It	  appears	  that	  absence	  of	  MMR	   from	   the	   first	   stage	   of	   embryogenesis	   hits	   genes	   that	   are	   particularly	  fragile	  such	  as	  the	  NF1	  gene	  or	  genes	  that	  are	  expressed	  in	  highly	  proliferating	  cells	   like	   hematopoietic	   cells.	   Only	   a	   few	   gastrointestinal	   cancers	   have	   been	  described	  in	  bi-­‐allelic	  carriers.	  A	  possible	  explanation	  is	  given	  by	  the	  fact	  that	  all	  the	   CRCs	   were	   diagnosed	   after	   the	   age	   of	   nine.	   Most	   patients,	   however,	   die	  before	  the	  age	  of	  five	  and	  thus	  gastrointestinal	  malignancies	  do	  not	  have	  time	  to	  develop.	  	  	  The	   phenotype	   of	   mice	   strains	   with	   MMR	   deficiency	   is	   consistent	   with	   the	  development	   of	   tumors	   in	   homozygous	   patients.	   The	  mice	   develop	   lymphoma	  malignancies	  after	   two	   to	   five	  months	  of	  age.	  Gastro-­‐intestinal	   tumors	  are	  rare	  and	  are	  only	  observed	  in	  older	  mice	  (83).	  Mice	  heterozygous	  for	  MMR	  genes	  do	  not	   show	  any	  phenotypes.	   The	  difference	   between	  mice	   and	  humans	  might	   be	  explained	  by	  the	  short	  life	  span	  of	  mice,	  which	  is	  not	  long	  enough	  for	  the	  second	  hit	  to	  occur	  (84).	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3.6 HNPCC-­‐associated	  germline	  mutations	  Genetic	  data	  from	  HNPCC	  patients	  and	  families	  have	  been	  collected	  over	  the	  past	  few	   years	   and	   are	   available	   on	   various	   databases	   including	   InSIGHT	   (16).	   For	  each	  HNPCC	  gene,	  the	  number	  of	  patients	  and	  variants	  as	  well	  as	  information	  on	  the	  variant	   such	  as	  MMR	   function,	  protein	  expression	  or	  protein	   localization	   is	  recorded.	  About	  50%	  of	  the	  individuals	  have	  mutations	  in	  the	  MLH1	  gene	  (6637	  of	   13849)	   followed	  by	  mutations	   in	  MSH2	  with	  37%.	  MSH6	   and	  PMS2	   are	   less	  frequently	  mutated	   (11%	   and	   4%,	   respectively).	   In	   general,	   the	  mutations	   are	  spread	   over	   the	  whole	   sequence	   of	   the	   genes.	   A	  minor	   enrichment	   is	   found	   in	  exons	  1	  and	  16	  in	  MLH1	  and	  exons	  3	  and	  12	  in	  MSH2	  (15).	  The	  majority	  (about	  80%)	  of	  the	  variants	  are	  unique	  in	  a	  way	  that	  they	  are	  found	  in	  only	  one	  HNPCC	  family.	  Missense	  mutations	  account	  for	  over	  40%	  of	  all	  mutations	  in	  MMR	  genes	  (50%	   in	   MLH1	   and	   34%	   in	   MSH2).	   Deletions,	   frame-­‐shift	   and	   nonsense	  mutations	   occur	   together	   in	   about	   30%	   of	   the	   patients	   (6/8%,	   16/19%	   and	  7/11%	  in	  MLH1	  and	  MSH2,	  respectively)	  (16).	  	  	  	  
3.6.1 Variety	  of	  MLH1	  mutations	  in	  HNPCC	  families	  The	  human	  MLH1	  gene	  is	  located	  on	  chromosome	  3,	  spans	  a	  region	  of	  55730	  bp	  and	  consists	  of	  19	  exons.	  The	  transcribed	  mRNA	  has	  2524	  bp	  and	  its	  translation	  results	   in	   a	   protein	  with	   756	   amino	   acids	   and	   a	  molecular	  weight	   of	   84.6	   kDa	  (85,86).	  The	  MLH1	  protein	  can	  be	  divided	  into	  two	  main	  functional	  domains:	  The	  amino	  terminal	  region	  contains	  the	  ATPase	  domain,	  which	  binds	  and	  hydrolyzes	  ATP,	   and	   the	  MutS	   homologs	   interaction	   domain;	   the	   carboxy	   terminal	   region	  consists	   of	   binding	   sites	   for	  PMS2,	   EXO1	  and	  other	  MutL	  homologs	   (Figure	  6).	  The	  interaction	  sites	  for	  PMS2	  are	  particularly	  important,	  because	  dimerization	  with	  PMS2	   results	   in	   the	   formation	   of	  MutLα,	   one	   of	   the	  main	   factors	   in	  MMR	  (87-­‐89).	   The	   last	   13	   aa	   form	   the	   C-­‐terminal	   homology	   (CTH)	   motif,	   which	   is	  highly	  conserved	   in	  eukaryotes.	  Crystal	  structures	  of	  yeast	  MLH1	  revealed	  that	  the	  CTH	  motif	  is	  closely	  packed	  against	  PMS1	  (PMS2	  homolog	  in	  yeast)	  and	  that	  the	  last	  yeast	  MLH1	  residue,	  Cys	  769,	  participates	  in	  the	  PMS1	  metal-­‐binding	  site	  and	   hence	   contributes	   to	   the	   endonuclease	   function	   (90).	   Missense	  mutations	  that	  affect	  the	  function	  of	  MLH1	  are	  found	  mainly	  in	  ATPase	  or	  PMS2	  interaction	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domains	   (11).	   Once	   an	   HNPCC	   family	   has	   been	   identified	   according	   to	   the	  Amsterdam	   criteria	   or	   Bethesda	   guidelines,	   genetic	   analysis	   is	   conducted	   to	  identify	   the	   underlying	   mutation	   (91).	   As	   a	   next	   step,	   functional	   testing	   is	  required	   to	  clarify	   the	  pathogenicity	  of	   the	  mutation.	  A	  wide	  range	  of	  methods	  has	   been	   used	   over	   the	   years	   to	   characterize	   patient	   MMR	   gene	   variants	  including	   testing	   of	   patient	   samples	   such	   as	   immunohistochemistry,	   genetic	  studies	   in	   yeast	   to	   identify	   mutator	   phenotypes,	   in	   vitro	   MMR	   assay	   and	  expression	  in	  human	  cell	  lines	  to	  analyze	  the	  expression	  pattern	  and	  location	  of	  the	  variant	   (11,92-­‐94).	  For	   the	  majority	  of	   the	  variants,	   these	   techniques	  were	  suitable	   to	   explain	   the	   pathogenicity	   of	   the	   mutation.	   For	   example	   the	   MLH1	  variants	  K84E	  and	  F80V	  show	  stable	  protein	  expression	  but	  are	  MMR-­‐deficient	  in	   in	   vitro	   MMR	   assay	   (11).	   Because	   both	   mutations	   lie	   within	   the	   ATPase	  domain,	  it	  seems	  that	  they	  negatively	  affect	  the	  ATPase	  function	  of	  MLH1,	  though	  this	   has	   not	   been	   proven.	   In	   contrast,	   in	   the	   variants	   S247P	   and	   H329P,	   the	  mutations	   are	   outside	   of	   functional	   domains,	   but	   still	   cause	   strong	  MSI.	  When	  expressed	   in	   human	   293T	   cells,	   strongly	   reduced	   protein	   levels	   could	   be	  observed.	  Mutations	  located	  in	  the	  PMS2	  interaction	  domain	  were	  found	  to	  cause	  deficiency	   in	   binding	   to	   PMS2,	   which	   prevents	   the	   formation	   of	   the	   MutLα	  complex	   and	   consequently	   impairs	  MMR	  activity.	   There	   are,	   however,	   variants	  for	  which	  the	  pathogenicity	  has	  not	  been	  clarified	  yet.	  One	  of	  those	  is	  the	  mutant	  R659Q.	  Although	  the	  variant	  has	  been	  identified	  in	  24	  patients	  with	  early	  onset	  of	  CRC,	  the	  molecular	  pathology	  is	  still	  unclear	  (11,12,16,95).	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3.6.2 Clinical	  studies	  to	  identify	  MMR	  gene	  mutations	  predisposing	  for	  
HNPCC	  	  Once	  a	  mutation	  has	  been	  identified	  in	  an	  HNPCC	  patient	  and	  their	  family,	  it	  is	  of	  significant	  importance	  to	  gain	  information	  about	  its	  molecular	  pathogenicity.	  It	  is	  required	   to	   verify	   that	   the	   mutation	   is	   indeed	   the	   cause	   of	   HNPCC	   in	   the	  respective	   family,	  which	   provides	   essential	   information	   to	   screen	   other	   family	  members.	  Moreover,	  it	  helps	  to	  estimate	  the	  risk	  of	  each	  patient	  and	  might	  even	  help	   to	   develop	   specialized	   treatment	   options	   for	   each	   family,	   a	   process	   also	  known	   as	   personalized	   medicine.	   Before	   the	   functional	   characterization	   of	  genetic	   variants,	   segregation	   studies	  were	   conducted	   to	  distinguish	  pathogenic	  mutations	   from	   polymorphisms.	   Those	   studies	   try	   to	   segregate	   an	   amino	   acid	  change	   with	   the	   phenotype	   of	   the	   family,	   which	   indicates	   that	   a	   variant	   is	   a	  pathogenic	  mutation	   but	   does	   not	   prove	   it.	   Only	   in	   the	   case	   of	  mutations	   that	  bring	  about	  premature	  termination	  of	  translation	  by	  the	  creation	  of	  stop	  codons	  can	  the	  molecular	  mechanism	  be	  anticipated.	  However,	  functional	  testing	  might	  still	  be	  required.	  In	  HNPCC,	  patient	  numbers	  for	  each	  variant	  are	  very	  small	  and	  a	  lack	  of	  clinical	  samples	  makes	  it	  difficult	  to	  conduct	  reliable	  segregation	  studies	  (8,14).	  	  	  	  The	  main	  molecular	   feature	   of	   HNPCC	   is	  MMR	   deficiency,	  which	   leads	   to	  MSI.	  Hence,	  tumor	  samples	  provide	  essential	  information.	  Specimens	  of	  colon	  cancers	  are	  checked	  for	  MSI	  and	  putative	  HNPCC	  patients	  are	  chosen	  for	  further	  studies,	  if	  they	  fulfill	  Bethesda	  guidelines	  developed	  by	  the	  InSiGHT	  study	  group:	  1)	  The	  patient	   was	   diagnosed	   with	   CRC	   before	   the	   age	   of	   50;	   2)	   Presence	   of	  synchronous,	   metachronous	   colorectal	   or	   any	   other	   HNPCC-­‐associated	   tumors	  regardless	  of	  age;	  3)	  CRC	  with	  MSI-­‐high	  status	  in	  a	  patient	  younger	  than	  60;	  4)	  CRC	  diagnosed	  at	   least	   in	  one	   first	  degree	   relative	  with	  HNPCC-­‐related	   tumors	  with	  one	  of	  the	  cancers	  being	  diagnosed	  before	  the	  age	  of	  50;	  5)	  CRC	  diagnosed	  in	   at	   least	   two	   first-­‐	   or	   second-­‐degree	   relatives	   with	   HNPCC-­‐related	   tumor	  independent	   of	   age	   (14).	   For	   MSI	   analysis,	   the	   National	   Cancer	   Institute	  microsatellite	  marker	   panel	   also	   known	   as	   Bethesda	   panel	   is	  widely	   used	   and	  contains	   five	  markers.	   According	   to	   the	   number	   of	   unstable	  markers,	   the	  MSI	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phenotype	  is	  classified	  as	  high	  in	  the	  case	  of	  at	  least	  2/5	  or	  40%,	  low	  in	  the	  case	  of	  1/5	  or	  20%	  and	  stable,	  if	  none	  of	  the	  markers	  is	  unstable.	  MSI	  is	  observed	  in	  about	   15-­‐25%	   of	   sporadic	   colorectal	   and	   endometrial	   cancers	   and	   more	   than	  90%	  of	  CRCs	  with	  MSI-­‐high	  are	  sporadic	  tumors.	  In	  sporadic	  cancers,	  epigenetic	  silencing	   of	  MLH1	   by	   promoter	  methylation	  mostly	   causes	  MSI.	   In	  HNPCC,	   the	  affected	   gene	   influences	   the	   MSI	   status:	   Mutations	   in	   MSH2,	   MLH1	   or	   PMS2	  usually	  show	  high	  MSI,	  while	  mutations	  in	  MLH3	  and	  MSH6	  result	  in	  variable	  MSI	  status	  from	  stable	  to	  high	  (15).	  	  	  Besides	  MSI	  analysis,	   tumor	  samples	  have	  been	  used	   for	   immunohistochemical	  (IHC)	  studies.	  IHC	  allows	  for	  the	  detection	  of	  a	  protein	  in	  a	  tissue	  with	  the	  help	  of	  antibodies	   and	   can	   provide	   information	   about	   the	   pathogenicity	   of	   a	   certain	  mutation.	   For	   instance,	   the	   absence	   of	   MMR	   factors	   in	   IHC	   hint	   towards	   a	  mutation	  that	  truncates	  the	  protein,	  affects	  the	  stability	  or	  other	  modes	  of	  gene	  silencing	   such	   as	   inactivating	   methylation.	   While	   IHC	   for	   MSH2	   has	   been	  successfully	  established	  in	  many	  laboratories	  and	  proven	  to	  be	  reliable,	  IHC	  for	  MLH1	   is	   more	   variable	   and	   it	   seems	   more	   difficult	   to	   interpret	   the	   results	  (96,97).	   To	   overcome	   these	   limitations,	   additional	   assays	   were	   developed	   to	  study	  the	  phenotype	  of	  mutations	  found	  in	  patients	  with	  a	  focus	  on	  those	  that	  do	  not	  cause	  premature	  termination.	  	  	  
3.6.3 Functional	  studies	  of	  HNPCC-­‐related	  mutations	  Several	   methods	   have	   been	   developed	   to	   study	   the	   phenotype	   of	   a	   given	  mutation	   in	   MMR	   genes	   and	   to	   provide	   information	   about	   the	   molecular	  pathogenicity.	   As	   the	   functional	   characterization	   is	   obvious	   for	  mutations	   that	  cause	  truncation	  of	  a	  protein,	  those	  methods	  were	  designed	  to	  study	  mutations	  that	  cause	  amino	  acid	  replacements	  and	   for	  which	   the	  phenotype	   is	  difficult	   to	  anticipate.	  	  	  The	  first	  assays	  to	  study	  the	  phenotype	  of	  MLH1	  mutations	  were	  established	  in	  
Saccharomyces	  cerevisiae.	  The	  first	  assay	  utilized	  the	  expression	  of	  human	  MLH1	  wt	  cDNA	  in	  MMR-­‐proficient	  yeast	  strains,	  which	  resulted	  in	  a	  dominant	  mutator	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effect	  judged	  by	  mutations	  in	  reporter	  genes	  for	  frameshift	  mutations,	  caused	  by	  the	   interaction	   of	   hMLH1	   with	   the	   yeast	   MMR	   system.	   The	   introduction	   of	  selected	  MLH1	  variants	  did	  not	  cause	  the	  mutator	  phenotype,	  which	  indicated	  a	  malfunctioning	  protein	  (93).	  	  The	  second	  yeast	  system	  utilized	  mutations	  in	  the	  yeast	   genome.	   Haploid	   as	  well	   as	   diploid	   heterozygous	   strains	  were	   analyzed.	  Interestingly,	   increased	   mutation	   rates	   in	   diploid	   strains	   were	   only	   observed	  when	  the	  wt	  allele	  was	  lost,	  which	  is	  consistent	  with	  observations	  in	  patients	  and	  indicates	   a	   dominant	   phenotype	   of	   the	   wt	   allele	   over	   the	   mutants.	   A	   clear	  advantage	   of	   the	   second	   system	  was	   the	   analysis	   of	   a	   yeast	   protein	   in	   a	   yeast	  system,	   which	   strongly	   improved	   the	   homology	   and	   the	   physiology	   of	   the	  system.	   Unfortunately,	   in	   this	   system	   only	   mutations	   that	   altered	   conserved	  residues	   between	   yeast	   and	   human	   could	   be	   studied	   (92).	   This	   drawback	  was	  overcome	  by	   a	   constructed	  human-­‐yeast	   hybrid	  MLH1	  protein	   introduced	   into	  yeast	  (98).	  	  	  Another	  approach	  to	  study	  the	   influence	  of	  MMR	  gene	  mutations	  was	  based	  on	  glutathione-­‐s-­‐transferase	   (GST)	   pulldowns.	   GST	   fusion	   proteins	   with	   either	  MLH1	  or	  MSH2	  were	  created	  to	  test	  the	  complex	  formation	  of	  MutLα	  or	  MutSα,	  respectively	  (99,100).	  Although	  this	  assay	  is	  capable	  of	  detecting	  mutations	  that	  abrogate	   MutLα	   or	   MutSα	   formation,	   it	   fails	   to	   identify	   mutations	   that	   affect	  MMR	  function	  in	  another	  way,	  such	  as	  ATP	  metabolism	  or	  substrate	  interaction.	  Also,	   co-­‐immunoprecipitation	   (Co-­‐IP)	   methods	   were	   used	   to	   study	   the	  interactions	  of	  MMR	  factors	  MLH1,	  MSH2	  and	  MSH6	  (101-­‐103).	  	  As	  it	  is	  laborious	  to	  create	  and	  analyze	  large	  numbers	  of	  MMR	  variants	  for	  GST	  pulldowns	  and	  Co-­‐IPs,	   Kondo	   and	   colleagues	   developed	   a	   yeast	   two-­‐hybrid	   system	   to	   study	   the	  interaction	   of	   many	  MLH1	   variants	   with	   PMS2	   and	   EXO1	   (104).	   Interestingly,	  they	   found	  that	  also	  mutations	   in	  the	  N-­‐terminal	  region	  of	  MLH1	  abolished	  the	  interaction	  with	   PMS2	   and	   EXO1,	  which	   is	   contradictory	   to	   previous	   data	   that	  localize	  the	  interaction	  domain	  to	  the	  C-­‐terminus	  (87,100,105).	  	  	  A	  very	  elegant	  method	  to	  study	  the	  function	  of	  MLH1	  variants	  is	  provided	  by	  the	  
in	   vitro	   MMR	   assay.	   Originally,	   nuclear	   extracts	   from	   cell	   lines	   were	   used	   to	  correct	  DNA	  heteroduplexes	  (106,107).	  Later,	  it	  was	  found	  that	  the	  extracts	  can	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be	  complemented	  with	  either	  recombinant	  MMR	  proteins	  or	  whole	  cell	  extracts	  (108-­‐110).	   The	   in	   vitro	   reconstituted	   system	   developed	   by	   the	   group	   of	   Paul	  Modrich	  provides	  another	  method	  to	  study	  the	  function	  of	  MMR	  factor	  mutants	  (24).	   To	  date,	   the	   in	  vitro	  MMR	  assay	  has	  proven	   to	   be	   the	  most	   sophisticated	  technique,	  as	  it	  gives	  information	  about	  the	  ability	  to	  perform	  MMR	  in	  a	  human	  system.	   However,	   it	   cannot	   provide	   information	   about	   the	   reason	   for	   MMR	  deficiency	   such	   as	   ATPase	   deficiency,	   interaction	   deficiency	   or	   protein	  localization	  errors.	  	  	  Over	   the	   course	   of	   time,	  many	  different	  methods	  were	  developed	   to	   study	   the	  phenotype	  of	  MMR	  gene	  mutations	  with	  the	  in	  vitro	  MMR	  assay	  regarded	  as	  the	  most	   informative	   one	   when	   it	   comes	   to	   clinical	   usage.	   However,	   none	   of	   the	  systems	   alone	   is	   capable	   of	   providing	   comprehensive	   information	   about	   all	  aspects	  of	  a	  given	  mutation	  that	  leads	  to	  HNPCC.	  So	  far,	  only	  the	  combination	  of	  different	  methods	  was	  sufficient	  to	  classify	  the	  vast	  majority	  of	  MLH1	  variants	  as	  pathogenic	   or	   non-­‐pathogenic.	   However,	   for	   many	   variants,	   e.g.	   R659Q,	   the	  classification	   is	   still	   uncertain	   and	   it	   requires	   more	   investigation	   or	   the	  development	  of	  new	  systems	  to	  study	  the	  phenotype	  (11,12,16,95).	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3.7 The	  MLH1	  interactome	  −	  methods	  and	  implications	  Although	   the	   techniques	   described	   above	   helped	   to	   understand	   the	  molecular	  pathogenicity	  of	  many	  HNPCC	  families,	   the	  focus	  was	  mainly	  on	  the	  function	  of	  MLH1	   in	  MMR.	  However,	  MMR	   genes	   have	   also	   been	   shown	   to	   play	   important	  roles	   in	   other	   aspects	   of	   DNA	   repair	   (13,54,59).	   The	   function	   or	   the	   mode	   of	  action	  of	  a	  given	  protein	  can	  often	  be	  anticipated	   if	   its	   interacting	  proteins	  are	  known.	   For	   MMR	   factors,	   several	   studies	   were	   conducted	   to	   identify	   new	  interaction	   partners	   and	   a	   wide	   range	   of	  methods	   has	   been	   applied	   including	  yeast	   and	   bacteria	   two-­‐hybrid	   screens,	   pulldowns	   and	   Co-­‐IPs	   combined	   with	  Western	  Blot	  or	  mass	   spectrometry	   (58,100,104,109,111).	  The	   results	  of	   those	  efforts	  associated	  MMR	  genes	  with	  other	  DNA	  repair	  pathways	  such	  as	  oxidative	  damage	  or	  ICL	  repair.	  But	  also	  interactions	  with	  proteins	  that	  are	  not	  primarily	  involved	  in	  DNA	  repair	  have	  been	  observed.	  For	  instance,	  an	  interaction	  of	  MLH1	  with	  Actin	  has	  been	  observed	  and	  further	  studies	  suggest	  a	  role	  in	  cytoskeleton	  organization	  (111).	  	  	  	  
3.7.1 Two-­‐hybrid	  systems	  	  The	  two-­‐hybrid	  system	  initially	  developed	  by	  Fields	  and	  Song	   in	  1989	   is	  based	  on	  two	  fusion	  proteins	  derived	  from	  the	  transcription	  factor	  GAL4	  (112).	  Protein	  X	  is	  fused	  to	  the	  DNA-­‐binding	  domain	  (BD)	  of	  GAL4	  that	  binds	  to	  Gal	  upstream	  activating	   sequence	   (UASG)	   sequences,	   while	   protein	   Y	   is	   fused	   to	   the	  transcriptional	  activator	  domain	  (AD).	  Only	  if	  X	  and	  Y	  can	  form	  a	  stable	  complex	  is	  the	  transcriptional	  activator	  domain	  recruited	  to	  the	  DNA	  and	  transcription	  of	  the	   reporter	   gene	   downstream	  of	  UASG	   occurs.	   Although	   the	  method	   has	   been	  applied	  in	  other	  organisms	  such	  as	  E.	  coli	   (113),	   for	  protein-­‐protein	  interaction	  screens	  mostly	  yeast	   is	  used.	   In	  principle,	   the	  protein	  of	   interest	   referred	   to	  as	  "bait"	  is	  fused	  to	  the	  BD,	  and	  a	  cDNA	  expression	  library	  encoding	  "prey"	  or	  "hit"	  proteins	   is	   fused	   to	   the	  AD.	  Both	   plasmids	   are	   introduced	   simultaneously	   and,	  upon	  interaction,	  the	  reporter	  gene	  is	  expressed.	  Most	  screens	  are	  based	  on	  cell	  survival.	   A	   mutant	   strain	   is	   used	   that	   is	   lacking	   an	   important	   enzyme	   for	   the	  biosynthesis	  of	  certain	  nutrients	  (amino	  acids	  or	  nucleic	  acids).	  If	  this	  mutant	  is	  grown	  on	  media	  without	   those	  nutrients,	   it	   fails	   to	   survive,	   unless	   the	  missing	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factor	   is	   expressed	   because	   of	   the	   hybrid	   system.	   Surviving	   cells	   are	   analyzed	  and	   implicate	   an	   interaction	   of	   the	   bait	   protein	   with	   the	   prey	   protein	   (114).	  Table	  1	  shows	  MLH1	  interaction	  partners	  that	  were	  identified	  using	  two-­‐hybrid	  systems.	  	  	  	  	  	  	  
Protein	   Role	  
BLM	   Bait/Hit	  
EXO1	   Bait/Hit	  
MBD4	   Prey	  
MLH3	   Bait/Hit	  
MSH3	   Prey	  
MYC	   Bait/Hit	  
ORC4	   Bait/Hit	  
PMS1	   Prey	  
PMS2	   Bait/Hit	  	  
Table	  1:	  MLH1	  interacting	  proteins	  that	  were	  identified	  using	  two-­‐hybrid	  system	  (87,111,115-­‐120).	  	  	  
3.7.2 Pulldown	  assays	  and	  mass	  spectrometry	  Genetic	   studies	  and	   the	   in	  vitro	   reconstituted	  system	  helped	   to	  understand	   the	  mechanism	   of	   MMR.	   It	   was	   anticipated	   that	   most	   factors	   identified	   in	   those	  studies	  would	  interact	  with	  each	  other.	  Indeed,	  when	  pulldowns	  and	  Co-­‐IPs	  were	  performed,	   interaction	  of	  MutSα	  with	  MutL	   complexes	   could	  be	  verified	   (121).	  Also,	   the	   interaction	   of	   MutS	   as	   well	   as	   MutL	   complexes	   with	   EXO1	   could	   be	  shown	  using	  the	  glutathione	  S-­‐transferase	  (GST)	  pulldown	  system	  (105,122).	  	  In	  Co-­‐IP	   assays,	   antibodies	   are	   used	   to	   capture	   specific	   proteins.	   Later	   on,	   the	  antibodies	  with	  the	  bound	  protein	  complexes	  are	  purified	  from	  cell	  extracts	  with	  Protein	  A-­‐	  or	  G-­‐	  coupled	  resins.	   In	  contrast,	  pulldown	  assays	  are	  based	  on	  tags	  fused	   to	   the	   protein	   of	   interest.	   GST-­‐,	   Flag-­‐,	   human	   influenza	   hemagglutinin	  	  	  (HA-­‐)	  and	  histidine	  (His-­‐)	  tags	  are	  among	  the	  most	  prominent	  ones.	  Instead	  of	  an	  antibody	  and	  Protein	  A	  or	  G	  coupled	  resins,	  molecules	  with	  high	  affinity	   to	   the	  tag	   coupled	   to	   resins	   are	  used.	   For	   instance,	  GST	  binds	   strongly	   to	   glutathione	  (GSH)	   and	   a	  matrix	   coupled	  with	   GSH	   is	   used	   for	   affinity	   purification	   of	   GST-­‐tagged	  fusion	  proteins	  and	   its	   interaction	  partners.	  The	  purified	  complexes	  can	  be	   separated	   by	   sodium	   dodecyl	   sulfate	   (SDS)	   polyacrylamide	   gel	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electrophoresis	  (PAGE)	  and	  specific	  proteins	  can	  be	  detected	  using	  Western	  Blot.	  Co-­‐IPs	  and	  pulldown	  assays	  were	  used	  to	  show	  the	  interaction	  of	  MSH6	  with	  the	  chromatin	  assembly	  factor	  CAF-­‐1	  and	  the	  histone	  mark	  H3K36me3	  (30,33).	  The	  combination	  of	  Co-­‐IPs	  or	  pulldowns	  and	  Western	  Blot,	  however,	  only	  allows	  for	  the	   identification	   of	   proteins	   one	   has	   been	   looking	   for,	   but	   it	   is	   not	   suited	   to	  identify	  unexpected	  or	  totally	  unknown	  interaction	  partners.	  This	  limitation	  has	  been	  overcome	  when	  pulldown	  assays	  were	  combined	  with	  mass	  spectrometric	  analysis.	  	  Mass	  spectrometry	  provides	  a	  very	  powerful	  tool	  to	  identify	  unknown	  proteins.	  When	   pulldown	   assays	   and	   mass	   spectrometry	   are	   combined,	   referred	   to	   as	  affinity	  purification	  mass	  spectrometry	  (AP-­‐MS),	  prey	  proteins	  can	  be	  identified.	  After	  purification	  of	   the	  complexes	  with	   the	   tagged	  bait	  protein,	   the	  mixture	   is	  digested	   with	   proteinases	   and	   the	   remaining	   peptides	   can	   be	   identified.	  Alignment	  of	  the	  peptides	  to	  databases	  provides	  information	  about	  the	  proteins	  that	  were	  bound	  to	  the	  bait	  protein	  and	  are	  considered	  as	  potential	  interactors.	  Cannavo	   et	   al.	   used	   TAP-­‐tagged	   MLH1	   and	   PMS2	   to	   characterize	   the	   MutLα	  interactome	  (58).	  Table	  2	  provides	  an	  overview	  of	  proteins	  that	  were	  identified	  as	  MLH1	  interactors	  using	  AP-­‐MS.	  	  	  	  	  
Protein	   Role	  
ATAD3A	   Hit	  
ATAD3B	   Hit	  
BLM	   Bait	  
BRCA1	   Hit	  
FANCJ	   Bait	  
EXO1	   Hit	  
FAN1	   Bait/Hit	  
MMS19	   Bait	  
MSH3	   Hit	  
PMS1	   Hit	  
PMS2	   Bait/Hit	  
PP2A	   Hit	  
P2BB	   Hit	  
RUVBL1	   Hit	  
RUVBL2	   Hit	  
	  
Table	  2:	  MLH1	  interacting	  proteins	  that	  were	  identified	  using	  AP-­‐MS	  (58,59,123-­‐127).	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  Although	  many	   interactors	   of	  MMR	   factors	   have	   been	   identified,	   the	   biological	  role	   of	   most	   of	   those	   interactions	   remains	   enigmatic	   and	   requires	   further	  investigation.	   Moreover,	   it	   is	   largely	   unknown	   in	   which	   pathways	   a	   certain	  interaction	  plays	  a	  critical	  role.	  Only	  a	  detailed	  study	  of	  the	  interactome	  of	  MMR	  factors	  in	  different	  aspects	  of	  DNA	  metabolism	  might	  help	  to	  decipher	  the	  many	  MMR	  interaction	  networks	  and	  to	  put	  them	  into	  functional	  context.	  In	  addition	  to	  the	   well-­‐established	   methods,	   novel	   techniques	   might	   provide	   a	   promising	  approach.	   One	   possibility	   is	   the	   application	   of	   the	   BioID	   system	   developed	   by	  Roux	  and	  colleagues	  (128).	  The	  principle	  of	  BioID	  relies	  on	  a	  promiscuous	  BirA	  ligase,	   which	   generates	   reactive	   biotin	   that	   can	   bind	   to	   all	   proteins	   in	   close	  proximity.	  When	  the	  BirA	   ligase	   is	   fused	  to	  a	  protein	  of	   interest,	   its	   interaction	  partners	  become	  labeled	  with	  biotin	  and	  can	  later	  be	  isolated	  with	  streptavidin-­‐	  coated	   resins.	   The	   Ting	   lab	   developed	   another	   interesting	   method;	   a	   mutated	  APEX	   peroxidase	   that	   generates	   reactive	   biotin-­‐phenol	  which	   can	   also	   bind	   to	  nearby	  proteins	  (129).	  Again,	  a	  fusion	  protein	  could	  be	  used	  to	  label	  interaction	  partners	  of	  a	  given	  protein.	  	  	  
A"BioID" B"APEX*
	  
Figure	  7:	  Principles	  of	  BioID	  and	  APEX	  (A)	  BirA*	  tagged	  to	  bait	  protein	  generates	  reactive	  biotin	  that	  binds	  to	  proteins	  in	  close	  proximity.	  Bioinylated	  proteins	  are	  isolated	  with	  streptavidin	  resins	  and	  are	   identified	   by	   mass	   spectrometric	   analysis.	   (B)	   APEX	   protein	   with	  mitochondria	  localization	  signal	  generates	  reactive	  biotin-­‐phenoxyl	  radicals	  that	  bind	   to	   proteins	   in	   close	   proximity.	   Labeled	   endogenous	   proteins	   are	   isolated	  and	  analyzed	  by	  MS	  (from	  Roux	  et	  al.,	  2012	  and	  Rhee	  et	  al.,	  2013).	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4 Aims	  of	  the	  Thesis	  Many	   studies	   have	   been	   conducted	   to	   study	   the	   phenotype	   of	   gene	   variants	  found	   in	  patients	  with	  different	  hereditary	  diseases.	  Despite	   a	   lot	  of	   effort	   and	  the	   development	   of	   several	   methods,	   not	   all	   mutations	   could	   be	   classified	   as	  pathogenic	  or	  non-­‐pathogenic.	  The	  first	  part	  of	  the	  present	  study	  aims	  to	  develop	  a	  universal	   tool	  suitable	   to	  study	  the	  phenotype	  of	  mutations	   found	   in	  patients	  with	   different	   diseases.	   The	   new	   system	   will	   be	   used	   to	   study	   the	   R659Q	  mutation	  of	  MLH1	  found	  in	  HNPCC	  patients,	  which	  is	  of	  uncertain	  classification.	  The	  specific	  aims	  of	  the	  first	  part	  are	  as	  follows:	  	  -­‐	  Development	  of	  a	  general	  system	  to	  study	  the	  phenotype	  of	  germline	  mutations	  suitable	  for	  various	  diseases	  -­‐	   Application	   of	   the	   system	   to	   study	   the	   phenotype	   of	   the	   HNPCC-­‐associated	  MLH1	  R659Q	  mutation	  	  	  In	   the	  second	  part,	   this	   thesis	   focuses	  on	  the	  development	  of	  methods	  to	  study	  the	   interaction	   of	   MMR	   factors	   in	   different	   aspects	   of	   DNA	   metabolism.	   The	  rationale	   for	   this	   investigation	   is	   given	  by	   the	   fact	   that	  most	  of	  what	   is	   known	  about	  MLH1	  came	  from	  in	  vitro	  data	  and	  focused	  mainly	  on	  canonical	  MMR.	  With	  this	   study,	  we	  aim	   to	   identify	  new	   interaction	  partners	  of	  MLH1	   in	  vivo	   and	   in	  other	   DNA	   repair	   pathways	   such	   as	   non-­‐canonical	   MMR	   and	   ICL.	   Different	  approaches	   will	   be	   tested	   to	   identify	   stable	   interaction	   partners,	   transient	  interaction	  partners	  and	  factors	  that	  change	  upon	  induction	  of	  DNA	  damage.	  The	  specific	  aims	  of	  the	  second	  part	  are	  as	  follows:	  	  -­‐	   Generation	   of	   different	   systems	   to	   study	  protein	   interactions	   including	  BioID	  and	  APEX	  -­‐	  Interaction	  studies	  using	  mass	  spectrometry	  -­‐	  Follow-­‐up	  of	  promising	  candidates	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5 Material	  and	  Methods	  	  
5.1 Protein	  replacement	  with	  all-­‐in-­‐one	  plasmids	  The	   all-­‐in-­‐one	   plasmid	   (pAIO)	   system	   provides	   an	   easy	   and	   reliable	   way	   to	  replace	   an	   endogenous	   protein	   with	   a	   protein	   variant	   such	   as	   a	   mutant	   or	   a	  tagged	  protein.	  The	  first	  pAIO	  system	  developed	  in	  the	  Jiricny	  group	  combines	  in	  one	  plasmid	  a	  cassette	  expressing	  a	  short-­‐hairpin	  RNA	  (shRNA)	  to	  knock	  down	  the	  endogenous	  mRNA	  by	  RNAi	  and	  a	  second	  cassette	  expressing	  a	  cDNA,	  which	  allows	   for	   simultaneous	   expression	   of	   a	   gene	   variant	   (130).	   The	   shRNA	   is	  expressed	  from	  an	  H1	  promoter	  that	  belongs	  to	  the	  RNA	  polymerase	  III	  class	  of	  promoters	   that	   drive	   the	   expression	   of	   short	   RNAs	   (e.g.	   rRNA	   and	   tRNA)	   and	  were	   shown	   to	   have	   ubiquitous	   robust	   activity	   in	   a	  wide	   range	   of	   cell	   lines.	   A	  CMV	   promoter,	   a	   widely	   used	   RNA	   polymerase	   II	   promoter,	   drives	   the	  expression	   of	   the	   cDNA.	   Importantly,	   both	   promoters	   contain	   tet	   repressor	  binding	   sites:	   one	   in	   the	   H1	   promoter	   and	   two	   in	   the	   CMV	   promoter,	  respectively.	   These	   are	   of	   great	   value,	   as	   they	   allow	   for	   the	   induction	   of	   the	  system	  in	  cells	  that	  express	  the	  tet	  repressor	  such	  as	  T-­‐REx-­‐293.	  In	  addition,	  the	  plasmid	  contains	  a	  Puromycin	  cassette,	  which	  is	  used	  for	  the	  selection	  of	  stable	  cell	   lines.	  This	   first	   version	  of	   the	   system	  was	  used	   to	   replace	   the	   endogenous	  Polδ	  subunit	  p125	  with	  variants	  that	  affect	  its	  function.	  Indeed,	  induction	  of	  the	  system	   led	   to	  higher	  mutation	  rates	  when	   the	  p125	  subunit	  was	  replaced	  with	  either	  an	  error-­‐prone	  variant	  or	  a	  proofreading-­‐deficient	  variant	  and	  was	  even	  stronger	  in	  the	  double	  mutant.	  These	  experiments	  showed	  that	  the	  system	  works	  reliably	  in	  the	  replacement	  of	  endogenous	  proteins	  with	  variants.	  	  	  Although	  the	  first	  version	  of	  the	  pAIO	  system	  worked	  efficiently,	   it	  expierenced	  some	  drawbacks,	  which	  could	  be	  overcome	  by	  improvements	  to	  the	  plasmid.	  The	  main	   features,	   the	   shRNA	  and	   cDNA	  expression	   cassette,	  were	  maintained	   and	  others	  were	  introduced	  into	  the	  plasmid	  (Figure	  8).	  Firstly,	  attR	  sites	  for	  easier	  cloning	   using	   the	   Gateway	   technology	   (Invitrogen)	   taken	   from	   pEF5/FRT/V5-­‐DEST	  plasmid	   (Invitrogen)	  were	   added.	  The	  Gateway	   technology	   is	   a	  powerful	  and	  efficient	  methodology	   for	  easy	  and	  reliable	  cloning.	  Once	  a	  cDNA	   is	  cloned	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into	   an	   Entry	   Vector,	   it	   can	   be	   easily	   transferred	   to	   any	   destination	   vector	   by	  site-­‐specific	   recombination	   with	   LR	   Clonase	   Mix.	   Moreover,	   we	   added	   an	   Flp	  Recombination	  Target	  (FRT)	  from	  pEF5/FRT/V5-­‐DEST	  site	  for	  faster	  generation	  of	   stable	   cell	   lines.	   This	   is	   a	   great	   advantage	   over	   the	   first	   pAIO	   plasmids,	   as	  stable	   Flp-­‐In	   293	   T-­‐REx	   cell	   lines	   can	   be	   generated	   within	   three	   weeks.	  Moreover,	  due	  to	  the	  efficient	  recombination	  into	  a	  specific	  genomic	  localization,	  tedious	  picking	  of	  single	  cell	  clones	  becomes	  dispensable.	  	  
pAIO%1st%genera.on% pAIO%2nd%genera.on%
	  
Figure	  8:	  Comparison	  of	  1st	  and	  2nd	  generation	  pAIO	  systems	  	  The	  main	  features	  of	  the	  pAIO	  system,	  the	  shRNA	  expression	  cassette	  with	  H1	  promoter	  and	   tet	   repressor	  binding	   site	   (TETO2)	  as	  well	   as	   cDNA	  promoter	  expression	   cassette	  with	  CMV	  promoter	  and	  two	  TETO2	  binding	  sites,	  were	  kept.	  The	  puromycin	  resistance	  gene	  (PuroR)	  for	  the	  selection	  of	  stable	  cell	  lines	  in	  the	  old	  pAIO	  plasmid	  was	  replaced	  by	   a	   hygromycin	   (HygrR)	   gene.	   In	   addition,	   the	   Gateway	   system	   with	   recombination	  sites	  (AttR1	  and	  2)	  and	  the	  ccdB	  toxin	  was	  inserted	  into	  the	  new	  plasmid.	  Moreover,	  the	  2nd	  generation	  vector	  contains	  an	  FRT	  site	  for	  efficient	  integration	  into	  Flp-­‐In	  cells.	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5.2 Cloning	  methods	  for	  final	  pAIO	  plasmids	  	  
5.2.1 Insertion	  of	  shRNA	  into	  pAIO	  plasmids	  In	   order	   to	   insert	   the	   shRNA	   into	   the	   pAIO	   plasmid,	   it	   was	   digested	   with	  restriction	   enzymes	   BglII	   and	   HindIII	   (NEB).	   As	   there	   is	   a	   stuffer	   sequence	  between	   the	   two	   restriction	   sites,	   the	   plasmid	   was	   run	   on	   an	   agarose	   gel	   to	  separate	   the	   fragments.	  The	  pAIO	  plasmid	  was	  purified	  with	   the	  QIAquick	  GEL	  Extraction	  Kit.	  The	  shRNA	  was	  ordered	  as	  DNA	  oligonucleotides	  and	  annealed	  as	  follows:	  	  90°C	  4	  min,	  70°C	  10	  min,	  37°C	  20	  min,	  24°C	  20	  min,	  10	  °C	  10	  min	  and	  4°C	  forever.	  The	  shRNA	  oligonucleotide	  sequences	  were	  as	  follows:	  shRNA	  MLH1	  cds	   forward	   5'	   GATCCCCGGGTTACATATCCAATGCAAACTTCAAGAGAG	  TTTGCATTGGATATGTAACCCTTTTTA	  3';	  reverse	  complement	  5'	  AGCTTAAAAAG	  GGTTACATATCCAATGCAAACTCTCTTGAAGTTTGCATTGGATATGTAACCCGGG	   3',	  MLH1	  3'UTR	   forward	  5'	  GATCCCCGGGTGTTCTTCTTTCTCTGTATTCTCGAGAATA	  CAGAGAAAGAAGAACACTTTTTA	   3';	   reverse	   complement	   5'	   AGCTTAAAAAGTG	  TTCTTCTTTCTCTGTATTCTCGAGAATACAGAGAAAGAAGAACACCCGGG	  3'.	  	  Importantly,	   the	  oligonucleotides	  had	  to	  have	  overhangs	  complementary	  to	  the	  sticky	  ends	  created	  by	  the	  restriction	  enzymes.	  The	  DNA	  oligos	  were	  ligated	  into	  the	  plasmid	  using	  T4	  DNA	  ligase	  (NEB).	  The	  ligated	  plasmids	  were	  transformed	  into	  E.	  coli	  DH10b	  cells	  by	  electroporation	  and	  selected	  on	  agarose	  plates	  with	  ampicillin.	   Candidate	   clones	   were	   grown	   in	   5	   ml	   cultures	   and	   plasmids	   were	  extracted	  using	  NucleoSpin	  Plasmid	  kit.	  Positive	  clones	  were	  identified	  with	  DNA	  restriction	  using	  BglII	  and	  verified	  by	  sequencing	  (Microsynth).	  	  	  
5.2.2 Gateway	  cloning	  to	  insert	  GFP-­‐MLH1	  into	  the	  pAIO	  plasmids	  The	   Gateway	   cloning	   system	   was	   used	   to	   integrate	   GFP-­‐MLH1	   into	   the	   pAIO	  plasmid.	   The	   entry	   vector	   containing	   GFP-­‐MLH1	   was	   mixed	   with	   the	   pAIO	  plasmid	  and	  LR	  Clonase	  Mix	  II	  (Invitrogen)	  was	  added	  for	  1	  h.	  Proteinase	  A	  was	  added	   for	   10	   min	   and	   the	   plasmids	   were	   transformed	   into	   E.	   coli	   cells	   and	  processed	  as	  described	  above.	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5.2.3 Site-­‐directed	  mutagenesis	  for	  shRNA-­‐resistant	  cDNA	  and	  mutations	  	  To	  mutate	  a	  specific	  site,	  primers	  complementary	  to	  the	  region	  close	  to	  the	  site	  to	   be	   mutated	   but	   containing	   the	   mutation	   are	   needed.	   After	   binding	   of	   the	  primers,	   Phusion	  DNA	  polymerase	   (NEB)	   synthesizes	   a	   new	  plasmid	  using	   the	  old	  one	  as	  a	   template.	  Several	  denaturation	  and	  amplification	  cycles	  enrich	   the	  mutated	  plasmid	  in	  the	  reaction.	  The	  conditions	  were	  the	  following:	  95°C	  2	  min;	  25x	  (95°C	  1	  min;	  55°C	  1	  min;	  63°C	  25	  min);	  68°C	  20	  min;	  4°C	  forever.	  In	  order	  to	  reduce	  the	  amount	  of	  non-­‐mutated	  plasmid,	  Dpn	  I	  enzyme	  was	  added	  after	  the	  reaction.	  Dpn	  I	  exclusively	  degrades	  methylated	  DNA.	  The	  parental	  non-­‐mutated	  plasmids	  produced	   in	  E.	  coli	   cells	  are	  methylated	  and	  will	   thus	  be	  degraded	  by	  Dpn	   I,	  while	   the	  newly	   synthesized	  plasmid,	  not	  methylated,	   is	  unaffected.	  The	  new	  construct	  was	  transformed	  into	  bacteria	  and	  the	  mutation	  was	  checked	  by	  sequencing	   after	   miniprep	   preparation.	   	   The	   primers	   to	   generate	   shRNA-­‐resistant	   MLH1	   cDNA	   were	   as	   follows:	   	   forward	   5'	   GCCTTCAA	  AATGAATGGTTACATATCGAACGCGAATTACTCAGTGAAGAAGTGCATCTTC	   3';	  reverse	   complement	   5'	   GAAGATGC	   ACTTCTTCACTGAGTAATTCGCGT	  TCGATATGTAACCATTCATTTTGAAGGC	   3'.	   The	   primers	   to	   generate	   MLH1	  mutants	   were	   as	   follows:	   K84E	   forward	   5'	   GTGAAAGGTTCACTACTAGTG	  AACTGCAGTCCTTTGAGGATTTAG	   3';	   5'	   reverse	   complement	   5'	   CTAAA	  TCCTCAAAGGACTGCAGTTCACTAGTAGTGAACCTTTCAC	   3',	   R659Q	   forward	   5'	  GACTGCCTATCTTCATTCTTCAACTAGCCACTGAGGTGAA	   TTG	   3';	   reverse	  complement 5' CAATTCACCTCAGTGGCTAGTTGAAGAATGAAG	   ATAGGCAGTC	  3'.	  	  	  	  	  	  	  	  	  
5.2.4 Polymerase	  chain	  reaction	  (PCR)	  PCR	  is	  one	  of	  the	  most	  used	  methods	  in	  molecular	  biology	  and	  was	  developed	  by	  Kary	  Mullis	  in	  1983	  (131).	  It	  is	  used	  to	  amplify	  specific	  DNA	  regions.	  In	  principle,	  the	  DNA	  is	  first	  denatured	  at	  95°C	  followed	  by	  cooling	  to	  allow	  for	  the	  annealing	  of	  primers	  complementary	  to	  a	  certain	  sequence	  and	  finally	  the	  elongation	  step,	  in	  which	  a	  DNA	  polymerase	  extents	   the	  primer	  by	  adding	  nucleotides	  3'	  of	   the	  primer	  complementary	  to	  the	  template.	  This	  process	  is	  repeated	  up	  to	  40	  times,	  producing	  millions	  of	  copies	  in	  an	  exponential	  manner.	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  In	   this	  work,	   PCR	  was	   used	   to	   generate	   fragments	   of	   the	   CMV	  promoter.	   	   The	  reverse	  complement	  primer	  was	  the	  same	  for	  all	  and	  is	  located	  3'	  of	  the	  TETO2	  sites.	  The	  forward	  primer	  was	  different	  to	  generate	  fragments	  of	  different	  sizes	  to	  generate	  medium,	  low	  and	  very	  low	  expression	  CMV	  promoters	  according	  to	  commercially	   available	   Flexi	   Vectors	   from	   Promega.	   Restriction	   sites	   for	   AflII	  and	   HindIII	   were	   added	   to	   the	   forward	   and	   the	   reverse	   complement	   primers,	  respectively,	   for	   later	   insertion	   into	   the	   pAIO	   plasmid.	   The	   primer	   sequences	  were	   the	   following:	   forward	   medium	   5'	   TAAGCAAAGCTTCCAAAATGT	  CGTAACAACCCG	  3',	   low	  5'	  TAAGCAAAGCTTGACGCAAATGGGCGGTAGGC	  3',	  very	  low	  5'	  TAAGCAAAGCTTATGGGCGGTAGGCGTGTACG	  3'	  and	  reverse	  complement	  5'	   CTGGACTAGTGGATCCGAGC	   3'.	   Phusion	   polymerase	   (NEB)	  was	   used	   for	   the	  reaction	  and	  it	  was	  run	  at	  95°C	  1	  min;	  34x(95°C	  30	  sec;	  62.5	  30	  sec;	  72°C	  1	  min);	  72°C	  10	  min;	  4°C	  forever.	  	  	  
5.2.5 DNA	  purification,	  restriction,	  ligation	  and	  transformation	  	  After	  the	  PCR	  reaction,	  the	  PCR	  products	  were	  purified	  using	  the	  QIAquick	  PCR	  Purification	  Kit	   (Quiagen)	   followed	   by	   restriction	   of	   the	   PCR	   products	   and	   the	  pAIO	   plasmid	   with	   restriction	   enzymes	   HindIII	   and	   AflII	   (NEB).	   The	   PCR	  products	  were	  again	  purified	  and	  the	  pAIO	  plasmid	  was	  run	  on	  an	  agarose	  gel	  to	  separate	   the	   plasmid	   backbone	   from	   the	   long	   CMV	   promoter	   fragment.	   The	  plasmid	   DNA	   was	   purified	   from	   the	   agarose	   band	   using	   the	   QIAquick	   GEL	  Extraction	   Kit	   (Quiagen).	   The	   different	   CMV	   promoter	   fragments	   were	   ligated	  into	  the	  plasmids	  and	  the	  ligated	  products	  were	  processed	  as	  described	  above.	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5.3 Cell	  culture	  methods	  
5.3.1 Cell	  lines	  Flp-­‐In	   293	   T-­‐REx	   cell	   lines	   were	   obtained	   from	   Life	   Technologies.	   Cells	   were	  grown	  in	  Dulbecco's	  Modified	  Eagle	  Medium	  (DMEM,	  GIBCO-­‐BRL)	  supplemented	  with	  5%	  tet-­‐approved	  fetal	  bovine	  serum	  (FBS-­‐superior,	  Biochem	  AG),	  100	  U/ml	  penicillin,	   100	   µg/ml	   streptomycin	   (GIBCO-­‐BRL)	   at	   37°C	   and	   6%	   CO2.	   For	   the	  selection	  of	   stably	   transfected	   cells	   250	  µg/ml	  hygromycin	   (Invivogen)	   and	  10	  µg/ml	  blasticidin	   (Invivogen)	  were	  added	   to	   the	  medium.	  For	  activation	  of	   the	  pAIO	  system,	  Dox	  was	  added	  at	  a	  final	  concentration	  of	  100	  µg/ml	  for	  at	  least	  4	  days	  if	  not	  otherwise	  stated.	  	  	  
5.3.2 Cell	  transfections	  Flp-­‐In	   293	  T-­‐REx	   cells	  were	   transfected	   using	   calcium	  phosphate	   as	   described	  (72).	  To	  generate	  stable	  cell	  lines,	  about	  100,000	  cells	  were	  seeded	  and	  200	  ng	  of	  pAIO	  plasmid	  and	  1.8	  µg	  of	  pOG44	  (Flp-­‐In	  recombinase)	  were	  transfected	  per	  6-­‐well	  after	  24	  h.	  On	  the	  next	  day,	  the	  cells	  were	  transferred	  to	  10	  cm	  dishes	  and	  the	  selection	  was	  started	  24	  h	  later.	  For	  transient	  transfections	  with	  Flag-­‐FAN1	  and	   Flag-­‐FANCJ	   plasmids,	   2	   million	   cells	   were	   seeded	   and	   40	   µg	   of	   DNA	   was	  transfected	  the	  next	  day.	  	  	  For	   transient	   RNAi	   treatments,	   200,000	   cells	   were	   seeded	   per	   6-­‐well	   and	  immediately	   transfected	  with	   Lipofectamine	  RNAiMAX	   (Life	   Technologies)	   and	  siRNAs	   obtained	   from	   Microsynth	   at	   a	   final	   concentration	   of	   1	   nM.	   The	  sequences	   for	   siRNAs	   were	   as	   follows:	   siMLH1	   3'UTR	   5'	  GUGUUCUUCUUUCUCUGUAUUdTdT	  3';	  siLuc	  5'	  CGUACGCGGAAUACUUCGA	  dTdT	  3';	   siBCCIP1	   5'	   GUGUGAUUAAGC	   AAACGGAUGdTdT	   3';	   siBCCIP2	   5'	  GCCAUGUGGGAAGUGCUACdTdT	  3'	  	  
5.3.3 Viability	  assay	  	  200,000	  cells	  were	  seeded	  per	  6-­‐well	  and	  treated	  with	  siRNA	  and	  Dox.	  After	  48	  h,	   cells	  were	   transferred	   into	  96-­‐well	  plates	   (500	  cells/well)	   and	  again	   treated	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with	   Dox	   and	   siRNA.	   24	   h	   later	   10	   µM	   O6-­‐Benzylguanine	   and	   MNNG	   or	   MMC	  were	  added.	  After	  96	  h	  of	  incubation	  time,	  cell	  viability	  was	  measured	  using	  Cell	  Titer	  Blue	  (Promega).	  	  
	  
5.3.4 Cell	  cycle	  analysis	  	  After	   the	   treatment,	   the	  cells	  were	  harvested	  and	  washed	   twice	  with	  cold	  PBS.	  The	  cells	  were	  resuspended	  in	  70%	  ethanol	  and	  kept	  at	  -­‐20°C	  for	  fixation.	  On	  the	  day	  of	  FACS	  analysis,	  the	  cells	  were	  washed	  with	  PBS	  once	  and	  resuspended	  in	  PBS	   containing	   100	   µg/ml	   RNaseA	   and	   20	   µg/ml	   propidium	   iodide.	   After	  incubation	   at	   room	   temperature	   for	   30	  min,	   the	   samples	  were	   analyzed	   using	  CyAn	  ADP	  (Beckmann).	  	  	  	  	  
5.4 mRNA	  quantification	  by	  real-­‐time	  PCR	  The	  cells	  were	  harvested	  and	  the	  total	  RNA	  was	  isolated	  using	  RNeasy	  Mini	  Kit	  (Quiagen).	  1	  µg	  of	  total	  RNA	  was	  converted	  into	  cDNA	  using	  High	  Capacity	  cDNA	  Reverse	   Transcription	   Kit	   (Applied	   Biosystems).	   cDNA	   was	   amplified	   and	  	  measured	  using	  Platinum®	  SYBR®	  Green	  qPCR	  SuperMix	  UDG	  (Invitrogen)	  and	  	  a	   LightCycler	   platform	   (Roche).	   The	   primers	   used	   for	   amplification	   were	   the	  following:	   GFP	   CAGTGGAGAGGGTGAA-­‐GGTG	   and	   CGGGAAAAGCATTGAACAC;	  GAPDH	  CCCCGGTTTCTATAAATTGAGC	  and	  CACCTTCCCCATGGTGTCT.	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5.5 Protein	  biochemistry	  	  
5.5.1 Whole	  cell	  protein	  extraction	  On	  the	  day	  of	  protein	  extraction,	  the	  cells	  were	  harvested	  and	  washed	  with	  PBS.	  The	  cells	  were	  lysed	  with	  RIPA	  buffer	  (50	  mM	  Tris	  pH	  7.6,	  150	  mM	  NaCl,	  0.1%	  SDS,	   1%	   Trition,	   0.5%	   Sodium	   Deoxycholate,	   5	   mM	   EDTA,	   1mM	   PMSF,	   1	   mM	  DTT,	  1x	  Roche	  Complete	  protease	  inhibitor	  cocktail,	  1mM	  Na3VO4,	  1	  mM	  NaF)	  for	  10	  min	  on	  ice	  and	  centrifuged	  at	  20,000	  x	  g	  at	  4°C.	  The	  supernatant	  was	  kept	  as	  whole	  cell	  extracts.	  	  
5.5.2 Nuclear	  extract	  preparation	  	  Nuclear	   extracts	   were	   prepared	   as	   described	   previously	   (72).	   Briefly,	   about	  8x108	   Flp-­‐In	   293	   T-­‐REx	   cells	   were	   washed	   in	   isotonic	   buffer	   and	   lysed	   in	  hypotonic	   buffer	   with	   five	   strokes	   of	   A-­‐type	   pestle.	   The	   samples	   were	  centrifuged	   at	   3,000	   x	   g	   for	   10	   min	   and	   the	   supernatant	   was	   discarded.	   The	  nuclei	   were	   resuspended	   in	   extraction	   buffer	   and	   NaCl	   was	   added	   to	   a	   final	  concentration	  of	  155	  mM.	  Proteins	  were	  extracted	  through	  mixing	  for	  60	  min	  at	  4°C.	  After	  centrifugation	  at	  14,500	  x	  g	  for	  20	  min	  the	  extracts	  (supernatant)	  were	  taken	   and	   dialyzed	   in	   extraction	   buffer	   followed	   by	   another	   round	   of	  centrifugation.	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5.5.3 SDS-­‐PAGE	  and	  Western	  Blot	  After	  protein	  quantification	  using	  Bio-­‐Rad	  Protein	  Assay	  (BIO-­‐RAD),	  the	  samples	  were	  boiled	  with	  loading	  buffer	  for	  5	  min,	  separated	  by	  SDS-­‐PAGE	  and	  blotted	  on	  polyvinyllidene	  diflouride	  membranes	   for	  2	  h	  at	  100	  V.	  After	  blocking	  with	  5%	  non-­‐fat	  powdered	  milk	   in	  0.1%	  TBST	   (0.1%	  Tween-­‐20	   in	  TBS)	   for	  30	  min,	   the	  membranes	  were	   incubated	  with	   primary	   antibodies	   in	   5%	   non-­‐fat	   powdered	  milk	  in	  0.1%	  TBST	  overnight	  at	  4°C.	  The	  following	  antibodies	  and	  dilutions	  were	  used:	   MLH1	   (Abcam,	   1:2000),	   Lamin	   B1	   (Abcam,	   1:3000),	   β-­‐Tubulin	   (Abcam,	  1:3000),	   PMS2	   (Santa	   Cruz,	   1:250),	   MSH2	   (Calbiochem	   1:1000),	   	   MSH6	   (BD	  Biosciences	   1:1000),	   FANCJ	   (Cell	   Signaling	   1:500),	   FAN1	   (kindly	   provided	   by	  John	   Rouse	   1:1000),	   TFIIH	   (Santa	   Cruz	   1:1000)	   and	   Streptavidin-­‐HRP	  (Invitrogen).	  The	  blots	  were	  washed	  3	  times	  with	  TBST	  and	  incubated	  with	  the	  appropriate	   secondary	   horseradish	   peroxidase-­‐conjugated	   antibodies	   (GE	  Healthcare)	   for	   1	   h	   at	   room	   temperature.	   After	   additional	   washing	   steps,	   the	  proteins	   were	   detected	   with	   ECL	   (Advansta)	   and	   Fusion	   Solo	   imaging	   system	  (Witec	  AG).	  	  	  
5.5.4 In	  vitro	  MMR	  assay	  	  The	   MMR	   in	   vitro	   assays	   were	   performed	   as	   described	   elsewhere	   (72).	  Heteroduplex	  DNA	  containing	  a	  G/T	  mismatch	  and	  a	  single-­‐strand	  nick	  307	  bps	  3'	  of	  the	  mismatch	  in	  the	  T-­‐containing	  strand	  was	  incubated	  with	  100	  µg	  NE	  for	  40	  min	  if	  not	  stated	  otherwise.	  Repair	  of	  the	  mismatch	  restores	  a	  SalI	  restriction	  site	  and	  digestion	  of	   the	  plasmid	  with	  SalI	  and	  DraI	   results	   in	   three	   fragments,	  which	   were	   analyzed	   by	   agarose	   gel	   electrophresis.	   The	   amount	   of	   repaired	  substrate	  was	  quantified	  by	  normalizing	  the	  upper	  repair	  band	  to	  the	  remaining	  non-­‐repaired	  band.	  	  	  
	  
5.5.5 Pulldown	  assay	  After	   treatment	   with	   Dox	   or	   transfection,	   the	   cells	   were	   lysed	   in	   NP40	   lysis	  buffer	  (10	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  0.5	  mM	  EDTA,	  0.5%	  NP40,	  1mM	  PMSF,	  1	  mM	  DTT,	  1x	  Roche	  Complete	  protease	   inhibitor	  cocktail,	  1mM	  Na3VO4,	  1	  mM	  NaF)	   for	   30	   min	   and	   were	   mixed	   repeatedly.	   The	   lysate	   was	   clarified	   by	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centrifugation	  at	  14,000	  rpm	  for	  10	  min	  at	  4°C.	  The	  protein	  concentration	  was	  measured	   using	   Bio-­‐Rad	   Protein	   Assay	   (BIO-­‐RAD).	   For	   pulldowns,	   1	   mg	   of	  protein	   in	   1,000	  µl	   dilution	  buffer	   (10	  mM	  Tris	   pH	  7.5,	   150	  mM	  NaCl,	   0.5	  mM	  EDTA,	   1mM	   PMSF)	   was	   incubated	   overnight	   with	   20	   µl	   slurry	   of	   GFP-­‐Trap-­‐A	  (Chromotek)	  or	  Anti	  Flag	  M2-­‐Agarose	  (Sigma)	  for	  GFP-­‐MLH1	  or	  Flag-­‐FANCJ	  and	  Flag-­‐FAN1,	   respectively.	   The	   resins	   were	   washed	   twice	   in	   dilution	   buffer	   and	  once	   in	   dilution	   buffer	   supplemented	   with	   500	  mM	   NaCl.	   To	   elute	   the	   bound	  proteins,	   the	   resin	  was	   boiled	   at	   95°C	   in	   2x	   loading	   buffer	   for	   6	  min.	   Samples	  were	  analyzed	  by	  SDS-­‐PAGE	  and	  Western	  Blot.	  	  	  
5.5.6 GFP-­‐Trap	  pulldown	  and	  mass	  spectrometry	  	  In	   order	   to	   analyze	   interaction	   partners	   of	   tagged	   MMR	   proteins	   with	   mass	  spectrometry,	   cells	   were	   lysed	   with	   NP-­‐40	   buffer	   as	   described	   above.	   For	  chromatin	   extracts,	   cells	   were	   treated	   as	   described	   in	   preparation	   of	   NE,	   but	  chromatin-­‐bound	  proteins	  were	  extracted	  with	  420	  nM	  NaCl.	   Instead	  of	  boiling	  in	  loading	  buffer,	  50	  µl	  0.2	  M	  glycine	  pH	  2.5	  were	  added	  for	  1	  min.	  Samples	  were	  centrifuged	  and	  the	  supernatant	  with	  eluted	  proteins	  was	  neutralized	  with	  5	  µl	  1	  M	  Tris	  buffer	  pH	  10.4.	  	  For	  mass	  spectrometric	  analyses,	  the	  samples	  were	  first	  incubated	  with	  TCEP	  at	  a	  final	  concentration	  of	  5	  nM	  in	  Tris	  pH	  8	  for	  20	  min	  at	  37°C	  followed	  by	  the	  addition	  of	  Iodoacetamide	  to	  a	  final	  concetration	  of	  10	  nM	  for	  20	  min.	  Proteins	  were	  digested	  with	  1	  µg	  trypsin	  (Promega)	  ON.	  	  On	  the	  next	  day,	  the	  digested	  peptides	  were	  cleaned	  up	  with	  ZipTip	  (Millipore)	  and	  dried	  in	  speed	   vac.	   The	   samples	   were	   resuspended	   in	   5	   µl	   3	   %	   acetontrile	   and	   0.1%	  formic	   acid	   for	  processing	   in	   liquid	   chromatography	  –	  mass	   spectrometry	   (LC-­‐MS),	  using	  Orbitrap	  Velos	  Mass	  Spectrometer	   (ThermoFischer).	  Data	   files	  were	  processed	   by	   the	   Functional	   Genomics	   Center	   Zurich	   and	   analyzed	   using	  Mass	  Scott	  and	  Scafold	  software.	  	  	  	  	  	  	  	  	  
5.5.7 Proximity-­‐dependent	  in	  vivo	  biotinylation	  with	  BioID	  Cells	   expressing	   BioID	   tagged	   proteins	   were	   incubated	   with	   biotin	   at	   a	   final	  concentration	   of	   50	   µM.	   They	   were	   then	   lysed	   with	   RIPA	   buffer	   followed	   by	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Western	   Blot	   with	   Streptavidin-­‐HRP	   (Invitrogen)	   to	   check	   for	   biotinylated	  proteins.	  	  
5.5.8 Proximity-­‐dependent	  in	  vivo	  biotinylation	  using	  APEX	  	  Cells	   expressing	   APEX2-­‐tagged	   proteins	  with	   the	   pAIO	   system	  were	   generated	  (132).	   After	   induction	   of	   the	   system	   for	   72	   h,	   the	   cells	   were	   treated	   with	  biotinphenol	  at	  a	  final	  concentration	  of	  500	  µM	  for	  30	  min	  and	  1mM	  H2O2	  for	  1	  min.	   The	   cells	  were	  washed	  with	  Quencher	   solution	   (10	  mM	   sodium	  azide,	   10	  mM	   ascorbic	   acid,	   10	   mM	   and	   Trolox	   5	   mM).	   The	   cell	   pellets	   were	   frozen	   in	  liquid	  N2	  and	  thawed	  in	  PBS.	  The	  samples	  were	  centrifuged	  for	  10	  min	  and	  3000	  x	  g	  at	  4°C.	  Supernatant	  was	  taken	  as	  a	  cytoplasmic	  extract	  and	  the	  nuclei	  were	  washed	  once	   in	  PBS.	  The	  nuclei	  were	  resuspended	   in	  0.5	  volumes	  of	   the	  pellet	  nuclear	   extraction	  buffer	   and	  0.031	   volumes	  of	   5	  M	  NaCl	  were	   added.	  Nuclear	  proteins	  were	   extracted	  by	   rolling	   for	  60	  min	   at	   4°C.	  The	   samples	  were	   either	  processed	  for	  Western	  Blot	  or	  LC-­‐MS.	  	  	  
5.5.9 Pulldown	  and	  LC-­‐MS	  of	  biotin-­‐labeled	  proteins	  	  Cytoplasmatic	  extracts	  and	  nuclear	  extracts	  were	   incubated	  with	  High	  Capacity	  Streptavidin	   Agarose	   (Pierce)	   ON	   at	   4°C	   with	   shaking.	   The	   resins	   were	  centrifuged	  at	  500	  x	  g	  and	  washed	  twice	  with	  wash	  buffer	  1	  (dH2O	  with	  2%	  SDS),	  once	  with	  wash	  buffer	  2	  [0.1%	  deoxycholate,	  1%	  Triton	  X-­‐100,	  500mM	  NaCl,	  1	  mM	  EDTA,	  50	  mM	  Hepes	  (ph	  7.5)],	  once	  with	  wash	  buffer	  3	  [250mM	  LiCl,	  0.5%	  NP-­‐40,	   0.5%	   deoxycholate,	   1mM	   EDTA,	   10	   mM	   Tris	   (ph8.1)],	   and	   twice	   with	  wash	  buffer	  4	  [50	  mM	  Tris	  (ph	  7.4)	  and	  50	  mM	  NaCl].	  In	  order	  to	  elute	  the	  bound	  proteins,	  the	  resins	  were	  boiled	  in	  2x	  loading	  dye	  at	  95°C	  for	  5	  min.	  For	  LC-­‐MS,	  the	   agarose	   resins	   were	   treated	   as	   described	   (133).	   Briefly,	   the	   resins	   were	  intensively	   washed	   with	   10	   ml	   0.5%	   Triton	   X-­‐100	   in	   50	   mM	   amonium	  bicarbonate,	   followed	   by	   10	   ml	   5M	   NaCl,	   followed	   by	   10	   ml	   100	   sodium	  carbonate	   and	   finally	   10	   ml	   ammonium	   bicarbonate.	   For	   washing,	   the	   resins	  were	   transferred	   into	   Mobicols	   to	   a	   Vac-­‐ManLaboratory	   Vacuum	   Manifold	  (Promega).	   The	   beads	   were	   treated	   with	   TCEP	   and	   Iodacetamide	   and	   the	  proteins	   were	   digested	   for	   4	   h	   with	   LysC	   (Calbiochem)	   and	   subsequently	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overnight	   with	   trypsin	   (Promega).	   The	   peptides	   were	   cleaned	   up	   with	   Ultra	  Micro	   SpinColumn	   (Harvard)	   and	   analyzed	   in	   an	   Exactive	   Plus	   Orbitrap	   Mass	  Spectrometer	  (Thermo	  Scientific).	  	  	  
5.5.10 Protein	  identification	  and	  data	  filtering	  	  For	   the	   AP-­‐MS	   experiments	  with	   GFP-­‐MLH1	   and	  MSH2-­‐eGFP	   acquired	   spectra	  were	   searched	   with	   Mascot	   software	   against	   the	   human	   proteome	  (www.uniprot.org)	   (134).	  The	   search	  parameters	  were	   set	   to	   only	   fully	   tryptic	  peptides	   with	   up	   to	   two	   missed	   cleavages.	   Oxidation	   on	   methionine	   and	  phosphorylation	  on	  serine,	  threonine	  and	  tyrosine	  were	  set	  as	  variable	  peptide	  modifications.	   Carbamidomethylation	   on	   cysteine	   was	   set	   as	   fix	   modification. Error	  tolerances	  on	  the	  precursor	  and	  fragment	  ions	  were	  ±25	  ppm	  and	  ±0.5	  Da,	  respectively.	   The	   obtained	   peptide	   spectrum	   matches	   were	   statistically	  evaluated	  using	  Scaffold	  software	  (v4.05)	  (135).	  Normalized	  total	  spectra	  (NTS)	  higher	   than	   five	   was	   considered	   as	   an	   interactor	   and	   lower	   than	   five	   was	  considered	  as	  negative	  resulting	  in	  a	  list	  of	  potential	  GFP-­‐MLH1	  interactors.	  In	  a	  next	  step	  the	  protein	  list	  of	  GFP-­‐MLH1	  was	  matched	  against	  GFP	  only.	  Proteins	  with	  NTS	  higher	  than	  five	  in	  the	  control	  were	  discarded.	  	  	  	  For	  APEX	  experiments	  a	  different	  approach	  was	  used.	  After	  data	  acquisition,	  the	  Prohits	   pipeline	   was	   applied	   (136).	   The	   obtained	   spectra	   were	   searched	   with	  search	  engines	  Comet	  and	  X!Tandem	  (137,138).	  The	  search	  parameters	  were	  set	  to	   only	   fully	   tryptic	   peptides	   and	   up	   to	   two	   missed	   cleavages.	  Carbamidomethylation	   on	   cysteine	   was	   set	   as	   a	   fix	   peptide	   modification.	  Oxidation	  on	  methionine	  and	  phosphorylation	  on	  serine,	  threonine	  and	  tyrosine	  were	  set	  as	  variable	  peptide	  modifications.	  The	  precursor	  mass	  tolerance	  was	  set	  to	  20	  ppm	  and	  the	  fragment	  mass	  error	  tolerance	  was	  set	  to	  0.015	  amu.	  Protein-­‐level	   validation	   and	   protein	   inference	   of	   the	   individual	   search	   engines	   were	  performed	   with	   Peptide	   Prophet	   and	   combined	   in	   iProphet	   (139)	   using	   the	  Trans-­‐Proteomic	  Pipeline	  (TPP,	  v4.7	  POLAR	  VORTEX	  rev	  1,	  Build	  201510301006	  (linux)).	  For	  further	  analysis	  only	  proteins	  with	  an	  iProphet	  probability	  of	  >0.95	  and	  minimum	  two	  peptides	  were	  considered.	   In	  order	   to	   identify	  and	  estimate	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high	  confident	  protein	  interactions,	  Saint-­‐express	  software	  (Version:exp3.3)	  was	  used	  (140,141).	  The	  resulting	  list	  contained	  of	  potential	  APEX-­‐MLH1	  interactors	  with	  average	  probability	  (AvgP)	  and	  Bayesian	  false	  discovery	  rate	  (BFDR).	  AvgP	  of	   higher	   than	   0.9	   and	   BFDR	   lower	   than	   0.02	   were	   considered	   as	   statistically	  significant.	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6 Results	  
6.1 Usage	  of	  second	  generation	  pAIO	  system	  to	  replace	  endogenous	  
MLH1	  	  	  The	  first	  aim	  of	  this	  study	  was	  to	  develop	  an	  easy	  and	  universal	  system	  that	  can	  be	  used	  to	  study	  the	  phenotype	  of	  mutations	  found	  in	  patients.	  In	  order	  to	  do	  so,	  the	  wild	  type	  protein	  needs	  to	  be	  inactivated	  or	  removed	  from	  the	  cell.	  The	  pAIO	  system	  makes	   use	   of	   RNAi	   through	   an	   shRNA	   to	   knock	   down	   the	   endogenous	  protein.	  We	   introduced	   two	   different	   shRNAs	   into	   the	   pAIO	   plasmid	   targeting	  either	  the	  cds	  or	  the	  3'UTR	  of	  the	  endogenous	  MLH1	  mRNA.	  We	  decided	  to	  use	  
MLH1	   as	   a	   representative	   example	   for	   diseases	   that	   are	   caused	   by	   inherited	  mutations	  in	  one	  single	  gene	  to	  study	  the	  phenotype	  of	  certain	  mutations	  in	  the	  
MLH1	   gene	   found	   in	   HNPCC	   patients.	   To	   differentiate	   the	   exogenous	   from	   the	  endogenous	  MLH1,	  we	  used	  GFP-­‐MLH1	  which	  has	  previously	  been	  reported	   to	  be	  functional	  (142).	  The	  GFP-­‐MLH1	  cDNA	  was	  introduced	  into	  the	  pAIO	  plasmid	  and	   stable	   cell	   lines	  were	   generated.	   Importantly,	   the	  GFP-­‐MLH1	   cDNA	   for	   the	  pAIO	   plasmid	  with	   the	   shRNA	   targeting	   the	   cds	  was	  made	   shRNA-­‐resistant	   by	  mutagenesis	  while	  retaining	  the	  peptide	  sequence	  (Figure	  9).	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Figure	  9:	  Replacement	  of	  endogenous	  MLH1	  with	  GFP-­‐MLH1	  using	  pAIO	  Schematic	  representation	  of	  pAIO	  GFP-­‐MLH1.	  Sequences	  of	  the	  H1	  and	  CMV	  promoter,	  positions	  of	   the	  shRNA	  and	  the	  tet	  binding	  sites	  (TETO2),	  open	  reading	   frames	  for	  the	  GFP-­‐MLH1	   cDNA,	   antibiotic	   resistance	  markers	   (AmpR	   and	   HygroR),	   positions	   of	   the	  Gateway	   (AttB1	   and	   2)	   and	   FRT	   recombination	   sites	   and	   bovine	   growth	   hormone	  polyadenylation	  signal	   (bGH	  PA)	  are	   indicated.	  Sequences	  of	   the	  shRNAs	  used	  and	   the	  position	  of	  the	  silent	  mutation	  in	  the	  MLH1	  cDNA,	  which	  does	  not	  alter	  the	  polypeptide	  sequence	  are	  shown	  below.	  	  	  
	  After	   transfection	  of	   Flp-­‐In	  293	  T-­‐Rex	   cells	  with	   the	  pAIO	  plasmids,	   stable	   cell	  lines	  were	  selected.	  Besides	  single	  cell	  clones,	  the	  bulk	  culture	  was	  also	  analyzed	  for	  MLH1	  replacement.	  As	  shown	  in	  Figure	  10	  A,	  both	  shRNAs	  could	  knock	  down	  endogenous	   MLH1	   efficiently	   and	   all	   single	   cell	   clones,	   as	   well	   as	   the	   bulk	  cultures	   (BC),	   expressed	   GFP-­‐MLH1.	   The	   expression	   was	   very	   homogenous	  between	  the	  different	  cell	  lines,	  which	  led	  to	  the	  conclusion	  that	  BCs	  are	  suitable	  for	  the	  generation	  of	  stable	  cell	  lines	  and	  that	  picking	  of	  single	  cell	  clones	  was	  not	  necessary.	  Although	  the	  knock	  down	  was	  efficient,	  endogenous	  MLH1	  could	  still	  be	  detected.	   It	  has	  been	  reported	  that	  only	  10%	  of	  MLH1	  protein	  is	  enough	  for	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Figure	  10:	  Overexpression	  of	  GFP-­‐MLH1	  and	  knock	  down	  of	  MLH1	  in	  pAIO	  (A)	  Western	  Blot	   of	   extracts	   of	   stable	   cell	   lines	   (bulk	   culture	  BC	   or	   single	   cell	   clones)	  expressing	   endogenous	   MLH1	   (-­‐	   Dox	   lanes)	   or	   the	   GFP-­‐tagged	   variant	   (+	   Dox	   lanes)	  with	  either	  the	  3'UTR	  directed	  shRNA	  or	  cds	  directed	  shRNA	  upon	  treatment	  with	  Dox	  (+)	   for	   96	   h.	   (B)	   Combination	   of	   cds	   shRNA	   induced	   with	   Dox	   and	   treatment	   with	  siMLH1	  against	  3'UTR	  for	  96	  h	  substantially	   improved	  the	  knock	  down	  of	  endogenous	  MLH1.	  	  In	  all	  cell	  lines	  analyzed	  so	  far,	  the	  expression	  of	  GFP-­‐MLH1	  was	  much	  stronger	  than	  that	  of	  the	  endogenous	  MLH1.	  Because	  overexpression	  of	  MLH1	  was	  shown	  to	   impair	  MMR	   in	   yeast	   and	   to	   activate	   apoptosis	   in	   human	   cells	   (66,143),	  we	  thought	   about	   strategies	   to	   reduce	   the	   GFP-­‐MLH1	   levels	   down	   to	   those	   of	  endogenous	   MLH1.	   The	   analysis	   of	   an	   additional	   cell	   clone	   verified	   the	   high	  homogeneity	   between	   the	   clones	   and	   we	   concluded	   that	   we	   would	   not	   find	  clones	  with	  much	  less	  expression	  (Figure	  11	  A).	  Moreover,	  the	  reduction	  of	  the	  Dox	   concentration	   did	   not	   reduce	   the	   GFP-­‐MLH1	   levels	   (Figure11	   B),	   but	   we	  found	   that	   a	   concentration	   which	   is	   1000-­‐fold	   (1	   ng/ml)	   lower	   than	   that	  recommended	  by	  Invitrogen	  was	  sufficient	  to	  activate	  our	  system.	  When	  treated	  with	  0.1	  ng/ml	  Dox,	  the	  GFP-­‐MLH1	  levels	  were	  reduced,	  but	  the	  knock	  down	  of	  endogenous	  MLH1	  was	  lost.	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Figure	  12:	  Reduction	  of	  GFP-­‐MLH1	  expression	  by	  promoter	  shortening	  	  (A)	  With	   the	   help	   of	   PCR	   and	   standard	   cloning	   techniques,	   the	   CMV	   promoter	   in	   the	  pAIO	   plasmid	   was	   shortened	   according	   to	   the	   scheme.	   (B)	   CMV	   variants	   were	  transiently	   transfected	   into	  Flp-­‐In	  293	  T-­‐Rex	  cells	  and	  Western	  Blot	  analyses	  revealed	  reduced	   GFP-­‐MLH1	   levels	   in	   shorter	   CMV	   promoters.	   The	   proteins	   were	   extracted	  already	   24	   h	   after	   transfection	   to	   allow	   for	   comparison	   of	   GFP-­‐MLH1	   to	   endogenous	  MLH1	  before	  the	  knock	  down	  by	  the	  shRNA	  became	  visible.	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  As	  the	  aim	  of	   the	  study	  was	  to	  analyze	  the	  phenotype	  of	  patient	  mutations,	  we	  then	  generated	  cell	  lines	  with	  medium	  CMV	  promoter	  and	  GFP-­‐MLH1	  K84E	  and	  R659Q.	   When	   comparing	   the	   protein	   levels,	   we	   found	   that	   the	   K84E	   mutant	  showed	   increased	   levels	  of	  GFP-­‐MLH1	   in	  whole	   cell	   extracts	   (WCE),	  but	  not	   in	  nuclear	  extracts	  (NE)	  (Figure	  13	  A-­‐C).	  The	  protein	  levels	  of	  GFP-­‐MLH1	  (R659Q),	  however,	  were	  decreased	  in	  WCE	  and	  in	  NE.	  Moreover,	  the	  levels	  of	  PMS2	  were	  reduced	  in	  WCE	  while	  other	  MMR	  factors	  were	  not.	  The	  mRNA	  levels	  were	  equal	  in	  wt	  and	  the	  mutants,	  which	  indicates	  that	  the	  R659Q	  mutation	  affects	  protein	  stabilization	   (Figure	   13	   D).	   We	   could	   not,	   however,	   exclude	   translational	  repression	  by	  RNAi.	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Figure	  13:	  The	  MLH1	  R659Q	  mutation	  leads	  to	  reduced	  GFP-­‐MLH1	  protein	  levels	  	  (A)	  pAIO	  GFP-­‐MLH1	  wt,	  K84E	  and	  R659	  with	  medium	  CMV	  were	  generated	  and	  GFP-­‐MLH1	  levels	  were	  measured	  by	  Western	  Blot	  96	  h	  after	  induction.	  (B)	  Quantification	  of	  GFP-­‐MLH1	   and	   PMS2	   levels	   of	   three	   independent	   replicates	   and	   SD.	   GFP-­‐MLH1	  K84E	  levels	   were	   higher	   than	  wt,	   whereas	   the	  mutant	   R659Q	   revealed	   reduced	   GFP-­‐MLH1	  and	   PMS2	   levels.	   (C)	  Nuclear	   extracts	   of	   the	   cell	   lines	  were	   prepared	   and	   the	   protein	  levels	   were	   analyzed.	   GFP-­‐MLH1	  WT	   and	   K84E	   showed	   similar	   levels	   to	   endogenous	  MLH1.	  The	  R659Q	  mutation	  also	  reduced	  the	  GFP-­‐MLH1	  levels	  in	  the	  nucleus.	  Note	  that	  the	   cells	   were	   additionally	   treated	   with	   siLuc	   (-­‐	   Dox)	   or	   siMLH1	   3'UTR	   (+	   Dox)	   to	  maximize	  the	  knock	  down	  of	  endogenous	  MLH1	  for	  WCE	  and	  NE.	  (D)	  mRNA	  levels	  were	  measured	  by	  qRT	  PCR	  of	  GFP-­‐MLH1	  in	  uninduced	  (-­‐	  Dox)	  or	  induced	  (+	  Dox)	  cell	   lines	  and	  no	  difference	  was	   observed.	  Non-­‐transfected	  Flp-­‐In	  293	  T-­‐Rex	   cells	  were	  used	   as	  the	  negative	  control.	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6.2 The	  K84E,	  but	  not	  the	  R659Q,	  mutant	  is	  MMR-­‐deficient	  In	  our	  next	  experiments,	  we	  focused	  on	  the	  MMR	  activity	  of	  the	  MLH1	  mutants.	  Time	   course	   in	  vitro	  MMR	  assays	   revealed	   very	   low	  MMR	  activity	   of	   the	  K84E	  mutant	  (Figure	  14	  A-­‐D).	  We	  also	  observed	  reduced	  activity	  of	  the	  R659Q	  mutant,	  but	   it	  was	  not	  significant	  over	  three	   independent	  experiments.	  To	  rule	  out	  that	  the	  MMR	  deficiency	  of	  the	  K84E	  mutant	  was	  caused	  by	  inactive	  nuclear	  extracts,	  purified	   Mutlα	   wt	   and	   PMS2	   endonuclease-­‐dead	   D699N	   mutant	   (DN)	   were	  added	  to	  the	  reaction	  (26).	  The	  wt	  complex	  could	  restore	  the	  MMR	  activity	  of	  the	  K84E	   extracts	   but	   the	   DN	  mutant	   failed	   to	   do	   so	   and	   thus	   implicated	   that	   the	  observed	   reduction	   of	   MMR	   activity	   is	   indeed	   caused	   by	   the	   K84E	   mutation,	  which	   is	   in	   line	   with	   observations	   by	   others	   (11,12,95).	   To	   verify	   the	   MMR	  activity	   of	   the	   R659Q	   mutant,	   we	   made	   use	   of	   293T	   Lα	   cells	   and	   the	   R659Q	  analogue	   (72).	   Again,	   the	   R659Q	  mutant	  was	   active.	  Moreover,	   the	   pAIO	   GFP-­‐MLH1	   variants	   were	   tested	   for	   MNNG	   sensitivity	   (Figure	   14	   E).	   MNNG	   was	  shown	   to	   activate	   MMR	   and	   MMR-­‐proficient	   cells	   are	   highly	   sensitive	   to	   the	  treatment.	  The	  R659Q	  mutant	  behaved	  exactly	  as	  wt	  GFP-­‐MLH1,	  but	  both	  were	  slightly	   resistant	   compared	   to	   non-­‐MLH1-­‐replaced	   cells.	   In	   contrast,	   the	   K84E	  mutant	  was	  highly	  resistant	  which	  underlines	  its	  MMR	  deficiency.	  These	  results	  strongly	  suggest	   that	   the	  R659Q	  mutation,	  despite	  reduced	  protein	   levels,	  does	  not	  severely	  reduce	  MMR	  activity	  and	  we	  concluded	  that	  impaired	  MMR	  activity	  might	  not	  be	  the	  main	  cause	  for	  tumor	  development	  in	  patients	  with	  the	  R659Q	  mutation.	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Figure	  14:	  The	  R659Q	  mutation	  does	  not	  affect	  MMR	  activity	  (A)	  MMR	   time	  course	  assay	   in	  NE	   from	  stable	   cell	   lines	  expressing	  endogenous	  MLH1	  (MLH1	  WT)	  or	  GFP-­‐MLH1	  variants	  (WT,	  K84E	  or	  R659Q)	  revealed	  no	  difference	  for	  the	  R659Q	  mutation.	  NE	  from	  the	  K84E	  mutant,	  however,	  was	  significantly	   less	  active.	  (B)	  Schematic	   explanation	   of	   in	  vitro	  MMR	   assay.	   (C)	  NE	   from	  K84E	  GFP-­‐MLH1	   are	  MMR	  active,	   when	   supplemented	   with	   WT	   MutLα,	   but	   not	   with	   PMS2	   endonuclease-­‐dead	  MutLα	   (DN).	   NE	   from	   GFP-­‐MLH1	   WT	   cells	   served	   as	   a	   positive	   control.	   (D)	  Quantification	  of	   three	   independent	  experiments	  and	  data	  are	   represented	  as	  mean	 ±	  SD.	  (E)	  NE	  from	  293T	  Lα+,	  293T	  Lα-­‐,	  293T	  R659Q+	  or	  293T	  R659Q-­‐	  cells	  were	  prepared	  and	  MMR	  assays	  performed.	  The	  results	  verified	  that	  the	  MLH1	  R659Q	  mutant	  is	  MMR-­‐proficient.	   (F)	   The	   K84E	   but	   not	   the	   R659Q	  mutation	   affects	   MMR	   activity	   in	   vivo	   as	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judged	   by	   cell	   viability	   assay	   of	   stable	   293	   cell	   lines	   expressing	   endogenous	   MLH1	  (MLH1	   WT)	   or	   GFP-­‐MLH1	   variants	   (WT,	   K84E	   or	   R659Q)	   treated	   with	   10	   µM	   O6-­‐Benzylguanine	   for	   1	   h,	   followed	   by	   MNNG.	   Data	   are	   represented	   as	   mean	   of	   three	  independent	  experiments	 ±	  SD.	  Asterick	  indicates	  significant	  differences	  between	  GFP-­‐MLH1	  WT	  and	  K84E	  with	  a	  p-­‐value	  below	  0.05	  according	  to	  t-­‐test.	  	  	  
6.3 Long-­‐term	  replacement	  with	  GFP-­‐MLH1	  K84E	  did	  not	  induce	  
MSI	  The	  previous	  experiments	  revealed	  that	  the	  K84E	  mutation,	  but	  not	  the	  R659Q	  mutation,	   impairs	   MMR	   in	   vitro	   as	   well	   as	   in	   vivo	   as	   judged	   by	   its	   resistance	  towards	  MNNG.	  As	  microsatellite	  instability	  (MSI)	  is	  a	  very	  prominent	  hallmark	  of	  MMR	  deficiency,	  we	  isolated	  the	  genomic	  DNA	  after	  four	  weeks	  of	  continuous	  induction	   of	   the	   pAIO	   system	   and	   checked	   for	   MSI.	   This	   was	   done	   in	  collaboration	   with	   Karl	   Heinimann	   from	   the	   Universitätsspital	   Basel.	   Genomic	  DNA	  from	  293T	  cells,	  which	  lack	  MLH1,	  was	  used	  as	  positive	  control	  and	  showed	  strong	   shortening	   in	   micro	   satellite	   BAT40	   compared	   to	   293	   MLH1	   wt	   cells	  (Figure	  15).	  The	  replacement	  of	  endogenous	  MLH1	  with	  the	  GFP-­‐MLH1	  variants,	  however,	   did	  not	   affect	   the	   length	  of	  BAT40.	   Similar	   results	  were	   obtained	   for	  other	  microsatellites	  including	  BAT26,	  BAT25	  and	  EWSR1	  (data	  not	  shown).	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Figure	  15:	  MSI	  analysis	  of	  GFP-­‐MLH1	  variants	  The	  pAIO	  system	  was	  induced	  in	  all	  the	  variants	  for	  four	  weeks	  and	  genomic	  DNA	  was	  isolated	  and	  submitted	  for	  MSI	  analysis.	  The	  MSI	  BAT40	  was	  chosen	  as	  a	  representative	  result	  for	  six	  markers	  in	  total.	  	  	  	  	  
6.4 The	  R659Q	  mutation	  impairs	  binding	  to	  FAN1	  and	  FANCJ	  MLH1	  was	  shown	  to	  play	  an	  important	  role	  also	  in	  other	  aspects	  of	  DNA	  repair	  and	  its	   interaction	  with	  other	  repair	   factors	  is	  crucial	   for	  genome	  maintenance.	  Several	   studies	   suggest	   an	   involvement	  of	  MLH1	   in	   ICL	   repair,	  which	  might	  be	  mediated	  by	  interaction	  of	  MLH1	  with	  FAN1	  and	  FANCJ	  (58,59,124).	  In	  order	  to	  analyze	  the	  binding	  of	  MLH1	  to	  certain	  factors,	  we	  made	  use	  of	  the	  GFP-­‐tag	  and	  performed	   a	   pulldown	   with	   GFP-­‐Trap.	   As	   shown	   in	   Figure	   16	   A,	   all	   variants	  strongly	   interacted	  with	   PMS2,	   and	  GFP-­‐MLH1	  wt	   as	  well	   as	   the	  K84E	  mutant	  also	   bound	   FAN1	   and	   FANCJ.	   The	   R659Q	   mutant,	   however,	   showed	   strongly	  reduced	  interaction	  with	  FAN1	  and	  no	  visible	  binding	  to	  FANCJ.	  To	  verify	  these	  findings,	   FLAG-­‐FANCJ	   and	   FLAG-­‐FAN1	   were	   expressed	   in	   the	   cell	   lines	   and	  pulldowns	   with	   Anti-­‐FLAG	   M2	   antibody	   were	   performed.	   Endogenous	   MLH1,	  GFP-­‐MLH1	  wt	   and	  K84E	   could	  be	   found	   in	   the	  pulldowns,	   but	  binding	  of	  GFP-­‐MLH1	   R659Q	   was	   significantly	   lower	   for	   both	   Flag-­‐FANCJ	   and	   FLAG-­‐FAN1	  (Figure	  16	  B,	  C).	  When	  we	  did	  a	  similar	  experiment	  in	  293T	  Lα	  and	  L	  R659Q	  cells	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Figure	  16:	  The	  R659Q	  mutation	  impairs	  binding	  of	  MLH1	  to	  FANCJ	  and	  FAN1	  (A)	   Pulldown	   assay	   of	   GFP-­‐MLH1	   variants	   with	   GFP-­‐Trap	  was	   performed	   and	  revealed	   impaired	   interaction	  of	   the	  R659Q	  mutant	  with	  FAN1	  and	  FANCJ.	   (B)	  Flag-­‐FANCJ	   or	   (C)	   Flag-­‐FAN1	   were	   transiently	   expressed	   in	   the	   cell	   lines	   and	  pulldown	  experiments	  verified	  impaired	  binding	  of	  GFP-­‐MLH1	  R659Q	  to	  FANCJ	  and	  FAN1.	  (D)	  Co-­‐IP	  of	  MLH1	  in	  293T	  R659Q	  cell	  extracts	  confirmed	  the	  reduced	  binding	  of	  MLH1	  R659Q	  to	  FANCJ	  and	  FAN1.	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6.5 The	  R659Q	  and	  K84E	  mutations	  alter	  ICL	  damage	  response	  As	   the	   interaction	   of	   MLH1	   R659Q	   with	   FANCJ	   and	   FAN1	   was	   found	   to	   be	  impaired,	  we	  then	  wanted	  to	  see	  how	  the	  mutant	  reacts	  to	  treatment	  with	  ICL-­‐inducing	   agent	  mitomycin	  C	   (MMC).	   Cell	   viability	   assays	  were	   performed	   after	  induction	   of	   the	   pAIO	   system	   and	   treatment	   with	   MMC.	   Interestingly,	   both	  mutants,	   the	  K84E	   and	   the	  R659Q,	   showed	   significant	   resistance	   against	  MMC	  compared	   to	   endogenous	   MLH1	   and	   wt	   GFP-­‐MLH1	   (Figure	   17	   A).	   Another	  hallmark	   of	   altered	   ICL	   damage	   response	   is	   a	   G2	   arrest	   after	  MMC	   treatment.	  When	  the	  cell	  lines	  were	  treated	  with	  MMC	  either	  for	  24	  h	  with	  100	  ng	  or	  with	  25	  ng	  for	  96	  h,	  we	  found	  a	  reduced	  arrest	  in	  G2	  phase	  for	  both	  conditions	  in	  the	  K84E	   and	   the	   R659Q	   mutants	   (Figure	   17	   B,C).	   We	   also	   performed	   viability	  assays	   with	   MMC	   treatment	   in	   293T	   Lα	   and	   L	   R659Q	   cells	   and	   again	   found	  resistance	   of	   the	   R659Q	   mutant	   compared	   to	   wt	   MLH1.	   These	   observations	  suggest	   that	   the	   impaired	   binding	   of	   MLH1	   R659Q	   alters	   the	   DNA	   damage	  response	  towards	  ICL	  lesions.	  It	  seems	  that	  the	  lesions	  are	  tolerated	  or	  repaired	  differently	  making	  the	  cells	  more	  resistant.	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Figure	  17:	  Altered	  DNA	  ICL	  damage	  response	  in	  MLH1	  R659Q	  mutant	  cells	  GFP-­‐MLH1	  K84E	  and	  R659Q	  mutants	  showed	  resistance	  against	  MMC	  treatment	  in	   cell	   viability	   assays.	   Data	   are	   represented	   as	   mean	   ±	   SD	   from	   three	  independent	   replicates.	   Asterick	   indicates	   significant	   differences	   between	   both	  mutants	  K84E	  and	  R659Q	  compared	  to	  GFP-­‐MLH1	  WT	  with	  a	  p-­‐value	  below	  0.05	  according	  to	  t-­‐test.	   	  (B)	  Cell	  cycle	  profile	  of	  MLH1	  variants	  after	  treatment	  with	  MMC	   25	   ng/ml	   for	   96	   h	   or	   100	   ng/ml	   for	   24	   h	   and	   release	   into	  medium	  was	  assessed	   with	   PI	   staining	   and	   FACS	   and	   the	   results	   indicate	   reduced	   DNA	  damage	   signaling	   in	   the	   K84E	   and	   the	   R659Q	  mutants	   as	   judged	   by	   increased	  portions	  of	  cells	  in	  the	  G1	  phase	  and	  decreased	  portions	  in	  the	  G2/M	  phase.	  (C)	  The	  ratio	  of	  cells	  in	  G1	  phase	  to	  G2/M	  revealed	  higher	  proportions	  of	  cells	  in	  G1	  phase	   for	   the	   K84E	   and	   R659Q	   variants.	   Data	   are	   shown	   as	   mean	   of	   three	  replicates	  ±	  SD.	  Asterick	   indicates	  p-­‐values	  below	  0.05	  compared	  to	  GFP-­‐MLH1	  WT.	   (D)	  Cell	   viability	  assay	  with	  MLH1	  variants	   in	   the	  293T	  cells	   confirms	   the	  resistance	  of	  MLH1	  R659Q	  against	  MMC	   treatment.	  Data	   are	   represented	   from	  three	  independent	  replicates	  and	  are	  displayed	  as	  mean	  ±	  SD.	  Astericks	  indicates	  significant	   differences	   between	   MLH1	   WT	   and	   MLH1	   R659Q	   with	   a	   p-­‐value	  below	  0.05	  according	  to	  t-­‐test.	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Figure	  18:	  The	  2nd	  generation	  pAIO	  system	  is	  reversible	  Cells	  with	  the	  pAIO	  system	  were	  induced	  with	  Dox	  (+)	  and	  treated	  with	  siRNAs	  for	  96	  h.	  A	   fraction	  was	   taken	   for	  Western	   Blot	   analysis	   and	   the	   remaining	   cells	   were	  washed	  twice	  with	  PBS	  and	  released	  into	  Dox-­‐free	  medium	  for	  120	  h.	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6.7 Usage	  of	  GFP-­‐tag	  for	  interactome	  studies	  of	  MMR	  factors	  In	   order	   to	   study	   the	   MMR	   interactome	   in	   different	   aspects	   of	   DNA	   damage	  repair,	   the	   MMR	   factors	   MLH1	   and	   MSH2	   were	   tagged	   with	   GFP	   and	   eGFP,	  respectively.	  For	  both	  proteins,	  the	  pAIO	  system	  was	  used.	  For	  pulldown	  assays,	  GFP-­‐Trap	  was	  used	   and	   the	   efficiency	  of	   the	  pulldown	  was	   assessed	  by	  bound	  interaction	   partners	   (Figure	   19).	   For	   GFP-­‐MLH1,	   PMS2	   and	   FAN1	   could	   be	  efficiently	   enriched,	   whereas	   the	   control	   PCNA	   was	   not	   found	   in	   the	   eluate.	  Similarly,	  MSH2-­‐eGFP	   could	   be	   used	   to	   pull	   down	  MSH6	   and	  MSH3.	   As	   a	   next	  step,	   the	   bound	   proteins	   were	   sent	   for	   LC-­‐MS	   analysis	   to	   identify	   novel	  interaction	  partners	  of	  MLH1.	   In	  addition,	   extracts	   from	  MNNG-­‐treated	  cells	   to	  induce	   non-­‐canonical	   MMR	   as	   well	   as	   chromatin-­‐enriched	   extracts	   were	  analyzed.	  Table	  3	  summarizes	  the	  findings	  of	  the	  LC-­‐MS	  analyses	  for	  GFP-­‐MLH1.	  The	  main	  interaction	  partners	  of	  MLH1	  including	  PMS2,	  PMS1,	  MLH3	  and	  FANCJ	  were	  identified	  in	  all	  three	  extracts.	  Except	  for	  PRRC2C	  (proline	  rich	  coiled-­‐coil	  2C),	   which	   was	   enriched	   in	   the	   non-­‐treated	   whole	   cell	   sample,	   no	   strong	  differences	  could	  be	  observed	  between	  the	  various	  samples	  with	  high	  values	  in	  normalized	   total	   spectra	   (NTS),	   unique	   peptide	   count	   (UP)	   and	   sequence	  coverage	   (SC).	   Two	   factors	   could	   be	   identified	   only	   in	   the	   MNNG-­‐treated	   or	  chromatin-­‐enriched	   extracts;	   KHRSP	   (KH-­‐type	   splicing	   regulatory	   protein)	   and	  NONO	   (Non-­‐POU	   domain-­‐containing	   octamer-­‐binding	   protein).	   	   For	   MSH2,	  prominent	   interaction	  partners	  such	  as	  MSH6	  and	  MSH3	  as	  well	  as	  EXO1	  were	  reliably	  identified	  (Table	  4).	  Some	  interesting	  factors	  were	  found	  with	  relatively	  high	  values	  such	  as	  WDHD1	  (WD	  Repeat	  And	  HMG-­‐Box	  DNA	  Binding	  Protein	  1),	  MCM8	   and	   9	   (Minichromosome	   Maintenance).	   However,	   no	   obvious	   changes	  between	  MNNG-­‐treated	  and	  untreated	  extracts	  could	  be	  observed.	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Figure	  19:	  Pulldown	  of	  tagged	  MMR	  proteins	  with	  GFP-­‐Trap	  (A)	  GFP-­‐MLH1	  or	  (B)	  MSH2-­‐eGFP	  was	  induced	  in	  the	  pAIO	  system	  and	  pulldown	  assays	  with	   GFP-­‐Trap	  were	   performed.	   For	  MLH1,	  well-­‐described	   interaction	   partners	   PMS2	  and	   FAN1	  were	   found	   bound	   to	   the	   beads,	   while	   PCNA	   as	   a	   negative	   control	   did	   not	  bind.	  For	  MSH2,	   the	  main	   interactors,	  namely	  MSH6	  and	  MSH3,	  could	  be	   found.	  Again,	  PCNA	  did	  not	  bind.	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NTS! UP! SC! NTS! UP! SC! NTS! UP! SC!
MLH1! 210! 3! 66%! 104! 2! 56%! 113! 1! 65%!
PMS1! 176! 31! 38%! 89! 22! 26%! 97! 50! 48%!
FANCJ! 60! 3! 23%! 27! 4! 15%! 50! 6! 26%!
PMS2! 54! 19! 25%! 20! 17! 27%! 31! 45! 36%!
PRRC2C! 33! 16! 9.2%! 0! 0! 0%! 0! 0! 0%!
MLH3! 23! 12! 11%! 4! 3! 2.3%! 16! 18! 16%!
GLI2! 21! 11! 11%! 2! 2! 2.6%! 8! 9! 9%!
ARID3B! 12! 6! 17%! 7! 6! 15%! 9! 10! 30%!
FMR1! 8! 4! 5.2%! 0! 0! 0%! 0! 0! 0%!
SEC22B! 8! 4! 20%! 0! 0! 0%! 0! 0! 0%!
BLM! 6! 3! 3.2%! 0! 0! 0.6%! 6! 7! 7.1%!
CYLD! 6! 3! 3.5%! 1! 1! 1%! 0! 0! 0%!
Exo1! 6! 3! 5.2%! 0! 0! 0%! 2! 2! 4%!
FXR2! 6! 3! 5.8%! 0! 0! 0%! 0! 0! 0%!
RPS27L! 6! 1! 29%! 2! 0! 15%! 3! 1! 29%!
FILA2! 4! 2! 1%! 2! 2! 1%! 3! 3! 2%!
NUP153! 4! 2! 1.6%! 0! 0! 0%! 2! 2! 2.2%!
ZC3H14! 4! 2! 3.4%! 4! 3! 6.1%! 0! 0! 0%!
FAN1! 2! 1! 1%! 0! 0! 0%! 4! 3! 3.8%!
MSH3! 2! 1! 1%! 0! 0! 0%! 5! 5! 7.2%!
FARSB! 0! 4! 7.3%! 5! 0! 0%! 7! 8! 15%!
KHSRP! 0! 0! 0%! 4! 3! 5.1%! 8! 9! 20%!
NONO! 0! 0! 0%! 0! 0! 0%! 6! 7! 14%! 	  
Table	  3:	  Results	  of	  LC-­‐MS	  of	  GFP-­‐MLH1	  interactome	  Interaction	   partners	   of	   GFP-­‐MLH1	   identified	   by	   GFP-­‐Trap	   pulldown	   and	   LC-­‐MS	   in	  untreated	  cells	  (MLH1),	  MNNG-­‐treated	  (MLH1	  MNNG)	  and	  chromatin-­‐enriched	  extracts	  were	  sorted	  according	  to	  scores	  in	  normalized	  total	  spectra	  (NTS),	  unique	  peptides	  (UP)	  and	  sequence	  coverage	  (SC).	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NTS! UP! SC! NTS! UP! SC!
MSH2! 139! 41! 52%! 170! 43! 53%!
MSH6! 100! 38! 34%! 114! 39! 34%!
MSH3! 40! 29! 36%! 62! 34! 41%!
WDHD1! 19! 15! 16%! 17! 12! 12%!
EXOI! 11! 9! 16%! 20! 11! 19%!
SMRCD! 4! 3! 4.4%! 5! 4! 5.3%!
MCM9! 4! 3! 3.5%! 7! 5! 6.3%!
CL023! 4! 3! 47%! 4! 3! 40%!
1433F! 4! 3! 13%! 4! 3! 13%!
MCM8! 2! 2! 3.3%! 4! 3! 5.1%!
MLH1! 2! 2! 4.9%! 3! 2! 4%!
CCNB1! 1! 1! 3.9%! 4! 3! 9%!
COPG2! 1! 1! 1.4%! 3! 2! 2.5%!
CD2AP! 2! 2! 3.8%! 1! 1! 2.2%!
SET! 2! 2! 8.7%! 0! 0! 0%!
CSRP2! 2! 2! 13%! 0! 0! 0%!
SPG20! 0! 0! 0%! 3! 2! 4.5%! 	  
Table	  4:	  Results	  of	  LC-­‐MS	  of	  MSH2-­‐eGFP	  interactome	  Interaction	   partners	   of	   MSH2-­‐eGFP	   identified	   by	   GFP-­‐Trap	   pulldown	   and	   LC-­‐MS	   in	  untreated	   (MSH2)	   and	   MNNG-­‐treated	   (MSH2	   MNNG)	   cells	   were	   sorted	   according	   to	  scores	  in	  normalized	  total	  spectra	  (NTS),	  unique	  peptides	  (UP)	  and	  sequence	  coverage	  (SC).	  	  	  
6.8 WDHD1	  levels	  decrease	  upon	  MSH2	  depletion	  and	  MNNG	  
treatment	  Because	   WDHD1	   was	   found	   as	   a	   strong	   binding	   partner	   of	   MSH2	   in	   both	  approaches	   (rank	   4	   directly	   behind	  MSH6	   and	  MSH3),	   we	   decided	   to	   conduct	  some	   further	   experiments	   with	   this	   candidate.	   The	   function	   of	   WDHD1	   [also	  known	  as	  Acidic	  Nucleoplasmic	  DNA	  binding	  Protein	  1	  (AND-­‐1)	  or	  Chromosome	  Transmission	  Fidelity	  Factor	  4	  Homolog	   (CTF4)]	   still	   remains	   enigmatic.	  Work	  done	  so	  far	  associates	  the	  DNA	  binding	  protein	  with	  genome	  maintenance	  such	  as	  signal	  transduction	  upon	  DNA	  damage,	  initiation	  of	  DNA	  replication	  and	  a	  role	  in	  homologous	  DNA	  double	  strand	  break	  repair	  (144-­‐147).	  Depletion	  of	  WDHD1	  was	  shown	  to	  increase	  DNA	  damage,	  prolong	  S	  phase,	  induce	  cell	  death	  in	  cancer	  cells	  and	  decrease	  repair	  of	  I-­‐SceI-­‐driven	  double-­‐strand	  breaks	  repair.	  Moreover,	  knock	   down	   of	   WDHD1	   impaired	   the	   formation	   of	   the	   CMG	   complex	   (Cdc45,	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MCM2-­‐7,	  GINS),	  which	  is	  believed	  to	  play	  an	  important	  role	  for	  DNA	  replication	  fork	  formation	  and	  progression.	  	  As	  a	  first	  experiment,	  HEK	  293	  cells	  were	  depleted	  of	  MSH2	  and	  protein	  levels	  of	  WDHD1	  were	  addressed.	   Interestingly,	   the	  protein	   levels	  of	  WDHD1	  decreased	  after	   72	   h	   and	   96	   h	   (Figure	   20	   A).	   As	   WDHD1	   has	   been	   associated	   with	  maintenance	   of	   genome	   stability	   and	   non-­‐canonical	   MMR	   can	   be	   induced	   by	  MNNG,	  we	  checked	  for	  recruitment	  of	  WDHD1.	  Surprisingly,	  unlike	  MMR	  factors,	  WDHD1	   levels	   decreased	  upon	  MNNG	   treatment	   in	   the	  nucleus	   in	  HEK	  293	   as	  well	   as	   in	   U2OS	   cells	   (Figure	   20	   B).	   For	   U2OS	   cells,	   a	   decrease	   in	   cytoplasmic	  fraction	  was	   also	   observed.	   As	   illustrated	   in	   Figure	   20C,	   depletion	   of	  MSH2	   in	  MNNG	  cells	  did	  not	  rescue	  or	  further	  decrease	  WDHD1	  levels,	  which	  implies	  that	  the	  decrease	  upon	  MNNG	  treatment	  is	  independent	  of	  MSH2.	  	  Recently,	   Chen	   and	   colleagues	   also	   identified	   WDHD1	   as	   a	   strong	   interaction	  partner	  of	  MSH2	  in	  an	  AP-­‐MS	  approach	  and	  could	  verify	  the	  interaction	  with	  Co-­‐IP.	  Moreover,	  they	  found	  that	  WDHD1	  depletion	  makes	  cells	  resistant	  towards	  6-­‐thioguanine	  (6-­‐TG)	  treatment,	  as	  does	  MSH2	  depletion	  (148).	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Figure	   20:	   Decrease	   of	  WDHD1	   protein	   levels	   upon	  MSH2	   depletion	   and	  MNNG	  
treatment	  (A)	   HEK	   293	   cells	   were	   treated	  with	   siRNA	  MSH2	   (+)	   or	   siLuc	   (-­‐)	   for	   indicated	   time	  periods.	  Western	  Blot	   analyses	   revealed	  decreased	   levels	  upon	  MSH2	  knockdown.	   (B)	  HEK	  293	  and	  U2OS	  cells	  were	  treated	  with	  10	  mM	  O6-­‐BG	  for	  1	  h	  and	  5	  µM	  MNNG	  for	  3	  h	  and	   cytoplasmic	   (Cyto)	   and	   nuclear	   (Nuc)	   proteins	   were	   isolated.	   For	   both	   cell	   lines,	  WDHD1	  levels	  decreased	  in	  the	  nucleus	  upon	  MNNG	  treatment.	  (C)	  Nuclear	  proteins	  of	  MNNG-­‐treated	   and	   siRNA-­‐treated	   cells	   were	   analyzed	   and	   revealed	   no	   influence	   of	  MSH2	  on	  the	  reduction	  of	  WDHD1	  levels	  upon	  MNNG	  treatment.	  	  	  
6.9 Proximity-­‐dependent	  biotin	  labeling	  using	  BioID	  	  	  The	  applied	  AP-­‐MS	  approach	  using	  GFP	  or	  eGFP-­‐tagged	  MMR	  proteins	  and	  GFP-­‐Trap	  for	  pulldowns	  revealed	  WDHD1	  as	  an	   interesting	  new	  interaction	  partner	  of	  MutSα	  and	  MutSβ,	  although	  our	  initial	  aim	  to	  develop	  a	  technique	  that	  could	  be	  used	  to	  analyze	  the	  MMR	  interactome	  before	  and	  after	  DNA	  damage	  could	  not	  be	  addressed.	  Therefore,	  we	  decided	  to	  explore	  other	  methods.	  The	  first	  one	  we	  tested	  is	  a	  technique	  called	  BioID.	  A	  mutated	  biotin	  ligase	  (BirA*	  R118G)	  fused	  to	  a	   protein	   of	   interest	   produces	   reactive	   biotinyl-­‐5'-­‐AMP	   from	   biotin,	  which	   can	  bind	  to	  lysine	  residues	  of	  any	  protein	  in	  close	  proximity	  (128).	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Figure	  21:	  PMS2-­‐BirA*,	  but	  not	  BirA*-­‐MLH1	  is	  active	  (A)	  Cytoplasmic	  and	  nuclear	  extracts	  of	  cells	  stably	  expressing	  BirA*-­‐MLH1	  with	  (+)	  or	  without	   (-­‐)	   MNNG	   treatment	   revealed	   erroneous	   localization	   of	   BirA*-­‐MLH1	   and	   no	  recruitment	   to	   the	   nucleus	   after	   MNNG	   treatment.	   (B)	   Western	   Blot	   with	   Strep-­‐HRP	  showed	   no	   biotinylation	   of	   endogenous	   proteins	   in	   BirA*-­‐MLH1	   cells.	   (C)	   Transiently	  expressed	  PMS2-­‐BirA*	  can	  biotinylate	  endogenous	  proteins.	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6.10 Proximity-­‐dependent	  biotin	  labeling	  using	  Apex	  As	   the	   Bio-­‐ID	  method	   did	   not	  work	   for	  MLH1,	  we	   decided	   to	   try	   an	   approach	  called	   APEX.	   APEX	   is	   an	   engineered	   ascorbate	   peroxidase	   from	   soybean	   that	  generates	   highly-­‐reactive	   phenol	   radicals	   that	   can	   bind	   to	   electron-­‐rich	   amino	  acids	   such	   as	   tyrosine,	   tryptophan,	   cysteine	   or	   histidine.	   The	   reaction	   is	  catalyzed	   by	   H2O2.	   When	   biotin-­‐phenol	   is	   used,	   endogenous	   proteins	   in	   close	  proximity	   are	   labeled	   with	   biotin-­‐phenol	   and	   can	   later	   be	   isolated	   on	  streptavidin-­‐coated	  resins	  (129).	  	  	  	  	  	  	  	  















































Figure	  22:	  APEX2-­‐MLH1	  is	  recruited	  to	  the	  nucleus	  and	  is	  enzymatically	  active	  (A)	  Western	  Blot	  of	  MNNG	  (+)	  and	  untreated	  cells	  (-­‐)	  showed	  enhanced	  recruitment	  of	  APEX2-­‐MLH1	  to	  the	  nucleus	  after	  DNA	  damage.	  (B)	  Cytoplasmic	  and	  nuclear	  proteins	  of	  cells	   treated	   with	   biotin-­‐phenol	   and	   H2O2	   reveal	   labeling	   with	   biotin	   as	   judged	   by	  staining	  with	  streptavidin-­‐HRP.	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Figure	  23:	  Enrichment	  of	  MLH1	  interactors	  after	  APEX2-­‐MLH1	  activation	  (A)	  Proteins	  purified	  with	  streptavidin	  agarose	  were	  made	  visible	  by	  silver	  staining.	  In	  the	  negative	  control	  (Flp-­‐In),	  only	  endogenous	  biotinylated	  proteins	  are	  visible,	  while	  in	  the	  extracts	  of	  APEX2-­‐MLH1	  cells,	  several	  protein	  bands	  appeared.	  (B)	  Western	  Blot	  of	  pulldowns	   from	   A	   revealed	   biotinylation	   of	   known	  MLH1	   interaction	   partners	   PMS2,	  FAN1	  and	  MSH2.	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6.10.2 MLH1	  interactome	  using	  APEX	  approach	  Having	   shown	   that	   APEX2-­‐MLH1	   is	   active,	   we	   went	   on	   to	   study	   the	   MLH1	  interactome	  with	  this	  system.	  We	  performed	  LC-­‐MS	  analyses	  of	  two	  replicates	  of	  each	  condition	  and	  fraction.	  Flp-­‐In	  cells	  were	  used	  as	  control.	  As	  shown	  in	  Figure	  24,	  over	  1,300	  proteins	  were	  detected	  in	  each	  APEX2-­‐MLH1	  sample	  and	  no	  more	  than	  900	  in	  all	  controls.	  Moreover,	  1,381	  proteins	  were	  identified	  in	  APEX-­‐MLH1	  samples	  alone.	  We	  also	  observed	  a	  difference	  between	  cytoplasmic	  and	  nuclear	  extracts.	   525	   factors	   were	   detected	   in	   both	   fractions,	   but	   337	   proteins	   were	  exclusively	   found	   in	   the	   cytoplasm	   and	   519	   in	   the	   nucleus,	   respectively.	   The	  sequence	  coverage	  of	  MLH1	  was	  rather	  high	  with	  about	  48	  -­‐	  68%.	  As	  a	  quality	  control	   and	   in	   order	   to	   validate	   our	   results,	   the	   data	   were	   aligned	   to	   protein	  interaction	   databases	   such	   as	   IntAct	   (149).	   Many	   known	   and	   well-­‐established	  interactors	   could	   be	   seen	   in	   our	   approach	   including	   PMS1,	   PMS2	   and	   Exo1.	  However,	   the	  data	  on	  some	   factors	  were	  quite	  unexpected.	  For	   instance,	  PMS2	  was	   identified	  with	  high	  spectra	  count	   in	   the	  cytoplasm	  but	  not	   in	   the	  nucleus.	  MSH2	  and	  FAN1,	  which	  were	   clearly	   identified	  by	  Western	  Blot	  did	  not	  match	  the	   threshold	  criteria	  and	  are	  absent	   in	   the	   list.	  For	  MSH2,	  20	  and	  13	  peptides	  could	   be	   identified	   in	   the	   cytoplasm	   and	   nucleus	   in	   the	   APEX2-­‐MLH1	   cells,	  respectively,	  but	  also	  7	  and	  3	  peptides	  in	  the	  control.	  FAN1	  was	  not	  assigned	  at	  all.	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Figure	  24:	  LC-­‐MS	  APEX2-­‐MLH1	  nuclear	  and	  cytoplasmic	  extracts	  (A)	  Cells	  expressing	  APEX2-­‐MLH1	  and	  293	  Flp-­‐In	  cells	  were	  treated	  with	  biotinphenol	  and	  H2O2	  followed	   by	   the	   extraction	   of	   cytoplasmic	   and	   nuclear	   proteins,	   streptavidin	  pulldown	  and	  LC-­‐MS.	  The	  total	  numbers	  of	  identified	  proteins	  and	  sequence	  coverage	  of	  MLH1	  and	  streptavidin	   in	  each	   fraction	  and	   replicate	  are	   shown.	   (B)	  Venn	  diagram	  of	  identified	   proteins	   reveals	   that	   1,381	   proteins	   were	   identified	   exclusively	   in	   APEX2-­‐MLH1	  samples,	  525	  of	  which	  were	  detected	  in	  the	  cytoplasmic	  and	  nuclear	  fraction.	  337	  proteins	   were	   found	   in	   the	   cytoplasmic	   fraction	   and	   519	   in	   the	   nuclear	   fraction,	  respectively.	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MSH6	   41|52	   47|50	   4|5|13|10	  
CKB	   41|49	   0|0	   0|0|5|2	  
FANCD2	   32|35	   9|11	   0|0|0|0	  
ALDOA	   25|28	   0|0	   5|0|0|0	  
PMS1	   21|32	   7|7	   0|0|0|0	  
ATM	   19|29	   8|7	   0|0|0|0	  
PMS2	   19|22	   0|0	   0|0|0|0	  
RUVBL2	   18|17	   22|22	   3|4|2|3	  
RUVBL1	   19|14	   21|21	   2|2|2|2	  
FANCJ	   12|14	   0|0	   0|0|0|0	  
MSH3	   12|11	   19|22	   0|0|2|3	  
NPP2R1A	   10|12	   0|0	   3|2|0|0	  
PSMA1	   11|9	   0|0	   0|0|0|0	  
MMS19	   10|9	   0|0	   2|0|0|0	  
SNW1	   7|10	   8|8	   0|0|0|0	  
NBN	   8|7	   7|6	   0|0|0|0	  
ANXA6	   3|7	   0|0	   0|0|0|0	  
BRCA1	   2|6	   6|6	   0|0|0|0	  
RAD23B	   3|4	   0|0	   0|0|0|0	  
MLH3	   5|2	   0|0	   0|0|0|0	  
PYGB	   2|4	   0|0	   0|0|0|0	  
CUTA	   3|3	   0|0	   0|0|0|0	  
SQSTM1	   3|2	   0|0	   0|0|0|0	  
PPP2R2A	   2|3	   0|0	   0|0|0|0	  
EXO1	   2|3	   6|6	   0|0|0|0	  NDGR1	   2|2	   0|0	   0|0|0|0	  
NONO	   0|0	   164|180	   7|9|40|39	  
ZC3H11A	   0|0	   25|27	   0|0|4|3	  
PRKDC	   0|0	   608|637	   64|64|208|189	  
YLPM1	   0|0	   67|89	   0|0|13|7	  
BARD1	   0|0	   4|4	   0|0|0|0	  
BLM	   0|0	   16|18	   0|0|0|2	  
RFC1	   0|0	   29|33	   0|0|8|10	  
	  
Table	  5:	  Known	  MLH1-­‐interacting	  proteins	  identified	  by	  APEX2-­‐MLH1	  approach	  Proteins	   identified	   in	   LC-­‐MS	   (Figure	   24)	   were	   scored	   by	   total	   spectra	   count	   and	  submitted	   to	   the	   IntAct	   database	   to	   align	   the	   hits	   against	   known	   MLH1	   interacting	  proteins	  (149).	  The	  results	  are	  listed	  according	  to	  their	  score	  in	  the	  cytoplasmic	  fraction.	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6.10.3 Differential	  MLH1	  interactome	  after	  MNNG	  treatment	  Despite	  the	  contradicting	  results	  from	  the	  Western	  Blot	  analyses	  and	  the	  LC-­‐MS	  regarding	  FAN1	  in	  particular,	  we	  went	  on	  to	  study	  the	  MLH1	  interactome	  after	  DNA	  damage.	  First,	  we	  decided	  to	  treat	  the	  cells	  with	  MNNG	  to	  study	  the	  MMR	  interactome	  after	  alkylation	  damage	  and	  induction	  of	  non-­‐canonical	  MMR.	  Cells	  expressing	  APEX-­‐MLH1	  were	  treated	  with	  O6-­‐BG	  for	  1	  h,	  followed	  by	  treatment	  with	  10	  µM	  MNNG	  or	  DMSO	  for	  3	  h.	  Biotin-­‐phenol	  was	  added	  2	  h	  after	  addition	  of	  MNNG.	  When	  we	  analyzed	  biotinylated	  proteins	  by	  LC-­‐MS,	  we	   found	  several	  factors	  enriched	  in	  the	  MNNG	  samples	  compared	  to	  DMSO	  treated	  (Table	  6).	  	  We	  found	  several	  factors	  involved	  in	  translation	  such	  as	  RPN1,	  TUFM	  and	  RPS18	  as	  well	   as	   proteins	   associated	   with	   protein	   folding	   and	   membrane	   trafficking	  including	   CANX	   and	   SSR4.	  We	   also	   found	  proteins	   associated	  with	  DNA	   repair	  such	   as	  WDR8,	   USP22	   and	   BCCIP.	   Interestingly,	  WDR18	   and	   BCCIP	   appear	   as	  interactors	  in	  a	  string	  network	  created	  with	  the	  identified	  proteins	  (Figure	  25).	  In	   addition	   to	   factors	   that	   appeared	   only	   after	   MNNG	   treatment	   as	   potential	  interactors	   of	  APEX2-­‐MLH1,	  we	   could	   identify	   some	  proteins	   that	   disappeared	  after	   MNNG	   treatment	   (Table	   7).	   Because	   BCCIP	   (BRCA2	   and	   CDKN1-­‐A	  interacting	  protein)	  has	  previously	  been	  shown	  to	   interact	  with	  RAD51	  as	  well	  as	  BRCA2	  and	  has	  been	  suggested	  to	  play	  a	  role	   in	  HR,	  we	  decided	  to	  do	  some	  follow-­‐up	   experiments	   (150).	   Sensitivity	   against	   alkylation	   damage	   is	   a	   very	  good	  readout	   for	  proteins	   involved	   in	  MMR	  and	  because	  BCCIP	  was	   found	  as	  a	  potential	  co-­‐factor	  of	  MLH1	  after	  MNNG	  treatment,	  we	  decided	  to	  check	  for	  cell	  survival	   after	   BCCIP	   single	   and	   BCCIP/MLH1	   double	   knockout.	   As	   expected,	  MLH1	   knockdown	   made	   the	   cells	   resistant	   against	   MNNG	   (Figure	   26).	   The	  phenotype	  of	  BCCIP	  depleted	  cells	  resembled	  the	  one	  of	  wt	  cells.	  Moreover,	  cells	  lacking	   both,	   MLH1	   and	   BCCIP,	   behaved	   as	   MLH1-­‐deficient	   cells.	   We	   could	  neither	  observe	  any	  effect	  after	  MNNG	  treatment	  of	  BCCIP	  knockdown	  alone	  nor	  additional	  or	  rescue	  effects	  of	  BCCIP	  on	  MLH1	  depleted	  cells.	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AvgP	   BFDR	  
RPN1	   8|8|4	   0|0|0	   1	   0	  PRDX4	   4|5|6	   0|0|0	   1	   0	  
CANX	   7|8|3	   0|0|0	   0.99	   0	  CPNE3	   4|3|3	   0|0|0	   0.98	   0	  
PTBP2	   4|4|2	   0|0|0	   0.95	   0.01	  
TUFM	   2|4|4	   0|0|0	   0.95	   0.01	  
USP22	   2|4|4	   0|0|0	   0.95	   0.01	  
INTS5	   4|2|3	   0|0|0	   0.94	   0.03	  
WDR18	   3|3|2	   0|0|0	   0.94	   0.03	  
RPS18	   2|4|2	   0|0|0	   0.91	   0.03	  
HSD17B12	   2|4|2	   0|0|0	   0.91	   0.03	  
SPDL1	   2|3|2	   0|0|0	   0.9	   0.05	  
ZFP91	   2|2|3	   0|0|0	   0.9	   0.05	  
BCCIP	   3|2|2	   0|0|0	   0.9	   0.05	  
EIF2B3	   3|2|2	   0|0|0	   0.9	   0.05	  
SSR4	   2|2|3	   0|0|0	   0.9	   0.05	  
LBR	   6|6|7	   0|2|2	   0.9	   0.04	  
CAPZA2	   3|2|2	   0|0|0	   0.9	   0.05	  
TRMT112	   3|2|2	   0|0|0	   0.9	   0.05	  
KRT77	   2|3|2	   0|0|0	   0.9	   0.05	  
ZNF11	   2|3|2	   0|0|0	   0.9	   0.05	  
RPLP1	   3|2|2	   0|0|0	   0.9	   0.05	  
	  
Table	  6:	  Factors	  with	  increased	  APEX2-­‐MLH1	  biotinylation	  after	  MNNG	  treatment	  Cells	  expressing	  APEX2-­‐MLH1	  were	   treated	  with	  10	  µM	  O6-­‐BG	   for	  1	  h	   followed	  by	  10	  µM	  MNNG	  or	  DMSO	  for	  3	  h	  before	  the	  activation	  of	  APEX2.	  The	  experiment	  was	  done	  in	  triplicates	  and	  the	  factors	  were	  scored	  according	  to	  the	  average	  probability	  using	  total	  spectra	  count.	  In	  addition,	  the	  Bayesian	  false	  discovery	  rate	  (BFDR)	  is	  shown.	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  
Figure	  25:	  String	  network	  of	  MLH1-­‐interacting	  proteins	  after	  MNNG	  treatment	  Data	   from	  Table	  6	  were	  used	   to	  create	  a	  string	  network	   for	   functional	  analysis	  (151).	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AvgP	   BFDR	  
HOXB6	   2|3|3	   0|0|0	   0.87	   0	  PPP4R2	   2|3|2	   0|0|0	   0.8	   0.13	  
ARID4A	   2|2|2	   0|0|0	   0.73	   0.16	  TFG	   2|2|2	   0|0|0	   0.73	   0.16	  
SUDS3	   2|2|2	   0|0|0	   0.73	   0.16	  
MLLT3	   2|2|2	   0|0|0	   0.73	   0.16	  
MEIS2	   2|2|2	   0|0|0	   0.73	   0.16	  
	  
























Figure	  26:	  BCCIP	  knockdown	  does	  not	  alter	  cell	  sensitivity	  towards	  MNNG	  293	  cells	  were	  treated	  with	  siRNAs	  against	  MLH1	  and	  BCCIP	  for	  24	  h	  and	  seeded	  in	  96-­‐well	   plates.	  After	   treatment	  with	  O6-­‐BG	  and	  MNNG,	   the	   cells	  were	   incubated	   for	  96	  h	  and	  the	  viability	  was	  measured.	  Data	  points	  are	  the	  average	  of	  3	  replicates.	  	  	  	  	  
6.10.4 MLH1	  interactome	  after	  MMC	  treatment	  In	   addition	   to	   MNNG	   treatment,	   we	   wanted	   to	   know	   how	   the	   interactome	   of	  MLH1	   might	   change	   after	   treatment	   with	   ICL	   inducing	   MMC.	   APEX2-­‐MLH1	  expressing	  cells	  were	  treated	  with	  MMC	  or	  DMSO	  and	  biotinylated	  proteins	  from	  nuclear	   abstracts	   were	   analyzed	   using	   LC-­‐MS.	   As	   shown	   in	   Table	   8,	   several	  factors	  reacted	  on	  the	  MMC	  treatment	  and	  can	  be	  considered	  as	  potential	  MLH1	  interactors	  after	  MMC	  damage.	  In	  addition	  to	  numerous	  proteins	  that	  have	  been	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associated	  with	   functions	   in	   development,	   pre-­‐mRNA	   splicing,	   transcription	   or	  protein	  trafficking,	  factors	  with	  functions	  in	  DNA	  repair	  could	  also	  be	  identified.	  RPA2	   is	   a	   well-­‐known	   factor	   of	   MMR	   and	   protects	   single	   stranded	   DNA	   (13).	  Moreover,	  Excision	  Repair	  Cross-­‐Complementation	  Group	  6	  (ERCC6)	  was	  found,	  which	   has	   been	   associated	   with	   transcription-­‐coupled	   DNA	   repair	   (152).	   In	  contrast	   to	   several	   new	   potential	   interactions	   of	   MLH1	   in	   response	   to	   MMC	  treatment,	  only	  a	  few	  factors	  were	  lost.	  The	  proteins	  that	  we	  could	  only	  detect	  in	  DMSO-­‐treated	   cells	   are	   summarized	   in	   Table	   9.	   Interestingly,	   two	   of	   the	   three	  proteins	  are	  associated	  with	  epigenetic	  gene	  regulation	  (153,154).	  	  	  	  	  	  




AvgP	   BFDR	  
CTNNBL1	   15|12|16	   3|2|4	   0.99	   0.01	  
TEX10	   4|3|5	   0|0|0	   0.99	   0	  
CSNK1E	   4|3|2	   0|0|0	   0.96	   0.01	  
RPA2	   5|6|5	   0|1|1	   0.95	   0.02	  
PHC2	   2|2|4	   0|0|0	   0.94	   0.03	  
SSB	   2|2|2	   0|0|0	   0.91	   0.04	  
DGKH	   2|2|2	   0|0|0	   0.91	   0.04	  
SLC25A6	   1|4|5	   0|0|0	   0.86	   0.05	  
KPNB1	   3|3|1	   0|0|0	   0.85	   0.06	  
TFCP2	   3|1|3	   0|0|0	   0.85	   0.06	  
COASY	   2|4|4	   1|0|0	   0.84	   0.08	  
NCAPG	   4|2|1	   0|0|0	   0.83	   0.08	  
NUP155	   4|2|1	   0|0|0	   0.83	   0.08	  
RBM42	   1|4|2	   0|0|0	   0.83	   0.08	  
PHF6	   3|1|2	   0|0|0	   0.82	   0.1	  
WBSCR22	   2|1|3	   0|0|0	   0.82	   0.1	  
BOP1	   2|2|1	   0|0|0	   0.8	   0.11	  
ERCC6	   2|1|2	   0|0|0	   0.8	   0.11	  
EYA3	   2|2|1	   0|0|0	   0.8	   0.11	  
MAGOH	   1|2|2	   0|0|0	   0.8	   0.11	  
	  
Table	  8:	  Factors	  with	  increased	  APEX2-­‐MLH1	  biotinylation	  after	  MMC	  treatment	  Cells	  expressing	  APEX2-­‐MLH1	  were	  treated	  with	  MMC	  (25	  µM)	  for	  1	  h	  before	  activation	  of	  APEX2.	  The	  experiment	  was	  done	  in	  triplicates	  and	  the	  factors	  were	  scored	  according	  to	   the	   average	   probability	   using	   total	   spectra	   count.	   In	   addition,	   the	   Bayesian	   false	  discovery	  rate	  (BFDR)	  is	  shown.	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AvgP	   BFDR	  
KMT2B	   4|4|3	   0|0|0	   0.95	   0	  KPNA1	   3|5|3	   0|0|0	   0.93	   0.05	  
EZH2	   3|2|2	   0|0|0	   0.69	   0.06	  
	  
Table	  9:	  Factors	  with	  decreased	  APEX2-­‐MLH1	  biotinylation	  after	  MMC	  treatment	  Cells	  expressing	  APEX2-­‐MLH1	  were	  treated	  with	  MMC	  (25	  µM)	  for	  1	  h	  before	  activation	  of	  APEX2.	  The	  experiment	  was	  done	  in	  triplicates	  and	  the	  factors	  were	  scored	  according	  to	   the	   average	   probability	   using	   total	   spectra	   count.	   In	   addition,	   the	   Bayesian	   false	  discovery	  rate	  (BFDR)	  is	  shown.	  	  	  	  	  	  
6.10.5 APEX2-­‐GFP	  labels	  proteins	  unspecifically	  When	   APEX2-­‐MLH1	   was	   used	   to	   find	   new	   co-­‐factors	   of	   MLH1,	   many	   known	  interactors	  could	  be	   identified.	  However,	  more	  than	  1,300	  proteins	  were	   found	  to	   be	   enriched	   in	   the	   APEX2-­‐MLH1	   samples	   compared	   to	   the	   control.	  Considering	   that	   more	   than	   1,300	   proteins	   account	   for	   about	   5%	   of	   the	   total	  human	  proteome	  and	  are	  too	  many	  to	  be	  followed	  up	  step-­‐by-­‐step,	  we	  decided	  to	  introduce	   another	   control	   to	   reduce	   the	   number	   of	   new	   potential	   MLH1-­‐	  interacting	   proteins.	   Hence,	   we	   generated	   an	   APEX2-­‐GFP	   fusion	   protein	   and	  made	   stable	   cell	   lines	   again	   using	   the	   pAIO	   system.	   After	   induction	   of	   APEX2-­‐GFP,	  we	  treated	  the	  cells	  with	  biotin-­‐phenol	  and	  H2O2	  and	  found	  that	  APEX-­‐GFP	  is	  active	  in	  labeling	  endogenous	  proteins	  with	  biotin-­‐phenol	  in	  the	  cytoplasm	  as	  well	  as	  in	  the	  nucleus	  (Figure	  27	  A).	  When	  we	  compared	  the	  activity	  of	  APEX2-­‐GFP	  with	  APEX2-­‐MLH1,	  we	  found	  that	  APEX2-­‐GFP	  is	  slightly	  more	  active	  in	  the	  cytoplasm	  than	  APEX2-­‐MLH1	  but	  has	  a	  similar	  activity	  in	  the	  nucleus	  (Figure	  27	  B).	  The	  activity	  of	  APEX2-­‐GFP	  was	  stronger	  in	  the	  nucleus	  than	  in	  the	  cytoplasm.	  The	  same	  was	  observed	  for	  APEX2-­‐MLH1.	  Fluorescence	  microscopy	  was	  used	  to	  check	   for	   the	  distribution	  of	  APEX2-­‐GFP	  within	   the	   cell.	  According	   to	   the	  GFP-­‐signal,	  APEX2-­‐GFP	  localized	  equally	  to	  the	  cytoplasm	  and	  to	  the	  nucleus	  (Figure	  27	  C).	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Figure	  27:	  APEX2-­‐GFP	  is	  active	  in	  the	  cytoplasm	  and	  the	  nucleus	  (A)	  Parental	  293	  Flp-­‐In	  cells	  and	  APEX2-­‐GFP	  expressing	  cells	  were	  treated	  with	  biotin-­‐phenol	   and	   H2O2	   which	   led	   to	   biotinylation	   of	   endogenous	   proteins,	   as	   judged	   by	  incubation	  with	   streptavidin-­‐HRP.	   (B)	   Flp-­‐In	  APEX2-­‐GFP	   and	  APEX2-­‐MLH1	   cells	  were	  treated	  with	  biotin-­‐phenol	   and	  H2O2	   to	   check	   for	  APEX2	  activity.	   (C)	  White	   light	   (left)	  and	  UV	  light	  (right)	  show	  the	  distribution	  of	  APEX2-­‐MLH1	  all	  over	  the	  cell.	  	  	  	  	  	  As	   a	   next	   step,	   a	   pulldown	   of	   proteins	   biotinylated	   by	   APEX2-­‐GFP	   and	   APEX-­‐MLH1	   was	   performed	   to	   check	   for	   unspecific	   biotinylation	   of	   MLH1-­‐binding	  proteins	   by	  APEX2-­‐GFP.	  Unfortunately,	   the	  Western	  Blot	   revealed	   that	  APEX2-­‐GFP	  seems	  to	   label	  all	  proteins.	  Every	  protein	  we	   looked	  at,	  even	   including	  the	  loading	  control	  β-­‐Tubulin,	  was	   found	   to	  be	  biotinylated	   (Figure	  28).	  Moreover,	  some	   interactors	   of	  MLH1	  were	   labeled	   even	   stronger	   by	   APEX2-­‐GFP	   than	   by	  APEX-­‐MLH1,	   such	   as	  FANCJ,	   FAN1	  and	  MSH2	   in	   the	   cytoplasmic	   fraction.	  Also,	  MLH1	  was	  found	  to	  be	  biotinylated	  by	  APEX2-­‐GFP.	  Only	  PMS2	  was	  significantly	  more	  enriched	  in	  the	  APEX2-­‐MLH1	  samples.	  As	  a	  next	  step,	  we	  had	  planned	  LC-­‐MS	  analyses	  to	  characterize	  the	  MLH1	  interactome	  using	  the	  APEX	  approach.	  For	  obvious	  reasons,	  we	  did	  not	  continue	  and	  started	  to	  develop	  other	  controls	  such	  as	  an	  APEX2-­‐TDG	  fusion	  protein.	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Figure	  28:	  APEX2-­‐GFP	  labels	  MLH1	  interactors	  and	  β-­‐Tubulin	  Cells	   expressing	   either	   APEX2-­‐GFP	   or	   APEX2-­‐MLH1	   were	   treated	   with	   biotin-­‐phenol	  and	   H2O2	  and	   cytoplasmic	   and	   nuclear	   proteins	   were	   extracted.	   After	   pulldown	   with	  streptavidin	   resins,	   the	   bound	   proteins	   were	   analyzed	   by	   Western	   Blot.	   All	   tested	  proteins	  were	  biotinylated	  by	  APEX2-­‐GFP.	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7 Discussion	  
7.1 The	  pAIO	  system	  –	  a	  powerful	  method	  to	  study	  gene	  variants	  	  The	   pAIO	   protein	   replacement	   system	   has	   been	   developed	   to	   study	   genotype-­‐phenotype	  correlations	  and	  in	  particular	  missense	  mutations.	  The	  original	  pAIO	  system	  consisted	  of	   two	  main	   features:	  an	  shRNA	  expression	  cassette	   to	  knock	  down	  the	  endogenous	  protein	  and	  a	  cDNA	  expression	  cassette	  for	  transcription	  of	  a	  protein	  variant.	  Importantly,	  both	  cassettes	  are	  inducible	  by	  Dox.	  The	  system	  has	  been	  used	   successfully	   to	   replace	   the	   catalytic	   subunit	   of	  DNA	  polymerase	  pol-­‐δ	   p125	   (POLD1)	   with	   a	   flag-­‐tagged	   variant	   of	   p125	   with	   either	   wt,	   error-­‐prone	  or	  proofreading	  deficient	  variants	  (130).	  Many	  different	  experiments	  and	  assays	  could	  be	  performed	  by	   the	  simple	  addition	  of	  Dox	   to	   induce	   the	  system	  instead	   of	   repeated	   transfection	   of	   cDNA	   variants	   and	   siRNAs.	   However,	   the	  generation	   of	   the	   final	   cell	   lines	   was	   work-­‐intensive	   and	   required	   many	  individual	  cloning	  steps	  as	  well	  as	  picking	  and	  testing	  of	  several	  individual	  single	  cell	  clones.	  	  	  	  	  To	   improve	   our	   system,	   we	   aimed	   to	   combine	   it	   with	   well-­‐established	   fast	  cloning	  methods	  and	  a	  system	  to	  overcome	  the	  tedious	  work	  of	  single	  cell	  clone	  analysis.	  Hence,	  we	  decided	  to	  introduce	  the	  Gateway	  system	  into	  our	  plasmid	  to	  speed	  up	   the	   integration	  of	   cDNAs	   into	   the	  pAIO	  plasmid.	  Using	   this	  approach,	  the	   integration	   of	   cDNA	   variants	   from	   Entry	   clones	   became	   more	   rapid	   and	  reliable.	  Another	  advantage	  of	   the	  Gateway	  system	   is	   clearly	  given	  by	   the	  easy	  generation	  of	  gene	  variants	  such	  as	  missense	  mutations.	  Instead	  of	  mutagenesis	  of	   the	  whole	   final	   plasmid,	   only	   the	   entry	   clone	   needs	   to	   be	  mutated	   and	   the	  variant	  can	  then	  be	  cloned	   into	   the	   final	  pAIO	  destination	  vectors.	  This	  saves	  a	  lot	  of	  time	  and	  resources	  regarding	  sequencing,	  because	  only	  the	  cDNA	  sequence	  in	  the	  Entry	  vector	  needs	  to	  be	  checked	  instead	  of	  the	  final	  plasmid.	  In	  order	  to	  advance	   the	   generation	   of	   stable	   cell	   lines,	   we	   made	   use	   of	   the	   Flp	  Recombination	   Target	   (FRT)	   system.	   Using	   this	   system,	   picking	   of	   single	   cell	  clones	   in	   Flp-­‐In	   293	   T-­‐REx	   cells	   became	   dispensable	   and	   it	   was	   possible	   to	  generate	  homogenous	  bulk	  cell	  lines	  in	  less	  than	  three	  weeks.	  Although	  the	  CMV	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Figure	  29:	  Scheme	  of	  the	  2nd	  pAIO	  protein	  replacement	  system	  	  The	  pAIO	  vector	  contains	  an	  H1	  promoter	   for	  shRNA	  expression	  and	  a	  CMV	  promoter	  for	  cDNA	  expression,	  both	  inducible	  due	  to	  tet	  binding	  sites.	  The	  shRNA	  oligonucleotide	  is	   easily	   integrated	   into	   the	   plasmid	   with	   BglII	   and	   HindIII	   digestion.	   The	   cDNA	   of	  interest	   is	   recombined	   into	   the	   vector	   via	   AttR	   sites	   for	   Gateway	   cloning.	   With	   PCR	  techniques,	   the	   CMV	   promoter	   can	   be	   adapted	   to	   the	   desired	   expression.	   For	   the	  generation	   of	   stable	   cell	   lines,	   the	   FRT	   site	   is	   used	   in	   Flp-­‐In	   cells	   and	   stable	   cells	   are	  selected	  with	  hygromycin.	  The	  usage	  of	  entry	  plasmids	  before	  Gateway	  recombination	  provides	  a	  reliable	  method	  to	  generate	  shRNA-­‐resistant	  cDNAs	  and	  mutant	  variants	  of	  the	  gene	  of	  interest.	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7.2 The	  pAIO	  system	  as	  an	  alternative	  to	  the	  CRISPR/Cas9	  system	  The	   CRISPR/Cas9	   (Clustered	   regularly-­‐interspaced	   short	   palindromic	  repeats/CRISPR	   associated	  protein	  9)	   system	  provides	   a	   very	  powerful	   tool	   to	  specifically	  knock	  out	  genes	  in	  any	  cell.	  In	  principle,	  a	  single	  guide	  RNA	  (sgRNA)	  binds	  homology-­‐dependently	  to	  a	  specific	  sequence	  in	  the	  genomic	  DNA	  utilized	  by	  its	  crRNA	  (CRISPR	  RNA)	  domain	  and	  recruits	  Cas9	  with	  its	  tracrRNA	  (trans-­‐activating	   crRNA)	   domain.	   The	   nuclease	   activity	   of	   Cas9	   creates	   a	   DNA	   DSB,	  which	   is	  subsequently	  repaired	  either	  by	  NHEJ	  or	  by	  homology-­‐directed	  repair	  (HDR)	  (155,156).	  In	  both	  cases,	  the	  aim	  is	  to	  disrupt	  the	  gene	  sequence	  leading	  to	  the	  loss	  of	  the	  functional	  gene	  product.	  Once	  a	  gene	  has	  been	  knocked	  out,	  it	  can	  be	  replaced	  by	  insertion	  of	  a	  cDNA	  copy	  similar	  to	  our	  pAIO	  plasmid.	  In	  the	  same	   manner,	   different	   cDNA	   variants	   such	   as	   missense	   mutations	   can	   be	  integrated	   into	   the	   knockout	   cell.	   	   Another	   way	   of	   creating	   a	   cell	   line	   with	   a	  specific	  mutation	   is	  provided	  by	   the	  HDR	  approach.	   In	   this	   case,	   a	  DNA	  DSB	   is	  induced	  and	  a	  plasmid	  containing	  the	  mutated	  sequence	  is	  used	  as	  a	  template	  for	  homologues	  repair	  resulting	  in	  a	  cell	  line	  with	  a	  mutated	  gene.	  	  	  	  	  	  The	  CRISPR/Cas9	  system	  has	  one	  big	  advantage	  over	  the	  pAIO	  system.	  While	  our	  pAIO	   system	   is	   based	  on	  RNAi,	  which	   leads	  only	   to	   a	   knockdown	  of	   the	   target	  gene,	   the	   CRISPR/Cas9	   system	   results	   in	   a	   complete	   gene	   knockout.	   For	   some	  target	   genes,	   an	   shRNA-­‐mediated	   knockdown	   is	   very	   efficient	   and	  basically	   no	  protein	  can	  be	  detected.	  For	  instance,	  no	  visible	  p125	  after	  knockdown	  with	  the	  1st	  generation	  pAIO	  plasmid	  was	  left	  (130).	  In	  contrast,	  the	  knockdown	  of	  MLH1	  with	  shRNA	  or	  siRNA	  alone	  was	  strong,	  but	  longer	  exposure	  times	  revealed	  more	  than	  10%	  of	  residual	  endogenous	  MLH1,	  which	  can	  many	  MLH1	  functions	  (72).	  Only	   the	   combination	   of	   both	   shRNA	   from	   the	   pAIO	   plasmid	   and	   transient	  transfection	   of	   siRNA	   reduced	  MLH1	  way	   below	  10%.	  Moreover,	   it	   is	   believed	  that	  RNAi-­‐mediated	  gene	  knockdown	  results	   in	  more	  off-­‐target	  effects	  than	  the	  use	  of	  CRISPR/Cas9.	  As	  we	  replace	  the	  endogenous	  protein	  with	  a	  tagged	  cDNA	  variant	  in	  our	  system,	  we	  expected	  to	  see	  no	  significant	  differences	  between	  the	  non-­‐induced	   situation	   and	   the	   replacement	   with	   the	   wt	   cDNA.	   This	   is	   exactly	  what	  we	  observed	  in	  most	  experiments	  meaning	  that	  the	  chance	  of	  artifacts	  due	  to	   off-­‐target	   effects	   is	   rather	   low.	   Only	   in	   the	   cell	   viability	   assay	   after	   MNNG	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treatment	  did	  we	  observe	  that	  wt	  GFP-­‐MLH1	  cells	  were	  slightly	  more	  resistant	  than	  non-­‐induced	  cells	  with	  endogenous	  MLH1.	  This	  could	  hint	  towards	  an	  off-­‐target	   effect,	   but	   it	   is	  more	   likely	   that	   GFP-­‐MLH1	   is	   slightly	   less	   efficient	   than	  MLH1	   in	  addressing	  MNNG-­‐induced	  DNA	   lesions.	  Another	  big	  advantage	  of	   the	  CRIPR/Cas9	   system	   is	   given	   by	   the	   HDR	   approach.	   If	   the	   desired	   mutation	   is	  induced	   within	   the	   genome	   by	   HDR,	   the	   gene	   is	   still	   expressed	   from	   its	   own	  promoter	   resulting	   in	   normal	   expression	   levels	   and	   still	   underlies	   endogenous	  gene	   regulation.	   Although	   this	   has	   not	   been	   a	   problem	   for	   the	   replacement	   of	  p125,	  the	  expression	  of	  MLH1	  from	  the	  wt	  CMV	  promoter	  was	  too	  strong,	  which	  was,	  however,	  overcome	  by	  adapting	  the	  promoter.	  	  	  Clearly,	   there	  are	  some	  strong	  advantages	  of	   the	  CRISPR/Cas9	  system	  over	   the	  pAIO	  system	  but	  it	  also	  has	  some	  disadvantages.	  First,	  a	  knockout	  is	  not	  possible	  for	  all	  genes.	  Some	  genes,	  mainly	  structural	  genes,	  are	  essential	  and	  a	  complete	  knockout	  ultimately	  leads	  to	  cell	  death,	  a	  fact	  that	  makes	  it	  impossible	  to	  create	  cell	  lines	  for	  later	  replacement	  with	  cDNA	  variants.	  The	  pAIO	  system,	  however,	  is	  inducible,	  which	   allows	   for	   simultaneous	   replacement	   of	   the	   endogenous	   gene	  with	  a	  cDNA	  variant.	  Thus,	  even	  essential	  genes	  could	  be	  studied	  with	  the	  pAIO	  system,	   because	   the	   knockdown	   is	   only	   induced	   after	   Dox	   treatment	   which	  allows	   for	   the	   selection	   of	   stable	   cell	   lines.	   Even	   the	  HDR	   approach	  might	   not	  help	  here,	  because	  missense	  mutations	  that	  abolish	  the	  function	  of	  an	  essential	  gene	  will	  also	  result	  in	  cell	  death.	  Second,	  depending	  on	  the	  efficiency	  of	  the	  gene	  knockout	   with	   CRISPR/Cas9,	   it	   can	   be	   much	   work	   to	   screen	   many	   single	   cell	  clones	  for	  every	  cDNA	  variant.	  Although	  this	  amount	  of	  work	  can	  be	  reduced	  by	  integrating	  a	   resistance	  gene	  using	  HDR,	   it	   is	   still	  much	  more	  work	   than	  using	  the	  pAIO	  system.	  Third,	  we	  have	  shown	  that	  very	  reliable	  bulk	  cell	   lines	  can	  be	  generated	  with	  Flp-­‐In	  293	  T-­‐REx	  cell	   lines.	   In	   the	  case	  of	  CRISPR/Cas9,	  several	  single	  cell	  clones	  ought	  to	  be	  used	  for	  every	  experiment	  to	  exclude	  clonal	  effects.	  	  	  	  	  	  	  	  	  	  	  	  Another	  limitation	  of	  the	  CRISPR/Cas9	  system	  concerns	  gene	  copy	  numbers.	  For	  most	  genes,	  cells	  carry	  two	  copies	  of	  a	  single	  gene	  and	  both	  need	  to	  be	  knocked	  out	  or	  replaced.	  However,	  cancer	  cell	  lines	  with	  altered	  karyotypes	  such	  as	  U2OS	  cells	  may	  not	  only	  have	  two	  but	  several	  copies	  of	  the	  target	  gene	  and	  all	  of	  them	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have	   to	   be	   hit.	   Besides	   changes	   of	   copy	   numbers	   due	   to	   cancerous	  transformation,	   there	   are	   genes	   that	   have	   naturally	   more	   than	   two	   copies.	  Histone	  genes	  have	  10	  -­‐	  20	  gene	  repeats	  in	  higher	  eukaryotes	  and	  up	  to	  100	  in	  
drosophila	  melanogaster	  (157,158).	  These	  numbers	  make	  it	  nearly	  impossible	  to	  knock	   out	   all	   of	   them	   step	   by	   step.	   An	   RNAi	   based	   approach,	   however,	   might	  provide	  a	  solution	  as	  it	  does	  not	  target	  the	  DNA	  but	  the	  transcripts.	  	  	  
7.3 Combination	  of	  pAIO	  and	  CRISPR/Cas9	  to	  overcome	  drawbacks	  	  The	  pAIO	  and	  the	  CRIPR/Cas9	  system	  have	  their	  advantages	  and	  disadvantages.	  While	   the	   biggest	   benefit	   of	   the	   CRISPR/Cas9	   system	   is	   clearly	   the	   complete	  knockout	  of	  a	  gene,	  the	  strongest	  argument	  for	  the	  pAIO	  system	  is	  provided	  by	  the	  fact	  that	  it	  is	  inducible	  and	  reversible.	  The	  Cas9	  protein	  has	  been	  engineered	  to	  be	  used	  for	  many	  other	  applications	  besides	  the	  induction	  of	  DNA	  DSBs.	  One	  interesting	  development	  of	  the	  Cas9	  toolbox	  is	  the	  fusion	  of	  a	  nuclease	  dead	  Cas9	  protein,	  which	   is	  now	  converted	   into	  a	   sequence-­‐specific	  DNA-­‐binding	  protein,	  with	   transcriptional	   repressors	   such	   as	   KRAB	   (Krüppel	   associated	   box)	   (159).	  The	  chromatin	  modifier	  KRAB	  recruits	  histone	  deacetylases	  and	  methylases	  such	  as	  Mi-­‐2α	  and	  SETDB1,	  respectively,	  which	  bring	  about	  an	  epigenetic	  change	  and	  thus	  can	  shut	  down	  the	  transcription	  of	  the	  target	  gene	  (160,161).	  This	  approach	  could	  be	  used	   in	   the	  pAIO	  system	  to	  silence	   the	  endogenous	  protein	   instead	  of	  using	   RNAi.	   It	   would	   improve	   the	   system	   in	   two	  ways:	   Firstly,	   the	   risk	   of	   off-­‐target	  effects	  is	  further	  reduced.	  Secondly,	  genes	  that	  are	  difficult	  to	  knock	  down	  with	  RNAi	  become	  targetable.	  	  	  	  	  	  	  	  
7.4 Reduced	  levels	  of	  MLH1	  R659Q	  due	  to	  decreased	  protein	  
stability	  When	  we	  used	   the	  pAIO	  system	   to	   replace	  endogenous	  MLH1	   in	  Flp-­‐In	  293	  T-­‐REx	   cells	  with	  mutant	   GFP-­‐MLH1	  R659Q,	  we	   first	   of	   all	   observed	   significantly	  lowered	  protein	   levels	   compared	   to	  wt	  GFP-­‐MLH1.	  Reduced	  GFP-­‐MLH1	  R659Q	  was	   found	   in	  whole	   cell	   extracts	   as	  well	   as	   in	   nuclear	   extracts.	   Similar	   results	  were	   obtained	   in	   previous	   studies.	   Takahashi	   and	   colleagues	   reported	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expression	  levels	  of	  MLH1	  R659Q	  of	  25-­‐75%	  after	  transient	  transfection	  in	  MLH-­‐deficient	  HCT116	  cells	  (12).	  Similarly,	  Hinrichsen	  and	  colleagues	  observed	  MLH1	  R659Q	   levels	   of	   about	   65%	   compared	   to	   wt	   when	   transiently	   expressed	   in	  MLH1-­‐deficient	  293T	  cells	  (95).	  Our	  data	  also	  suggest	  a	  decrease	  to	  65%.	  Taken	  together,	   protein	   levels	   are	   clearly	   reduced	   due	   to	   the	   R659Q	   mutation.	   We	  wondered	  if	  this	  was	  caused	  by	  reduced	  transcription	  of	  the	  R659Q	  construct	  or	  by	  decreased	  mRNA	  stability.	  Because	  the	  mRNA	  levels	  were	  equal	  in	  all	  tested	  GFP-­‐MLH1	   variants,	   our	   results	   suggest	   that	   neither	   transcription	   nor	   mRNA	  levels	  are	  affected	  in	  the	  R659Q	  mutant.	  The	  same	  was	  observed	  in	  the	  study	  of	  Hinrichsen	  et	  al.	   (95).	  Although	  we	  cannot	  rule	  out	   that	   there	   is	  a	   translational	  block,	   it	   seems	   that	   the	  R659Q	  mutation	  affects	   the	  protein	  stability	  and	  might	  lead	   to	   increased	   protein	   turnover.	   Complex	   formation	   of	   proteins	   increases	  their	  stability	  and	  although	  the	  R695Q	  mutant	  still	  interacts	  strongly	  with	  PMS2,	  it	   showed	   impaired	  binding	   to	  FANCJ	  and	  FAN1.	  The	   loss	  of	   the	  ability	   to	   form	  those	   complexes	  might	   explain	  why	   this	   fraction	   undergoes	   early	   degradation,	  resulting	  in	  overall	  decreased	  levels	  of	  the	  R659Q	  mutant.	  Interestingly,	  the	  K84E	  mutant	  showed	  increased	  protein	  levels	  in	  the	  cytoplasm,	  but	  not	  in	  the	  nucleus,	  which	  implies	  that	  the	  nuclear	  import	  of	  MLH1	  molecules	  is	   tightly	   regulated.	   Obviously,	   increased	   levels	   in	   the	   cytoplasm	   do	   not	  automatically	   lead	   to	   increased	   levels	   in	   the	   nucleus.	   An	   explanation	  might	   be	  that	  strongly-­‐increased	  MLH1	  levels	  in	  the	  nucleus	  might	  impair	  MMR	  integrity,	  which	  has	  been	  observed	  in	  yeast	  (143).	  	  	  	  	  	  
7.5 Impaired	  MMR	  is	  not	  the	  cause	  of	  genome	  instability	  in	  MLH1	  
R659Q	  cells	  When	  we	  initiated	  this	  study,	  our	  aim	  was	  to	  develop	  an	  improved	  pAIO	  system	  to	   study	   genotype-­‐phenotype	   correlations.	   To	   test	   our	   system,	   we	   wanted	   to	  clarify	  the	  molecular	  pathogenesis	  of	   the	  MLH1	  missense	  mutation	  R659Q.	  Our	  first	   results	   revealed	   decreased	   protein	   levels	   and	   we	   speculated	   that	  significantly	   decreased	   protein	   levels	  might	   also	   reduce	  MMR	   activity.	   To	   test	  this	  hypothesis,	   time-­‐lapse	  mismatch	  repair	  assays	  with	  nuclear	  extracts	  of	   the	  different	  MLH1	   variants	  were	   performed.	  Although	   the	   extracts	   containing	   the	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R659Q	   mutant	   were	   slightly	   less	   active	   than	   those	   containing	   wt	   MLH1,	   the	  difference	  was	  not	  significant	  over	  three	  independent	  experiments.	  This	  suggests	  that,	  despite	   reduced	  protein	   levels	  of	   the	  R659Q	  mutant,	   it	   is	  MMR-­‐proficient.	  MMR	   proficiency	   was	   also	   observed	   in	   other	   studies	   using	   the	   in	   vitro	   MMR	  assay.	  Hinrichsen	  et	  al.	  as	  well	  as	  Raevaara	  et	  al.	  observed	  normal	  MMR	  activity	  of	   the	  R659Q	  mutant	  compared	   to	  wt	  MLH1	  (11,95).	  Takahashi	  and	  colleagues	  reported	   slightly	   decreased	  MMR	   activity	   of	   about	   80%	   of	   the	   R659Q	  mutant	  (12).	  A	  question	  that	  remains	  is	  whether	  the	  in	  vitro	  MMR	  assay	  is	  a	  suitable	  tool	  to	  predict	  if	  slightly	  reduced	  MMR	  activities	  are	  still	  enough	  to	  prevent	  increased	  mutation	  rates	  in	  vivo.	  We	  tried	  to	  investigate	  this	  question	  by	  conducting	  a	  long-­‐term	   experiment	  with	   the	  MLH1	   variants.	   Over	   a	   period	   of	   four	  weeks,	  which	  accounts	  for	  about	  40	  cell	  divisions,	  we	  kept	  the	  cells	  in	  media	  with	  Dox	  to	  keep	  the	   pAIO	   system	   activated	   and	   repeatedly	   transfected	   the	   cells	   with	   siRNA	   to	  reduce	   endogenous	   MLH1	   even	   further.	   Afterwards,	   several	   markers	   for	   MSI	  were	   analyzed.	   As	   we	   only	   observed	   a	   MSI	   phenotype	   in	   genomic	   DNA	   from	  293T	  cells,	  which	  served	  as	  a	  positive	  control,	  but	  not	  in	  the	  MLH1	  K84E	  mutant,	  which	   is	   known	   to	   cause	  MSI	   in	   patients,	  we	   came	   to	   the	   conclusion	   that	   this	  experimental	   setup	   is	   not	   suited	   to	   analyze	   the	   effect	   on	   genome	   stability	   of	  MLH1	   mutations	   in	   vivo.	   This	   might	   have	   several	   causes.	   First,	   the	   time	   and	  number	  of	  cell	  divisions	  might	  not	  have	  been	  enough	  to	  cause	  MSI.	  Second,	  the	  remaining	  endogenous	  MLH1	  might	  have	  been	  sufficient	  to	  prevent	  MSI	  because	  10%	  of	  MLH1	  are	  sufficient	  for	  the	  full	  MMR	  activity	  in	  vitro	  (72).	  To	  address	  this	  question,	   the	   generation	   of	   cell	   lines	   with	   mutated	   endogenous	   MLH1	   by	  applying	  the	  CRISPR/Cas9	  HSR	  approach	  might	  be	  helpful.	  	  Taken	   together,	   the	   findings	   from	   this	   study	   and	   also	   the	   observations	   from	  previous	  studies	  strongly	  suggest	  that	  the	  R659Q	  mutation	  does	  not	  significantly	  impair	  MMR	  function	  and	  can	  therefore	  not	  be	  regarded	  as	  the	  driving	  force	   in	  tumor	  development	  in	  patients	  with	  the	  MLH1	  R659Q	  mutation.	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7.6 Loss	   of	   MLH1/FANCJ	   and	   FAN1	   interactions	   might	   increase	  
genomic	  instability	  As	   the	   data	   from	   our	   study	   and	   others	   strongly	   imply	   that	   the	   MLH1	   R659Q	  mutant	   is	   MMR-­‐proficient,	   it	   remains	   unclear	   how	   carriers	   of	   this	   mutation	  acquire	  increased	  mutation	  rates	  that	  lead	  to	  an	  early	  onset	  of	  cancer.	  When	  we	  determined	   the	   interactome	   of	   the	  mutant,	   we	   found	   that	   binding	   to	   the	   DNA	  repair	   factors	   FANCJ	   and	   FAN1	   was	   significantly	   impaired	   compared	   to	   GFP-­‐MLH1	  wt	  and	  K84E.	  FANCJ	  and	  FAN1	  have	  been	  strongly	  associated	  with	  DNA	  interstrand	  crosslink	  (ICL)	  repair	  and	   it	  has	  been	  suggested	   that	  MLH1	  plays	  a	  role	   here	   (59,62,65,124).	   When	   we	   tested	   the	   MLH1	   variants	   against	   the	   ICL	  inducing	   agent	   MMC,	   we	   found	   that	   the	   K84E	  mutant	   and	   the	   R659Q	  mutant	  were	  more	  resistant	  than	  MLH1	  wt.	   In	  the	  case	  of	  the	  R659Q	  mutant,	  we	  could	  confirm	  the	  result	  also	  in	  stably	  transfected	  293T	  cells,	  which	  provide	  evidence	  in	  another	  cell	  system.	  We	  also	  observed	  a	  reduced	  arrest	   in	  G2/M	  phase	  after	  MMC	   treatment	   in	   the	  mutants,	  which	  was	   in	   line	  with	   increased	   cell	   survival	  rates.	  Together,	   these	  experiments	   support	   the	   idea	  of	  an	  altered	  DNA	  damage	  response.	  Reports	  from	  literature	  are	  very	  diverse	  when	  it	  comes	  to	  the	  question	  of	   how	   MLH1-­‐depleted	   cells	   react	   towards	   MMC	   treatment.	   In	   some	   studies,	  MLH1-­‐depleted	   cells	   were	   shown	   to	   be	   more	   resistant	   than	   wt	   cells,	   which	  confirms	  the	  findings	  of	  our	  study	  (51,52).	  However,	  there	  are	  also	  reports	  in	  the	  literature	   showing	   that	   MLH1-­‐depleted	   cells	   are	   more	   sensitive	   to	   MMC	  treatment	  (50,162).	  	  Although	  all	  of	  these	  studies	  suggest	  that	  MLH1	  plays	  a	  role	  in	  the	  repair	  of	  lesions	  that	  arise	  from	  MMC,	  the	  mechanism	  remains	  enigmatic.	  One	  model	  suggests	   that	  MLH1	  plays	  a	  role	   in	   the	  recruitment	  of	  FANCJ	   to	   ICL	  lesions	   (57).	   It	   was	   observed	   that	   in	   MLH1-­‐deficient	   HCT116	   cells,	   the	  recruitment	   to	   laser-­‐induced	   psoralen	   crosslinks	   was	   delayed	   compared	   to	  HCT116	  +	  Chromosome	  3	  cells	  which	  have	  MLH1.	  Another	  model	  suggests	  that	  MLH1	   plays	   a	   role	   in	   unhooking	   the	   lesion,	   but	   this	  model	   lacks	   experimental	  evidence	  (54).	  For	  both	  scenarios,	  MLH1	  is	  directly	  involved	  in	  the	  repair	  of	  the	  ICL	  lesion	  and	  depletion	  of	  MLH1	  might	  lead	  to	  sensitivity	  against	  ICL-­‐inducing	  agents	  as	  was	  observed	  in	  some	  studies	  (50,162).	  Considering	  that	  other	  studies	  reported	   resistance	   against	   MMC	   treatment	   in	   MLH1-­‐depleted	   cells,	   other	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explanations	  of	  the	  mechanism	  seem	  plausible	  (51,52).	  A	  similar	  situation	  occurs	  when	  cells	  are	  treated	  with	  MNNG.	  MMR-­‐deficient	  cells	  are	  much	  more	  resistant	  to	  MNNG	  than	  MMR-­‐deficient	  cells.	  The	  attempted	  repair	  of	   the	   lesions	  creates	  conditions	  that	  are	  very	  toxic	  for	  the	  cell	  and	  lead	  to	  cell	  death,	  while	  unrepaired	  lesions	  are	  much	  less	  toxic,	  but	  at	  the	  expense	  of	  an	  increased	  mutation	  rate.	  It	  is	  tempting	   to	   argue	   that	   this	   might	   be	   the	   same	   for	   MMC-­‐induced	   lesions.	   An	  attempt	  to	  repair	  those	  with	  the	  help	  of	  MLH1	  might	  lead	  to	  the	  creation	  of	  more	  toxic	  DNA	  structures	  such	  as	  DNA	  DSBs	  than	  the	  repair	  process	  without	  MLH1.	  This	   might	   be	   mutagenic,	   but	   less	   toxic	   for	   the	   cells.	   It	   seems	   that	   an	   MLH1-­‐dependent	  repair	  process	  of	  MMC	  induced	  lesions	  requires	  ATPase	  active	  MLH1	  as	   well	   as	   the	   capability	   to	   interact	   with	   FANCJ	   and	   FAN1,	   because	   both	  mutations	  altered	  the	  DDR	  after	  MMC	  treatment.	  With	  the	  data	  collected	  so	  far	  it	  is	   difficult	   to	   determine	   if	   only	   the	   interaction	   with	   FANCJ,	   FAN1	   or	   both	   is	  required	  for	  the	  MLH1-­‐dependent	  repair	  of	  the	  lesions.	  To	  answer	  this	  question,	  an	  MLH1	  mutant	  that	  can	  only	  interact	  with	  FAN1	  or	  FANCJ	  is	  required.	  Xie	  and	  colleagues	   reported	   that	   the	   MLH1	   mutant	   L607H,	   which	   they	   found	   to	   be	  deficient	   in	   binding	   to	   FANCJ,	   was	   more	   sensitive	   to	   MMC	   treatment	   than	   wt	  MLH1	   in	  HCT116	   cells.	   In	   the	   same	  assay,	   however,	  MLH1-­‐deficient	   cells	  were	  even	   more	   resistant	   (163).	   Unfortunately,	   there	   is	   no	   information	   about	   the	  interaction	  with	  FAN1.	   It	   appears	   that	   the	  genetic	  background	  of	  HCT116	  cells	  significantly	  influences	  the	  outcome	  of	  cell	  survival	  assays	  with	  MMC	  depending	  on	   the	   MLH1	   status,	   because	   the	   studies	   that	   showed	   resistance	   after	   MLH1	  depletion	   and	   also	   ours	  with	   different	  mutants	  were	   conducted	   in	   several	   cell	  lines	   such	   as	   293,	  HeLa	   and	  U2OS.	  Another	   explanation	   for	  MMC	   resistance	   in	  MLH1-­‐depleted	   or	   MLH1	   mutant	   cells	   might	   be	   that	   the	   interaction	   of	   MLH1	  inhibits	  the	  activity	  of	  FANCJ	  and	  FAN1.	  A	  slower	  but	  controlled	  repair	  of	  the	  ICL	  lesions	  might	  be	  important	  for	  accurate	  repair	  and	  could	  prevent	  the	  creation	  of	  toxic	  lesions.	  A	  summary	  of	  the	  different	  models	  is	  given	  in	  Figure	  30.	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Figure	  30:	  Roles	  of	  MLH1	  variants	  in	  ICL	  repair	  (A)	  After	  FA	  core	  complex	  activation,	  MLH1	  recognizes	  the	  ICL	  lesion	  and	  recruits	  FAN1	  to	   unhook	   the	   lesion	   followed	   by	   TLS-­‐dependent	   repair.	   The	   resulting	   structures	   are	  resolved	  by	  FANCJ,	  which	   is	   also	   recruited	  by	  MLH1.	   (B)	  MLH1	  R659Q	   cannot	   recruit	  FAN1	  and	  the	  lesion	  is	  left	  unaddressed	  or	  canonical	  ICL	  repair	  factors	  take	  over.	  Later	  on	  FANCJ	  is	  not	  recruited	  for	  resolution	  and	  remodeling	  of	  the	  replication	  fork.	  	  	  	  Also,	  the	  initiation	  of	  DNA	  damage	  signaling	  might	  play	  a	  role	  in	  the	  resistance	  of	  the	  MLH1	  R659Q	  mutant.	  If	  it	  cannot	  bind	  to	  FAN1	  and	  FANCJ,	  MLH1	  might	  lose	  the	   interaction	   with	   the	   lesion	   and,	   in	   turn,	   signaling	   pathways	   may	   not	   be	  triggered.	  Although	  it	  seems	  clear	  that	  a	  lack	  of	  MLH1	  or	  mutations	  that	  affect	  its	  activity	  or	  its	   interaction	  with	  FANCJ	  and	  FAN1	  alter	   the	  DDR	  towards	   lesions	   induced	  by	  MMC,	  this	  mechanism	  clearly	  requires	  more	  investigation.	  Still,	  the	  data	  provide	  a	   potential	   explanation	   of	   how	   carriers	   of	   the	   MLH1	   R659Q	   variant	   acquire	  mutations	   that	   trigger	   tumor	  development.	   ICL	   lesions	   induced	  by	  endogenous	  or	   exogenous	   agents	   such	   as	   acetaldehyde	   after	   alcohol	   consumption	  might	  be	  more	  repaired	  in	  a	  way	  that	  ensures	  cell	  survival,	  but	  at	  the	  expense	  of	  increased	  mutation	  rates	  (164).	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7.7 AP-­‐MS	   of	   MSH2-­‐eGFP	   identifies	   WDHD1	   as	   an	   interactor	   of	  
MutSα 	  	  	  In	   order	   to	   identify	   new	   factors	   that	   might	   facilitate	   MMR	   in	   vivo	   and	   be	   of	  importance	  for	  non-­‐canonical	  MMR,	  we	  fused	  the	  MMR	  factors	  MLH1	  and	  MSH2	  to	  GFP	  or	  eGFP,	  respectively.	  After	  pulldown	  with	  GFP-­‐Trap	  followed	  by	  LC-­‐MS,	  we	   could	   identify	  many	   known	   interaction	   partners,	   but	   also	   found	   some	  new	  interesting	  candidates.	  One	  of	   them	  is	  WDHD1.	  Follow-­‐up	  experiments	  showed	  that	   MSH2	   knockdown	   reduces	   WDHD1	   levels.	   Moreover,	   WDHD1	   levels	  decrease	  after	  MNNG	  treatment.	  Work	  of	  Chen	  and	  colleagues	  also	  demonstrated	  the	  interaction	  of	  WDHD1	  with	  MSH2.	  They	  could	  map	  the	  interaction	  domain	  to	  the	  C-­‐terminal	  region	  of	  WDHD1	  and	  in	  MSH2	  to	  the	  region	  between	  the	  clamp	  domain	  and	  the	  ATPase	  domain.	  Moreover,	  they	  observed	  resistance	  of	  WDHD1-­‐	  depleted	   cells	   towards	   6-­‐TG	   similar	   to	  MSH2	   depletion	   (148).	   Together,	   these	  results	  suggest	  that	  WDHD1	  plays	  a	  role	  in	  in	  vivo	  MMR.	  However,	  the	  resistance	  of	   WDHD1	   could	   also	   be	   MMR-­‐independent.	   Further	   studies	   are	   needed	   to	  explore	   a	   potential	   role	   of	   WDHD1	   in	   MMR	   in	   vivo.	   First	   of	   all,	   it	   would	   be	  interesting	   to	   see	   how	   WDHD1	   depletion	   affects	   cell	   survival	   after	   MNNG	  treatment.	  If	  WDHD1	  is	  indeed	  needed	  for	  in	  vivo	  MMR,	  depletion	  should	  lead	  to	  resistance.	   Surprisingly,	   MNNG	   treatment	   resulted	   in	   decreased	   levels	   of	  WDHD1.	  Chen	  and	  colleagues	  also	  reported	  that	  WDHD1	  is	  mutated	  in	  numerous	  cancers	   and	  might	   contribute	   to	   tumorigenesis.	   It	  might	  be	  of	   great	   interest	   to	  test	   if	   those	  cancers	  show	  MSI	   instability,	  which	  could	  be	  another	  hint	  towards	  the	  involvement	  of	  WDHD1	  in	  MMR.	  	  We	   also	   found	   the	   helicases	   MCM8	   and	   MCM9	   in	   our	   AP-­‐MS	   data	   for	   MSH2.	  Researchers	   have	   for	   a	   long	   time	   searched	   for	   helicases	   involved	   in	   MMR	   in	  eukaryotes	  that	  might	  be	  functional	  homologous	  to	  the	  UvrD	  helicase	  in	  bacterial	  MMR.	  Interestingly,	  a	  study	  by	  Traver	  et	  al.	  now	  suggests	  that	  MCM9	  helicase	  is	  needed	  for	  in	  vivo	  MMR	  in	  a	  way	  that	  its	  helicase	  activity	  unwinds	  the	  mismatch-­‐containing	   DNA	   region,	   thus	   catalyzing	   the	   removal	   of	   the	   mismatch.	   They	  showed	   that	  MCM9	   strongly	   interacts	  with	  MMR	   initiation	   factors	   and	  provide	  data	  that	  MCM9	  is	  needed	  to	  recruit	  MLH1	  to	  chromatin	  (31).	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7.8 AP-­‐MS	   does	   not	   identify	   DNA	   damage-­‐dependent	   change	   of	  
MMR	  interactomes	  In	  addition	  to	  gathering	  information	  about	  the	  general	  interactome	  of	  MLH1	  and	  MSH2,	  we	  treated	  the	  cells	  with	  MNNG	  to	   track	  changes	  and	  to	   identify	   factors	  important	   for	   non-­‐canonical	   MMR.	   However,	   when	   comparing	   the	   data	   of	  untreated	   and	   treated	   cells,	   we	   could	   not	   find	   significant	   changes.	   This	   might	  have	  several	  reasons.	  First	  of	  all,	  if	  changes	  occur,	  they	  might	  only	  be	  transient	  or	  weak	  and	  thus	  might	  be	  lost	  during	  the	  pulldown.	  Furthermore,	  there	  might	  only	  be	  minor	  changes	  that	   fall	  below	  the	  threshold	  and	  are	   filtered	  out.	  The	  strong	  binding	  of	  MLH1	  to	  PMS2	  and	  PMS1	  or	  of	  MSH2	  to	  MSH3	  and	  MSH6	  might	  mask	  the	  appearance	  or	  loss	  of	  factors	  after	  MNNG	  treatment.	  Different	  approaches	  to	  study	  transient	  and	  weak	  interactions	  have	  been	  developed	  including	  the	  use	  of	  crosslinking	  agents	  or	  proximity-­‐dependent	  labeling	  techniques	  such	  as	  BioID	  or	  APEX.	  	  	  	  	  	  	  Prominent	   protein-­‐protein	   crosslinkers	   include	   the	   imidoester	   crosslinker	  dimethyl	   suberimidate	   or	   the	  N-­‐hydroxysuccinimide-­‐ester	   crosslinker	   BS3	   and	  formaldehyde.	  Each	  of	  these	  crosslinkers	  reacts	  with	  the	  amino	  groups	  of	  lysines	  to	   form	  covalent	  bonds.	   	  Another	  method	  of	   in	  vivo	   crosslinking	  applies	  photo-­‐reactive	   amino	   acid	   analogs.	   Cells	   are	   grown	   with	   photoreactive	   diazirine	  analogs	  to	  methionine	  as	  well	  as	  leucine	  and	  are	  incorporated	  into	  the	  proteins	  during	  translation.	  Exposure	  to	  UV	  light	  activates	  the	  diazirines,	  which	  then	  bind	  to	   interacting	   proteins	   (165).	   In	   this	   study,	   we	   explored	   BioID	   and	   Apex	   as	  methods	  to	  label	  proteins	  in	  close	  proximity,	  which	  can	  be	  later	  pulled	  down	  by	  affinity	  purification.	  	  	  	  	  	  	  	  
7.9 Drawbacks	  of	  BioID	  and	  APEX	  technologies	  	  As	   we	   could	   not	   identify	   changes	   in	   the	   interactome	   of	   MLH1	   and	   MSH2	  following	   MNNG	   treatment,	   we	   decided	   to	   explore	   BioID	   and	   APEX	   for	   our	  purposes	  (128,129).	  First,	  we	  found	  that	  BirA*	  fused	  N-­‐terminally	  to	  MLH1	  was	  inactive	  and	  moreover	  impaired	  the	  stability	  of	  MLH1	  and	  its	  localization.	  There	  might	   be	   ways	   to	   circumvent	   these	   problems.	   The	   usage	   of	   a	   longer	   linker	  between	   the	   two	   proteins	   could	   help	   them	   fold	  more	   independently	   and	   thus	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help	   sustain	   their	   functions.	   In	   general,	   BirA*	   could	   also	   be	   fused	   to	   the	   C-­‐terminus	   which	   might	   solve	   the	   problem.	   In	   the	   case	   of	   MLH1,	   this	   is	   not	  recommended,	  because	  the	  last	  residue	  of	  yeast	  MLH1	  was	  shown	  to	  contribute	  to	  the	  endonuclease	  function	  of	  PMS1	  (90).	  Also,	  studies	  with	  human	  MLH1	  have	  demonstrated	   that	   C-­‐terminal	   tagging	   of	   MLH1	   impairs	   its	   function	   (142).	  Alternatively,	   one	   could	   fuse	   BirA*	   within	   the	   MLH1	   sequence	   between	   the	  functional	   domains.	   For	   instance,	   the	  mid-­‐region	   between	   the	   binding	   site	   for	  MutS	   homologs	   and	   EXO1	   appears	   suitable	   for	   such	   an	   approach.	   However,	  experience	  from	  other	  labs	  suggests	  that	  these	  changes	  might	  not	  be	  successful	  to	  obtain	  an	  active	  and	  functional	  BirA*-­‐MLH1	  fusion	  protein	  (Richard	  Lutz	  and	  Kerstin	   Gari,	   IMCR	   University	   of	   Zurich,	   personal	   communication).	   Hence,	   it	  might	  be	  more	  promising	  to	  use	  PMS2-­‐BirA*	  which	  we	  have	  shown	  to	  be	  active.	  As	  a	  next	  step,	  it	  needs	  to	  be	  verified	  whether	  PMS2-­‐BirA*	  is	  functional	  in	  MMR	  and	  localizes	  to	  the	  nucleus.	  	  As	  another	  approach	  based	  on	  proximity	  labeling,	  we	  explored	  the	  APEX	  system.	  In	   contrast	   to	  BirA*-­‐MLH1,	  APEX2-­‐MLH1	  was	  active	  and	  behaved	  as	  wt	  MLH1.	  We	  used	   the	   system	   to	   study	  changes	   in	   the	   interactome	  of	  MLH1	  after	  MNNG	  and	  MMC	  treatment	  and	  could	  identify	  some	  interesting	  factors.	  However,	  when	  we	   introduced	   an	   APEX2-­‐GFP	   as	   another	   control,	   we	   found	   that	   APEX	  unspecifically	   labeled	   nearly	   every	   protein	   we	   tested.	   One	   could	   argue	   that	   a	  Western	  Blot	  might	  not	  be	  enough	  to	  conclude	  that	  APEX2	  is	  too	  unspecific,	  but	  LC-­‐MS	  data	   from	  colleagues	  (Kerstin	  Gari	  and	  Richard	  Lutz,	   IMCR	  University	  of	  Zurich)	  who	  also	  used	  our	  APEX2-­‐pAIO	  plasmid	   for	  protein-­‐protein	   interaction	  studies	  confirmed	  that	  APEX2	  is	  too	  unspecific	  and	  seems	  to	  label	  every	  protein	  (personal	   communication).	   Instead	   of	   APEX2-­‐GFP,	   they	   used	   APEX2	   alone	   but	  also	  with	  that	  approach,	  very	  well	  described	  binding	  proteins	  of	  the	  bait	  proteins	  were	   found	   in	   the	   APEX2	   control.	  With	   these	   findings,	   we	   concluded	   that	   the	  background	   in	   this	   approach	   is	   too	   strong	   to	   search	   for	   important	   new	  interactions	  after	  DNA	  damage	  and	  we	  thought	  about	  ways	  to	  limit	  the	  unspecific	  activity.	   	  One	   idea	   is	   to	   fuse	  APEX2	   to	  another	  DNA	  repair	   factor	   such	  as	  TDG.	  This	  might	  help	  to	  limit	  the	  labeling	  of	  proteins	  and	  to	  restrict	  the	  area.	  Another	  possibility	   is	   to	   use	   APEX	   instead	   of	   APEX2.	   APEX2	   has	   been	   developed	   to	  increase	   its	  activity	  (132).	  As	   in	  our	  case	  the	  strong	  activity	  of	  APEX2	  could	  be	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the	  reason	  for	  its	  low	  specificity,	  a	  limited	  generation	  of	  biotinphenol	  radicals	  by	  using	  less	  active	  APEX	  could	  be	  a	  solution.	  	  	  	  	  	  	  	  	  
7.10 Alternative	  strategies	  to	  study	  the	  MMR	  interactome	  after	  DNA	  
damage	  Although	   using	   PMS2-­‐BirA*	   and	   APEX	   instead	   of	   APEX2	   to	   reduce	   its	   activity	  provide	   potential	   solutions	   to	   the	   drawbacks,	   it	   is	   worthwhile	   to	   think	   about	  alternative	   approaches	   to	   study	   the	   MMR	   interactome	   in	   different	   aspects	   of	  DNA	   metabolism.	   Previous	   work	   from	   our	   group	   has	   demonstrated	   that	   non-­‐canonical	  MMR	  cannot	  only	  be	  activated	  by	  MNNG	  treatment	  of	   living	  cells,	  but	  also	  by	  plasmids	  containing	  U-­‐G	  mismatches	  if	  BER	  is	  inactivated	  (74).	  Using	  this	  approach,	  it	  might	  be	  possible	  to	  induce	  non-­‐canonical	  MMR	  in	  nuclear	  extracts	  and	   to	  pull	  down	   important	   factors	   involved	   in	   the	  process	  either	  by	   targeting	  the	  plasmid	  or	  tagged	  proteins	  such	  as	  GFP-­‐MLH1	  or	  MSH2-­‐eGFP.	  If	  the	  system	  proves	  to	  be	  informative,	  it	  might	  also	  be	  interesting	  to	  see	  what	  other	  proteins	  take	  part	  in	  canonical	  MMR	  using	  nuclear	  extracts.	  	  	  	  A	   very	   elegant	   method	   to	   study	   the	   proteins	   involved	   in	   ICL	   repair	   called	  CHROMASS	   (chromatin	   mass	   spectrometry)	   has	   been	   recently	   described	   by	  Raschle	   and	   colleagues	   (166).	   They	   used	   replicating	   Xenopus	   egg	   extracts	   and	  ICL-­‐containing	  chromatin	  and	  analyzed	  the	  proteins	  that	  bound	  to	  the	  chromatin	  and	  studied	  how	  they	  might	  contribute	  to	  ICL	  repair.	  	  It	  is	  not	  difficult	  to	  imagine	  that	  this	  system	  could	  be	  adapted	  to	  study	  the	  proteome	  of	  non-­‐canonical	  MMR.	  Indeed,	  our	  group	  had	  used	  Xenopus	  egg	  extracts	  before	  to	  study	  the	  hypothesis	  of	  futile	  cycling	  in	  a	  replicative	  system	  (44).	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8 Conclusion	  and	  Outlook	  	  	  	  The	   pAIO	   system	   has	   proven	   to	   be	   a	   very	   useful	   technique	   to	   study	   the	  phenotype	  of	  gene	  variants.	  With	   the	  help	  of	   the	   first	  generation	  pAIO,	  our	   lab	  could	   study	   polymerase	   δ	   variants	   in	   a	   human	   system	   in	   vivo	   and	   the	   second	  generation	   pAIO	   plasmid	   helped	   to	   study	   the	  MLH1	  R659Q	  mutation	   that	   had	  been	  contradictive	  for	  many	  years.	  We	  were	  able	  to	   integrate	  some	  very	  useful	  features	  into	  the	  new	  pAIO	  plasmid,	  which	  make	  the	  system	  much	  easier	  to	  work	  with	   and	  more	   efficient.	   If	   an	   entry	   clone	  plasmid	   is	   available,	   it	   is	   possible	   to	  clone	   the	   desired	   plasmids	   within	   a	   week	   and	   stable	   cell	   lines	   are	   available	  within	  three	  to	  four	  weeks.	  This	  is	  very	  fast	  compared	  to	  other	  techniques	  used	  to	   replace	   or	   reconstitute	   gene	   variants.	   Although	   the	   cDNA	   in	   our	   system	   is	  driven	   by	   an	   exogenous	   CMV	   promoter	   and	   lacks	   endogenous	   regulation,	   we	  found	   ways	   to	   adapt	   the	   expression	   level	   of	   our	   gene	   of	   interest	   to	   be	  comparable	   to	   that	   of	   the	   endogenous	   protein.	   We	   used	   our	   cell	   system	   for	  various	   cell	  biology	  and	  biochemistry	  assays	  and	   it	   is	   fair	   to	   say	   that	  we	  could	  use	  the	  system	  for	  nearly	  every	  experiment	  that	  is	  based	  on	  or	  uses	  cell	  lines.	  	  	  	  	  Although	   the	   protein	   replacement	   based	   on	   RNAi	   worked	   very	   efficiently	   for	  polymerase	  δ	   as	  well	   as	   for	  MLH1	  when	   supported	  with	   siRNA,	   some	  proteins	  are	  difficult	   to	  knock	  down	  with	  RNAi	  and	  there	   is	  always	  the	  risk	  of	  off-­‐target	  effects.	   Hence,	   it	  might	   be	  worthwhile	   to	   think	   about	   another	   improvement	   of	  our	   system	   by	   combining	   it	   with	   the	   latest	   development	   of	   the	   CRISPR/Cas9	  technique.	  It	  should	  be	  possible	  to	  generate	  a	  cell	  line	  that	  expresses	  a	  nuclease-­‐dead	   Cas9	   fusion	   protein	   that	   induces	   transcriptional	   repression	   through	  epigenetic	   silencing	   such	   as	   KRAB.	   Now,	   instead	   of	   cloning	   an	   shRNA	   into	   the	  pAIO	  vector,	  an	  sgRNA	  guides	  the	  fusion	  protein	  to	  the	  promoter	  of	  the	  gene	  of	  interest,	  which	   leads	   to	   its	   repression,	  while	  a	  variant	  of	   the	  gene	   is	  expressed	  driven	  by	  the	  CMV	  promoter	  in	  the	  pAIO	  plasmid.	  	  	  We	  have	  used	  the	  second	  generation	  pAIO	  system	  to	  produce	  stable	  cell	  lines	  in	  which,	   upon	   Dox	   induction	   endogenous	   MLH1	   is	   replaced	   by	   GFP-­‐tagged	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variants.	   One	   of	   the	   variants	   we	   created	   is	   the	   MLH1	   R659Q	   mutant.	   The	  mutation	  has	  been	  found	  in	  several	  HNPCC	  families	  but	  the	  molecular	  pathology	  remained	   unclear.	   With	   the	   help	   of	   our	   system,	   we	   could	   confirm	   that	   the	  mutation	  results	  in	  reduced	  levels	  of	  MLH1	  in	  whole	  cell	  extracts	  as	  well	  as	  in	  the	  nucleus,	   but	   nevertheless	   it	   is	   MMR-­‐active.	   A	   very	   striking	   difference	   was	  observed	  when	  we	   studied	   its	   interactions	  with	   the	  DNA	   repair	   factors	   FANCJ	  and	  FAN1.	  Compared	  to	  wt	  GFP-­‐MLH1,	  binding	  to	  both	  was	  strongly	  reduced.	  As	  both	  factors	  are	  associated	  with	  ICL	  repair,	  we	  checked	  for	  the	  response	  towards	  ICL-­‐inducing	  MMC	  treatment	  and	  found	  resistance	  in	  cell	  survival	  assays	  as	  well	  as	   a	   reduced	   G2/M	   phase	   arrest.	   It	   appears	   that	   the	   limited	   binding	   to	   either	  FANCJ	   and/or	   FAN1	   alters	   the	   MLH1-­‐dependent	   DDR	   towards	   MMC	   induced	  lesions.	   This	   might	   give	   a	   hint	   as	   to	   how	   R659Q	   mutation	   carriers	   acquire	  mutations	   despite	   the	   fact	   that	   the	   cells	   are	   MMR-­‐proficient.	   In	   further	  experiments,	   we	   should	   try	   to	   decipher	   the	  molecular	   mechanism	   of	   how	   the	  MLH1	   R659Q	   mutant	   affects	   ICL	   lesion	   processing.	   This	   understanding	   might	  then	   help	   to	   develop	   strategies	   on	   how	   to	   prevent	   or	   decrease	   mutations	   in	  mutation	  carriers.	  At	  the	  moment,	  it	  seems	  that	  a	  reduction	  of	  ICLs	  could	  reduce	  the	  number	  of	  mutations.	  Although	  it	  is	  difficult	  to	  prevent	  ICLs	  that	  arise	  from	  endogenous	  sources,	  it	  might	  be	  worthwhile	  to	  reduce	  exogenous	  sources	  of	  ICLs	  such	  as	  acetaldehyde,	  which	  is	  the	  degradation	  product	  of	  alcohol	  consumption.	  	  	  In	   the	  second	  part	  of	   the	   study	  we	   focused	  on	   the	  MMR	   interactome	  and	  were	  especially	   interested	   in	   the	   changes	   of	   the	   interactome	   after	   induction	   of	   non-­‐canonical	  MMR	  causing	  DNA	  damage.	  First,	  we	  used	  GFP-­‐	  and	  eGFP-­‐tagged	  MMR	  proteins	  and	  enriched	  those	  and	  their	  binding	  partners	  by	  pulldown	  with	  GFP-­‐Trap.	  Although	  we	  could	  identify	  some	  intersting	  candidates	  such	  as	  WDHD1	  or	  MCM9,	  which	  have	  later	  been	  proposed	  to	  play	  a	  role	  in	   in	  vivo	  MMR	  (31,	  139),	  this	  approach	  did	  not	  help	  to	  identify	  changes	  in	  the	  MMR	  interactome	  after	  DNA	  damage.	  Hence,	  other	  techniques	  were	  needed	  and	  we	  explored	  the	  BioID	  as	  well	  as	   the	  APEX	   technique	   for	  our	  purposes.	  We	   could	   show	   that	  both	  approaches	  can	  be	   applied	   to	   biotinylate	   endogenous	  polypeptides	   and	  managed	   to	   enrich	  these	   labeled	   proteins.	   However,	   both	   methods	   had	   their	   drawbacks	   and	   still	  need	  to	  be	  improved	  before	  they	  can	  be	  used	  reliably	  on	  a	  regular	  basis.	  It	  seems	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that	   the	   APEX	  method	   in	   particular	   can	   only	   be	   applied	   if	   targeting	   a	   specific	  compartment	   of	   the	   cells	   as	   in	   the	   case	   of	   the	  mitochondrial	   proteome	   (129).	  Only	  if	  the	  protein	  of	  interest	  focuses	  on	  one	  or	  more	  very	  defined	  sites	  can	  the	  unspecific	  binding	  be	  reduced	  and	  only	   the	  proteins	   that	   localize	   to	   those	  sites	  become	   labeled	   and	   will	   be	   identified	   in	   later	   analyses.	   In	   order	   to	   study	   the	  interactome	   of	   MMR	   after	   DNA	   damage	   and	   thus	   to	   better	   understand	   non-­‐canonical	  MMR,	  it	  will	  be	  necessary	  to	  explore	  other	  techniques	  such	  as	  protein-­‐protein	  crosslinking	  or	  CHROMASS	  (157).	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  First	   of	   all,	   I	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   to	   thank	   Prof.	   Dr.	   Josef	   Jiricny.	   Starting	   already	   in	   the	  interview,	   Joe	   has	   been	   a	   great	   adviser	   regarding	   not	   only	   research-­‐related	  questions	  but	  also	  other	  fields	  of	  life.	  He	  advised	  me	  to	  do	  my	  PhD	  in	  Zurich	  and	  also	  to	  join	  his	  laboratory	  and	  I	  believe	  it	  was	  a	  very	  good	  decision.	  I	  could	  follow	  my	   ideas	   under	   his	   supervision	   and	   explore	   many	   different	   techniques.	   He	  always	  has	  an	  open	  door	  and	  tries	  to	  find	  solutions	  together	  rather	  than	  telling	  me	  what	  to	  do	  next.	  He	  has	  always	  been	  very	  helpful	  and	  motivating	  when	  things	  did	  not	  go	  as	  I	  wished	  and	  he	  never	  gave	  me	  the	  feeling	  that	  failed	  experiments	  were	   my	   fault.	   He	   encouraged	   me	   to	   try	   new	   things	   and	   helped	   me	   to	   find	  collaborators	  for	  the	  mass	  spectrometry	  experiments.	  Thanks	  to	  the	  fact	  that	  he	  motivated	  me	  to	  go	  and	  to	  talk	  the	  people	  at	  ETH	  by	  my-­‐self	  I	  found	  out	  that	  I	  can	  achieve	  a	  great	  deal	  in	  the	  scientific	  world	  without	  a	  powerful	  person	  around.	  I	  really	   like	   the	   team	  and	   the	   friendly	   atmosphere	   in	  our	   lab.	   I	   think	   that	   this	   is	  Joes	  merit	  as	  he	  knows	  how	  to	  pick	  the	  right	  people	  to	  keep	  the	  up	  freedom	  and	  the	  fun.	  Besides	  the	  actual	  research,	  Joe	  was	  always	  interested	  in	  my	  future	  and	  that	  of	   all	   the	  other	   lab	  members.	   It	   is	   a	  very	  nice	   feeling	   that	  he	  atually	   cares	  about	   our	   future.	   Although,	   he	  would	   like	   all	   of	   us	   to	   continue	  with	   academic	  research,	  he	  has	  never	  put	  any	  obstacles	  in	  peoples	  way	  but	  even	  helped	  them	  to	  find	  their	  way	  outside	  academia.	  I	  never	  regretted	  moving	  to	  Zurich	  and	  joining	  Joes	   lab.	   I	  am	  very	  grateful	   that	  he	  gave	  me	  the	  opportunity	   to	  do	  a	  PhD	   in	  his	  laboratory.	  	  Secondly,	   I	   would	   like	   to	   thank	  my	   committee	  members	   Dr.	  Matthias	   Gstaiger	  and	  Prof.	  Dr.	  Petr	  Cjeka.	  I	  am	  very	  grateful	  that	  they	  agreed	  to	  join	  my	  committee	  and	  actively	  contributed	  to	  the	  development	  of	  my	  projects.	  It	  was	  very	  easy	  to	  communicate	   with	   them	   and	   to	   identify	   the	   important	   aims	   of	   my	   projects	  together.	  It	  was	  great	  to	  discuss	  the	  new	  techniques	  for	  LC-­‐MS	  such	  as	  BioID	  and	  APEX	  and	  I	  would	  like	  to	  thank	  Matthias	  for	  helping	  me	  with	  the	  APEX	  approach	  and	   for	   supporting	  me	   to	   start	   a	   collaboration	  with	   Emanuela	  Milani	   from	   the	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Wollscheid	   lab.	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   was	   an	   excellent	   experience	   to	   work	   with	   her	   and	   to	   find	  solutions	   for	   the	   APEX	   project.	   It	   is	   thanks	   to	   her	   that	   I	   now	   understand	   the	  basics	  of	  the	  MS	  analyses	  and	  the	  statistics.	  I	  also	  want	  to	  thank	  Peter	  Gehrig	  of	  the	  Funtional	  Genomics	  Center	  Zurich	  for	  his	  assistance	  with	  the	  GFP-­‐MLH1	  MS	  data.	  	  	  A	  big	  word	  of	  thanks	  goes	  to	  my	  colleagues	  in	  the	  lab.	  I	  think	  we	  are	  a	  great	  team	  and	  had	  a	  very	  nice	  time	  together	  during	  the	  last	  four	  years.	  We	  could	  not	  only	  discuss	   our	   science-­‐related	   problems	   and	   tried	   to	   help	   each	   other	   but	   also	  became	  very	  close	  friends	  and	  did	  and	  still	  do	  a	  lot	  of	  thinks	  togehter.	  We	  did	  so	  many	  things	  outside	  the	  lab	  like	  our	  skiweekends	  and	  our	  trip	  on	  the	  Aare	  and	  the	   lunch	   and	   coffe	   breaks	   are	   allways	   something	   to	   look	   forward,	   when	   the	  experiments	  do	  not	  work	  out	  as	  planned.	  What	  I	  like	  a	  lot	  is	  that	  we	  can	  always	  share	  and	   talk	  about	  problems	   that	   come	  along	  during	  a	  PhD.	  So	   thank	  you	  so	  much	  Tine,	   Lia,	   Julia,	   Anja,	   Svenja,	   Simone,	   Sascha,	   Saho,	  Mariela,	   Rachel,	   Sara,	  Antonio,	  Shun,	  Steffi,	  Medini	  and	  Maite.	  	  I	   want	   to	   thank	   Mariela	   again	   in	   a	   separate	   section	   for	   all	   the	   work	   she	   has	  invested	  in	  my	  projects.	  Starting	  with	  making	  the	  MMR	  substrates,	  showing	  and	  helping	   me	   to	   make	   nuclear	   extracts	   and	   finally	   performing	   the	   MMR	   assays.	  Without	   her	   those	   experiments	   would	   not	   have	   been	   possible.	   I	   am	   really	  grateful	  for	  this.	  	  	  	  	  I	   also	   want	   to	   thank	   the	   PhD	   Program	   Cancer	   Biology	   and	   the	   Life	   Science	  Graduate	   Program,	   which	   made	   my	   PhD	   life	   more	   easy	   and	   provided	   great	  opportunities	  to	  make	  friends	  and	  meet	  fellow	  PhD	  students.	  	  	  Als	   nächstes	   möchte	   ich	   meiner	   Familie	   danken,	   die	   mich	   in	   all	   den	   Jahren	  meines	  Studiums	  nicht	  nur	  finanziell	  unterstützt	  hat.	  Meine	  Eltern	  waren	  immer	  für	  mich	  da,	  besonders	  dann,	  wenn	  ich	  sie	  am	  meisten	  gebraucht	  habe.	  Ich	  fand	  es	  immer	  toll,	  dass	  sie	  mich	  an	  allen	  Orten	  meiner	  Studienzeit	  und	  während	  des	  Doktors	   mehrmals	   pro	   Jahr	   besucht	   haben	   und	   wir	   so	   zusammen	   die	   Städte	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Rostock,	  Heidelberg,	  Penzberg	  und	  Zürich	  kennenlernen	  konnten.	  Ich	  freue	  mich	  riesig,	  dass	  die	  ganze	  Familie	  zu	  meiner	  Verteidigung	  nach	  Zürich	  kommt.	  	  	  	  Zum	  Ende	  geht	  ein	  riesiges	  und	  herzliches	  Dankeschön	  an	  Leonie.	  	  Seit	  6	  Jahren	  hat	   sie	   mit	   mir	   zusammen	   alle	   Höhen	   und	   Tiefen	   des	   Studiums	   und	   der	  Doktorzeit	   erlebt	  und	  einen	   sehr	   großen	  Teil	   dazu	  beigetragen,	   dass	   ich	   es	  bis	  hierhin	   geschafft	   habe.	   Ich	   weis	   gar	   nicht	   mehr	   wieviele	   Präsentationen	   und	  Abstracts	   sie	   für	  mich	  korrigiert	  hat.	  Und	  natürlich	  hat	   sie	  meine	  Masterarbeit	  gegengelesen	   und	   nun	   auch	   die	   Doktorarbeit.	   Dank	   ihr	   konnte	   ich	   diese	   mit	  bestmöglichem	  Englisch	  und	  viel	  weniger	  Rechtschreibfehlern	   an	   Joe	   schicken.	  Vielen	  Dank,	  dass	  du	  mir	  dabei	  geholfen	  hast	  und	  mich	  immer	  unterstützt	  hast.	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  name:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Martin	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Last	  name:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Falke	  Date	  of	  birth:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   February	  18,	  1986	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Place	  of	  birth:	   Schwedt/Oder,	  Germany	  Nationality:	  	  	   German	  	  Address:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Keltenstrasse	  42	  	   8044	  Zurich	  	   Switzerland	  Phone:	   +41	  44	  635	  34	  79	  Mobile:	   +41	  78	  634	  33	  40	  E-­‐mail:	  	   falke@imcr.uzh.ch	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  10/2006	  -­‐	  09/2009:	  	  	  	  	  	  	  	   University	  of	  Rostock,	  Bachelor	  studies	  in	  Medical	  Biotechnology	  (09/2009:	  B.Sc.	  degree	  in	  Medical	  Biotechnology,	  grade:	  1.4;	  Bachelor	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Curriculum	  Vitae	  
117	  	  	  	  	  
thesis	  "Generation	  of	  a	  Microglia-­‐Specific	  Expression	  Plasmid")	  07/2005	  -­‐	  03/2006:	   Military	  service	  	  06/2006:	   German	  A-­‐level	  (Abitur),	  grade:	  1.5	  
	  
Publications	  Loss	   of	   lamin	   B1	   results	   in	   prolongation	   of	   S	   phase	   and	   decondensation	   of	  chromosome	  territories.	  Camps,	  J.,	  Wangsa,	  D.,	  Falke,	  M.,	  Brown,	  M.,	  Case,	  C.	  M.,	  Erdos,	  M.	  R.,	  and	  Ried,	  T.	  (2014)	  Faseb	  J	  28,	  3423-­‐3434	  	  Second	   generation	   protein	   replacement	   system	   to	   study	   MLH1	   missense	  mutations.	  Falke,	  M.,	  Artola	  Borán,	  M.,	  Kapaklikaya,	  E.,	  Jiricny,	  J.	  (Manuscript	  in	  preparation)	  	  
Practical	  Experience	  10/2011	  –	  04/2012	   Master	  thesis	  at	  the	  German	  Cancer	  Research	  
	   Center	  (Deutsches	  Krebsforschungs-­‐	  
	   zentrum,	  DKFZ)	  	  	   Heidelberg,	  Germany;	  Tumorgenetics,	  	  	   Supervision	  by	  Dr.	  Frank	  Westermann	  	  	   and	  Dr.	  Kai-­‐Oliver	  Henrich	  	  05/2011	  –	  08/2011:	   Internship	  at	  Roche	  Diagnostics	  GmbH	  	  Penzberg,	  Germany;	  Pharma	  Research	  and	  Early	  Development;	  Laboratory	  of	  Dr.	  Claudio	  Sustmann	  01/2011	  –	  03/2011:	  	   Internship	  at	  the	  German	  Cancer	  Research	  
	   Center	  (Deutsches	  Krebsforschungs-­‐	  
	   zentrum,	  DKFZ)	  	  	   Heidelberg,	  Germany;	  Molecular	  RNA	  Biology	  	   and	  Cancer,	  	  	   Laboratory	  of	  	  Dr.	  Sven	  Diederichs	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08/2010	  -­‐	  01/2011:	   Internship	  at	  the	  National	  Institutes	  of	  
	   Health/National	  Cancer	  Institute	  	  	   in	  Bethesda,	  USA;	  	   	   Laboratory	  of	  Dr.	  Thomas	  Ried	  10/2008	  -­‐	  06/2009:	   Student	  assistant	  at	  the	  University	  of	  Rostock,	  	   Clinic	  for	  Neurology,	  	  	   Neurodegeneration	  Research	  Lab;	  	   Laboratory	  of	  Prof.	  Jens	  Pahnke	  08/2008	  -­‐	  09/2008:	   Internship	  at	  the	  University	  of	  Rostock,	  	  	   Clinic	  for	  Neurology,	  	  	   Neurodegeneration	  Research	  Lab;	  	   Laboratory	  of	  Prof.	  Jens	  Pahnke	  04/2006	  -­‐	  07/2006:	   Internship	  at	  the	  Hospital	  "Klinikum	  
Südstadt"	  in	  Rostock,	  Germany	  	  	   	   	  
Additional	  Skills	  and	  Qualifications	  	  	  	  
	  	  	  	  	  Language	  skills:	  	   German	  (native	  speaker)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   English	  (fluent)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Russian	  (basic	  knowledge)	  	   	  IT:	   	   Excellent	  knowledge	  of	  the	  MS	  Office	  	   programs	  	  	  	  
	  
